Guardant Health, Inc. Form 10-Q Quarterly Report Filed 2021-08-05

SECURITIES AND EXCHANGE COMMISSION

FORM 10-Q Quarterly report pursuant to sections 13 or 15(d)

Filing Date: 2021-08-05 | Period of Report: 2021-06-30 SEC Accession No. 0001576280-21-000080

(HTML Version on secdatabase.com)

FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 10-Q | Act: 34 | File No.: 001-38683 | Film No.: 211148786 855-698-8887 SIC: 8071 Medical laboratories

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______FORM 10-Q ______(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 ______GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) ______

Delaware 45-4139254

(State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

505 Penobscot Dr. Redwood City, California, 94063 Registrant’s telephone number, including area code: (855) 698-8887 ______

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 GH The Nasdaq Global Select Market

As of July 30, 2021, the registrant had 101,298,669 shares of common stock, $0.00001 par value per share, outstanding.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Page Item 1. Unaudited Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations 5 Condensed Consolidated Statements of Comprehensive Loss 6 Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to the Unaudited Condensed Consolidated Financial Statements 11 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 39 Item 3. Quantitative and Qualitative Disclosures About Market Risk 54 Item 4. Controls and Procedures 55

PART II – OTHER INFORMATION

Item 1. Legal Proceedings 56 Item 1A. Risk Factors 56 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 56 Item 3. Defaults Upon Senior Securities 56 Item 4. Mine Safety Disclosures 56 Item 5. Other Information 56 Item 6. Exhibits 57 Signatures 58

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections as well as the current beliefs and assumptions of our management, including about our business, our financial condition, our results of operations, our cash flows, and the industry and environment in which we operate. Statements that include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “would,” “could,” “should,” “intend” and “expect,” variations of these words, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,“Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2020, in Part II,

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Item 1A, “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.

Each of the terms the “Company,” “we,” “our,” “us” and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated.

PART I—FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements

Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document December 31, June 30, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 938,590 $ 832,977 Short-term marketable securities 853,072 961,903 Accounts receivable, net 53,667 53,299 Inventory 26,494 22,716 Prepaid expenses and other current assets, net 19,236 17,466 Total current assets 1,891,059 1,888,361 Long-term marketable securities 55,368 246,597 Property and equipment, net 89,737 62,782 Right-of-use assets 200,958 37,343 Intangible assets, net 15,189 16,155 Goodwill 3,290 3,290 Other assets, net 36,284 17,253 Total Assets(1) $ 2,291,885 $ 2,271,781 LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 21,399 $ 7,340 Accrued compensation 34,735 28,280 Accrued expenses 31,998 22,639 Deferred revenue 8,480 8,550 Total current liabilities 96,612 66,809 Convertible senior notes, net 1,133,539 806,292 Long-term operating lease liabilities 211,783 41,565 Other long-term liabilities 2,486 1,520 Total Liabilities(1) 1,444,420 916,186 Redeemable noncontrolling interest 59,400 57,100 Stockholders’ equity: Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 101,265,100 and 100,213,985 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 1 1 Additional paid-in capital 1,597,419 1,902,389 Accumulated other comprehensive income 33 2,697 Accumulated deficit (809,388) (606,592) Total Stockholders’ Equity 788,065 1,298,495 Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity $ 2,291,885 $ 2,271,781

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document (1) As of June 30, 2021 and December 31, 2020, this balance includes $27.5 million and $35.0 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $3.8 million and $4.9 million, respectively, of liabilities of the consolidated VIE and VIE’s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See Note 3, Investment in Joint Venture.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Guardant Health, Inc.

Condensed Consolidated Statements of Operations (unaudited) (in thousands, except per share data)

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

Revenue: Precision oncology testing $ 72,604 $ 50,991 $ 136,333 $ 111,237 Development services and other 19,497 15,344 34,433 22,608 Total revenue 92,101 66,335 170,766 133,845 Costs and operating expenses: Cost of precision oncology testing 24,887 17,809 48,477 36,000 Cost of development services and other 5,040 4,626 10,197 6,941 Research and development expense 63,724 36,319 119,232 73,335 Sales and marketing expense 47,716 25,015 82,054 50,130 General and administrative expense 48,376 37,186 116,311 56,971 Total costs and operating expenses 189,743 120,955 376,271 223,377 Loss from operations (97,642) (54,620) (205,505) (89,532) Interest income 1,037 2,640 2,588 5,958 Interest expense (644) (10) (1,290) (22) Other income (expense), net (243) 2,285 (533) 2,076 Loss before provision for income taxes (97,492) (49,705) (204,740) (81,520) Provision for income taxes 83 34 193 48 Net loss (97,575) (49,739) (204,933) (81,568) Adjustment of redeemable noncontrolling interest — (4,900) (2,300) (800) Net loss attributable to Guardant Health, Inc. common stockholders $ (97,575) $ (54,639) $ (207,233) $ (82,368) Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted $ (0.96) $ (0.57) $ (2.05) $ (0.87) Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted 101,172 96,011 101,064 95,196

The accompanying notes are an integral part of these condensed consolidated financial statements.

Guardant Health, Inc.

Condensed Consolidated Statements of Comprehensive Loss (unaudited) (in thousands)

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

Net loss $ (97,575) $ (49,739) $ (204,933) $ (81,568) Other comprehensive income (loss), net of tax impact: Unrealized gain (loss) on available-for-sale securities (878) (2,338) (1,584) 4,233 Foreign currency translation adjustments 7 25 (1,080) 48 Other comprehensive income (loss) (871) (2,313) (2,664) 4,281 Comprehensive loss $ (98,446) $ (52,052) $ (207,597) $ (77,287) Comprehensive income (loss) attributable to redeemable noncontrolling interest — (4,900) (2,300) (800) Comprehensive loss attributable to Guardant Health, Inc. $ (98,446) $ (56,952) $ (209,897) $ (78,087)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity (unaudited) (in thousands, except share data)

Three Months Ended June 30, 2021

Accumulated Common Stock Redeemable Additional Other Total Noncontrolling Paid-in Comprehensive Accumulated Stockholders’ Interest Shares Amount Capital Income (Loss) Deficit Equity

Balance as of March 31, 2021 $ 59,400 101,085,653 $ 1 $ 1,557,954 $ 904 $ (711,813) $ 847,046 Issuance of common stock upon exercise of stock options — 88,832 — 926 — — 926 Vesting of restricted stock units — 29,717 — — — — — Vesting of common stock exercised early — — — 13 — — 13 Common stock issued under employee stock purchase plan — 60,898 — 5,401 — — 5,401 Taxes paid related to net share settlement of restricted stock units — — — (1,382) — — (1,382) Stock-based compensation — — — 34,507 — — 34,507 Other comprehensive loss — — — — (871) — (871) Net loss — — — — — (97,575) (97,575)

Balance as of June 30, 2021 $ 59,400 101,265,100 $ 1 $ 1,597,419 $ 33 $ (809,388) $ 788,065

Accumulated Common Stock Redeemable Additional Other Total Noncontrolling Paid-in Comprehensive Accumulated Stockholders’ Interest Shares Amount Capital Income (Loss) Deficit Equity

Balance as of March 31, 2020 $ 45,500 94,509,011 $ 1 $ 1,157,945 $ 7,705 $ (380,538) $ 785,113 Issuance of common stock in public offering, net of offering costs of $1,130 — 4,312,500 — 354,600 — — 354,600 Issuance of common stock upon exercise of stock options — 412,554 — 2,044 — — 2,044 Vesting of restricted stock units — 20,008 — — — — — Vesting of common stock exercised early — — — 13 — — 13 Common stock issued under employee stock purchase plan — 58,164 — 3,956 — — 3,956 Stock-based compensation — — — 25,815 — — 25,815 Adjustment of redeemable noncontrolling interest 4,900 — — — — (4,900) (4,900) Other comprehensive loss — — — — (2,313) — (2,313) Net loss — — — — — (49,739) (49,739)

Balance as of June 30, 2020 $ 50,400 99,312,237 $ 1 $ 1,544,373 $ 5,392 $ (435,177) $ 1,114,589

Accumulated Common Stock Redeemable Additional Other Total Noncontrolling Paid-in Comprehensive Accumulated Stockholders’ Interest Shares Amount Capital Income (Loss) Deficit Equity

Balance as of December 31, 2020 $ 57,100 100,213,985 $ 1 $ 1,902,389 $ 2,697 $ (606,592) $ 1,298,495 Cumulative effect adjustment for ASU 2020-06 adoption — — — (330,403) — 4,437 (325,966) Issuance of common stock upon exercise of stock options — 371,711 — 5,388 — — 5,388 Vesting of restricted stock units — 618,506 — — — — — Vesting of common stock exercised early — — — 26 — — 26 Common stock issued under employee stock purchase plan — 60,898 — 5,401 — — 5,401 Taxes paid related to net share settlement of restricted stock units — — — (74,958) — — (74,958) Stock-based compensation — — — 89,576 — — 89,576 Adjustment of redeemable noncontrolling interest 2,300 — — — — (2,300) (2,300) Other comprehensive loss, net of tax impact — — — — (2,664) — (2,664) Net loss — — — — — (204,933) (204,933)

Balance as of June 30, 2021 $ 59,400 101,265,100 $ 1 $ 1,597,419 $ 33 $ (809,388) $ 788,065

Accumulated Common Stock Redeemable Additional Other Total Noncontrolling Paid-in Comprehensive Accumulated Stockholders’ Interest Shares Amount Capital Income (Loss) Deficit Equity

Balance as of December 31, 2019 $ 49,600 94,261,414 $ 1 $ 1,150,090 $ 1,111 $ (352,809) $ 798,393 Issuance of common stock in public offering, net of offering costs of $1,130 — 4,312,500 — 354,600 — — 354,600 Issuance of common stock upon exercise of stock options — 654,557 — 3,548 — — 3,548 Vesting of restricted stock units — 25,602 — — — — — Vesting of common stock exercised early — — — 26 — — 26 Common stock issued under employee stock purchase plan — 58,164 — 3,956 — — 3,956 Stock-based compensation — — — 32,153 — — 32,153 Adjustment of redeemable noncontrolling interest 800 — — — — (800) (800) Other comprehensive gain, net of tax impact — — — — 4,281 — 4,281 Net loss — — — — — (81,568) (81,568)

Balance as of June 30, 2020 $ 50,400 99,312,237 $ 1 $ 1,544,373 $ 5,392 $ (435,177) $ 1,114,589

The accompanying notes are an integral part of these condensed consolidated financial statements.

Guardant Health, Inc.

Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands)

2021 2020

OPERATING ACTIVITIES: Net loss $ (204,933) $ (81,568) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 10,637 7,109 Non-cash operating lease costs 10,839 3,386 Charge of in-process research and development costs with no alternative future use — 8,500 Re-valuation of contingent consideration 875 (190) Non-cash stock-based compensation 89,576 32,153 Amortization of debt issuance costs 1,282 — Amortization of premium (discount) on marketable securities 6,528 1,065 Other 8 (19) Changes in operating assets and liabilities: Accounts receivable, net (368) 6,894 Inventory (3,778) (5,173) Prepaid expenses and other current assets (3,036) 438 Other assets (4,282) (242) Accounts payable 7,112 (2,476) Accrued compensation 6,455 (31) Accrued expenses and other liabilities 7,304 (1,820) Operating lease liabilities (3,033) (3,881) Deferred revenue (70) (792) Net cash used in operating activities (78,884) (36,647) INVESTING ACTIVITIES: Purchases of marketable securities (126,163) (465,302) Maturity of marketable securities 418,110 197,548 Purchase of non-marketable equity and other related investments (12,750) — Purchases of property and equipment (28,261) (19,105) Purchase of intangible assets and capitalized license obligations — (17,886) Net cash provided by (used in) investing activities 250,936 (304,745) FINANCING ACTIVITIES: Payments made on finance lease obligations (91) (79) Proceeds from issuance of common stock upon exercise of stock options 5,388 3,548 Proceeds from issuances of common stock under employee stock purchase plan 5,401 3,956 Taxes paid related to net share settlement of restricted stock units (74,958) — Proceeds from public offering, net of underwriting discounts and commissions — 355,730 Payment of offering costs related to public offering — (369) Payment of offering costs related to borrowings on convertible senior notes (784) — Net cash (used in) provided by financing activities (65,044) 362,786

Six Months Ended June 30,

2021 2020

Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (1,080) 49 Net increase in cash, cash equivalents and restricted cash 105,928 21,443 Cash and cash equivalents—Beginning of period 832,977 143,228 Cash, cash equivalents and restricted cash—End of period $ 938,905 $ 164,671 Supplemental Disclosures of Cash Flow Information: Operating lease liabilities arising from obtaining right-of-use assets $ 170,911 $ 11,373 Supplemental Disclosures of Noncash Investing and Financing Activities: Purchases of property and equipment included in accounts payable and accrued expenses $ 10,289 $ 5,396 Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses $ 587 $ — Follow-on public offering issuance costs included in accounts payable and accrued expenses $ — $ 761

Property and equipment acquired under finance leases $ 236 $ — Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 938,590 $ 164,671 Restricted cash – included in other assets, net 315 — Total cash, cash equivalents and restricted cash $ 938,905 $ 164,671

The accompanying notes are an integral part of these condensed consolidated financial statements.

Guardant Health, Inc. Notes to Unaudited Condensed Consolidated Financial Statements

1. Description of Business

Guardant Health, Inc. (the “Company”) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a liquid or tissue biopsy. The Guardant Health Oncology Platform is designed to leverage the Company’s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company provides its Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. In February 2021, the Company launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, the Company launched Guardant360 TissueNext, the Company's first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. The Company is also developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's tests, the Company has also developed the GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker- driven cancers.

The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the “Joint Venture”) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (“SoftBank”). Under the terms of the joint venture agreement, the Company holds a 50% ownership interest in the Joint Venture. As of June 30, 2021, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, Investment in Joint Venture) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc., its consolidated Joint Venture and majority owned subsidiary. Other stockholders’ interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.

The Company believes that its existing cash and cash equivalents and marketable securities as of June 30, 2021, will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. If the Company’s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.

Use of Estimates

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

The extent to which the coronavirus 2019, or COVID-19 pandemic will ultimately impact the Company’s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.

Unaudited Interim Condensed Financial Statements

The accompanying condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations for the three and six months ended June 30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders’ equity for the three and six months ended June 30, 2021, and 2020, and cash flows for the six months ended June 30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.

The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Foreign Currency

The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders’ equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June 30, 2021, and 2020, foreign currency transaction gains and losses were immaterial.

Restricted Cash

Restricted cash consists of payroll withholding related to the Company's enrollment in certain voluntary disability insurance plan. Restricted cash balance as of June 30, 2021, was $0.3 million, which was included in other assets in the accompanying consolidated balance sheets. The Company did not have any restricted cash as of December 31, 2020.

Non-Marketable Securities

The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investee. The Company's non-marketable equity and other related investments totaled $13.3 million as of June 30, 2021, and are included in other assets, net on the accompanying condensed consolidated balance sheets. The Company did not have such non-marketable equity and other related investments as of December 31, 2020. Non-marketable securities are subject to periodic impairment reviews and

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee’s ability to remain in business.

Pursuant to one of the investments in non-marketable securities purchased by the Company, and subject to the Company purchasing additional non-marketable securities from the same investee, the Company acquired rights to purchase the investee at a pre-determined price subject to additional adjustments based on the performance of the investee, on or before December 31, 2022. As of June 30, 2021, no impairment or adjustments to carrying value of non-marketable securities have been recorded. The Company’s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.

Concentration of Risk

The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.

The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.

A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:

Revenue Accounts Receivable, Net

Three Months Ended June 30, Six Months Ended June 30, December 31, 2021 2020 2021 2020 June 30, 2021 2020

(unaudited) (unaudited) Customer A * * * 14 % * 11 % Customer B 29 % 23 % 27 % 21 % * 13 % Customer C * 10 % * * * 12 % Customer D * * * * 16 % 11 %

* less than 10%

The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0 million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0 million. The Company has evaluated and recorded a credit loss for the remaining $7.0 million considering the third-party's credit worthiness and lack of financial history. The following table presents the receivable and the related credit loss amounts:

Gross Amount Allowance for Credit Losses Net Amount

Three and Six Months Ended June 30, 2021

Charged to (Reversed from) Other December 31, Beginning Income Reclassi- Ending December 31, June 30, 2021 2020 Balance (Expense), Net fication Balance June 30, 2021 2020

(unaudited) (unaudited) (unaudited)

(in thousand) Prepaid expenses and other current assets $ 1,100 $ — $ — $ — $ (1,100) $ (1,100) $ — $ — Other assets 5,900 7,000 (7,000) — 1,100 (5,900) — $ —

Accounts Receivable, Net

Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management’s best estimate of the amount of probable credit losses. As of June 30, 2021, and December 31, 2020, the Company had immaterial allowance for credit losses related to its accounts receivable.

Contract assets are presented under accounts receivable, net and other assets, net on the Company’s condensed consolidated balance sheets and include balances from commercial and governmental payers. Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services and other revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. As of June 30, 2021, the Company had contract assets of $24.8 million which was recorded in accounts receivable, net. As of December 31, 2020, the Company had contract assets of $15.6 million which was recorded in accounts receivable, net, which included $8.4 million of unbilled receivable relating to Guardant360 CDx.

Asset Acquisition

If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. Transaction costs allocated to in-process research and development technology with no future alternate use is expensed as incurred. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.

Goodwill and Intangible Assets, net

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Intangible assets related to in-process research and development costs (“IPR&D”) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of June 30, 2021, there has been no impairment of goodwill or IPR&D.

Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6—12 years.

Leases

The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (“ROU”) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company’s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.

Convertible Senior Notes

In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.

Revenue Recognition

The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology testing services include genomic profiling and the delivery of other genomic information derived from the Company’s platform. Development services and other include companion diagnostic development, clinical trial setup, monitoring and maintenance, information solutions and laboratory services, and other miscellaneous revenue streams. The Company currently receives

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies, research institutes and international distributors.

Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

Precision oncology testing

The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2021, and 2020, the Company recorded $9.6 million and $9.1 million as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the six months ended June 30, 2021, and 2020, the Company recorded $14.6 million and $16.5 million as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.

Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company’s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.

Development services and other

The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.

The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.

The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company’s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.

The Company also has other miscellaneous revenue streams that are recognized in addition to development services noted above such as clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM and Guardant-19, and kits fulfillment related revenues. Revenues related to clinical trial setup, monitoring and maintenance, referral fees, liquid biopsy testing development and support, GuardantConnect, GuardantINFORM are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed. Guardant-19 and kits fulfillment related revenues are recognized when such products are delivered.

Contracts with multiple performance obligations

Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.

For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.

Deferred revenue

Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of June 30, 2021, and December 31, 2020, the deferred revenue balance was $8.5 million and $8.6 million, respectively, which included $2.9 million and $3.0 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the six months ended June 30, 2021, that was included in the deferred revenue balance as of December 31, 2020, was $6.4 million, of which $3.0 million represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers. Revenue recognized in the six months ended June 30, 2020, that was included in the deferred revenue

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document balance as of December 31, 2019, was $7.6 million, which primarily represented revenue from provision of development services under the collaboration agreements with biopharmaceutical customers.

Transaction price allocated to the remaining performance obligations

Costs of Precision Oncology Testing

Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.

Cost of Development Services and Other

Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company’s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.

Research and Development Expenses

Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company’s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.

Stock-Based Compensation

Stock-based compensation related to stock options granted to the Company’s and the Joint Venture's employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.

The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options granted under the 2012 Stock Plan, the 2018 Incentive Award Plan, and the Joint Venture's 2020 Equity Incentive Plan, and stock purchase rights granted under the 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield. The board of directors of the Joint Venture has determined the fair value of common stock of the Joint Venture. Forfeitures are accounted for as they occur.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.

The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company’s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company’s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award.

Net Loss Per Share Attributable to Common Stockholders

The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.

Accounting Pronouncements Adopted

Convertible Instruments and Contracts in an Entity’s Own Equity

In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from stockholders’ equity to liabilities as it relates to the Company’s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share. The Company early adopted ASU 2020-06 in the first quarter of fiscal 2021 using the modified retrospective approach which resulted in the re-classification of the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs as of December 31, 2020 from additional paid-in capital to convertible senior notes, net.

3. Investment in Joint Venture

Variable Interest Entity (“VIE”)

In May 2018, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of the Company’s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document consisting of 80,000,000 shares of Class A common stock and 9,000,000 shares of Class B (non-voting) common stock; and authorized 80,000,000 shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for 1,000 shares of Series A preferred stock. As a result, each of the Company and the affiliate of

SoftBank held 40,000,000 shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $0.05 per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture’s 2020 Equity Incentive Plan pursuant to which 4,595,555 shares of Class B common stock have been reserved for issuance. As of June 30, 2021, and December 31, 2020, 91,109 and no shares of Class B common stock have been issued and outstanding, and no shares of Class A common stock have been issued and outstanding. As of June 30, 2021 and December 31, 2020, 80,000,000 shares of Series A preferred stock have been issued and outstanding.

Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (“VIE”) and the Company has been identified as the VIE’s primary beneficiary. As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.

As of June 30, 2021, and December 31, 2020, the Joint Venture had total assets of approximately $27.5 million and $35.0 million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company’s general credit or assets. Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of June 30, 2021, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.

Put-call arrangements

The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the “put right”), and the Company has a right to purchase all such shares (the “call right”).

Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture’s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company’s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within 20 business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm’s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank’s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company’s condensed consolidated financial statements.

In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a 20% internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.

In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than 40% of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of 40% of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.

The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company’s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company’s initial public offering (the “IPO”) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.

4. Condensed Consolidated Balance Sheet Components

Property and Equipment, Net

Property and equipment, net consist of the following:

June 30, 2021 December 31, 2020

(unaudited) (in thousands) Machinery and equipment $ 50,960 $ 40,216 Leasehold improvements 35,542 34,037 Computer hardware 15,929 10,862 Construction in progress 26,892 7,833 Furniture and fixtures 3,591 3,043 Computer software 1,094 1,136 Property and equipment, gross $ 134,008 $ 97,127 Less: accumulated depreciation (44,271) (34,345) Property and equipment, net $ 89,737 $ 62,782

Depreciation expense related to property and equipment was $5.1 million and $3.2 million for the three months ended June 30, 2021, and 2020, respectively, and $9.6 million and $6.2 million for the six months ended June 30, 2021, and 2020, respectively.

Accrued Expenses

Accrued expenses consist of the following:

(unaudited) (in thousands) Operating lease liabilities $ 7,547 $ 6,632 Accrued tax liabilities 4,500 4,634 Accrued professional services 6,564 3,397 Accrued clinical trials and studies 2,625 1,264 Accrued legal expenses 2,081 2,875 Purchases of property and equipment included in accrued expenses 2,383 1,156 Accrued royalty obligations 179 146 Others 6,119 2,535 Total accrued expenses $ 31,998 $ 22,639

5. Fair Value Measurements, Cash Equivalents and Marketable Securities

Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.

Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

June 30, 2021

Fair Value Level 1 Level 2 Level 3

(unaudited) (in thousands) Financial Assets: Money market funds $ 838,114 $ 838,114 $ — $ — Total cash equivalents $ 838,114 $ 838,114 $ — $ —

U.S. government debt securities $ 853,072 $ — $ 853,072 $ — Total short-term marketable securities $ 853,072 $ — $ 853,072 $ —

U.S. government debt securities $ 55,368 $ — $ 55,368 $ — Total long-term marketable securities $ 55,368 $ — $ 55,368 $ — Total $ 1,746,554 $ 838,114 $ 908,440 $ —

Financial Liabilities: Contingent consideration $ 2,120 $ — $ — $ 2,120 Total $ 2,120 $ — $ — $ 2,120

December 31, 2020

Fair Value Level 1 Level 2 Level 3

(in thousands) Financial Assets: Money market funds $ 620,630 $ 620,630 $ — $ — Total cash equivalents $ 620,630 $ 620,630 $ — $ —

U.S. government debt securities $ 961,902 $ — $ 961,902 $ — Total short-term marketable securities $ 961,902 $ — $ 961,902 $ —

U.S. government debt securities $ 246,597 $ — $ 246,597 $ — Total long-term marketable securities $ 246,597 $ — $ 246,597 $ — Total $ 1,829,129 $ 620,630 $ 1,208,499 $ —

Financial Liabilities: Contingent consideration $ 1,245 $ — $ — $ 1,245 Total $ 1,245 $ — $ — $ 1,245

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.

operations. As of June 30, 2021, and December 31, 2020, contingent consideration liability of $2.1 million and $1.2 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets.

The Company considers the fair value of the redeemable noncontrolling interest as of June 30, 2021, and December 31, 2020, to be a Level 3 measurement. The fair value of the redeemable noncontrolling interest was determined using a of the income approach and the market approach, and estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others.

The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June 30, 2021, and 2020:

Redeemable Noncontrolling Interest Contingent Consideration

Three Months Ended June Six Months Ended June Three Months Ended June Six Months Ended June 30, 30, 30, 30,

2021 2020 2021 2020 2021 2020 2021 2020

(unaudited)

(in thousands) Fair value — beginning of period $ 59,400 $ 45,500 $ 57,100 $ 49,600 $ 1,245 $ 1,175 $ 1,245 $ 1,365 Increase (decrease) in fair value 1,645 6,186 5,932 3,159 875 — 875 (190) Net loss for the period (1,645) (1,286) (3,632) (2,359) — — — —

Fair value — end of period $ 59,400 $ 50,400 $ 59,400 $ 50,400 $ 2,120 $ 1,175 $ 2,120 $ 1,175

The Company considers the fair value of the Convertible Notes as of June 30, 2021 and December 31, 2020 to be a Level 2 measurement. The fair value of the Convertible Notes is primarily affected by the trading price of the Company's common stock and market interest rates. As such, the carrying value of the Convertible Notes does not reflect the market rate. See Note 8, Debt, for additional information related to the fair value of the Convertible Notes.

Cash Equivalents and Marketable Securities

The following tables summarizes the Company’s cash equivalents and marketable securities’ amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:

June 30, 2021

Gross Unrealized Gross Unrealized Estimated Fair Amortized Cost Gain Loss Value

(unaudited) (in thousands) Money market fund $ 838,114 $ — $ — $ 838,114 U.S. government debt securities 907,832 613 (5) 908,440 Total $ 1,745,946 $ 613 $ (5) $ 1,746,554

Gross Unrealized Gross Unrealized Estimated Fair Amortized Cost Gain Loss Value

(in thousands) Money market fund $ 620,630 $ — $ — $ 620,630 U.S. government debt securities 1,206,195 2,339 (35) 1,208,499 Total $ 1,826,825 $ 2,339 $ (35) $ 1,829,129

There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company’s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and six months ended June 30, 2021, and 2020, respectively. The maturities of the Company’s long-term marketable securities range from 1.3 to 2.0 years as of June 30, 2021.

6. Patent License Acquisition

In January 2017, the Company entered into a license agreement with a biotechnology company, KeyGene N.V. (“KeyGene”). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the “SPLA”) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene’s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $18.5 million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $0.6 million of certain capitalizable transaction costs, was allocated to various components of the SPLA.

The Company allocated $9.4 million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of 6-12 years. The Company allocated $8.5 million to IPR&D technology, which have no alternative future use and was included in research and development expenses for the six months ended June 30, 2020. The remaining $1.2 million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the six months ended June 30, 2020.

7. Intangible Assets, Net and Goodwill

The following table presents details of purchased intangible assets as of June 30, 2021, and December 31, 2020:

June 30, 2021

Remaining Weighted Gross Carrying Accumulated Net Carrying Average Useful Amount Amortization Amount Life

(unaudited) (in thousands) (in years) Intangible assets subject to amortization: Acquired license $ 11,886 $ (1,915) $ 9,971 9.3 Non-compete agreements and other covenant rights 5,100 (1,482) 3,618 4.4 Total intangible assets subject to amortization 16,986 (3,397) 13,589 Intangible assets not subject to amortization: IPR&D 1,600 — 1,600 Goodwill 3,290 — 3,290 Total purchased intangible assets $ 21,876 $ (3,397) $ 18,479

Remaining Weighted Gross Carrying Accumulated Net Carrying Average Useful Amount Amortization Amount Life

(in thousands) (in years) Intangible assets subject to amortization: Acquired license $ 11,886 $ (1,367) $ 10,519 9.8 Non-compete agreements 5,100 (1,064) 4,036 4.9 Total intangible assets subject to amortization 16,986 (2,431) 14,555 Intangible assets not subject to amortization: IPR&D 1,600 — 1,600 Goodwill 3,290 — 3,290 Total purchased intangible assets $ 21,876 $ (2,431) $ 19,445

Amortization of finite-lived intangible assets was $0.5 million and $0.5 million for the three months ended June 30, 2021 and 2020, respectively, and $1.0 million and $0.8 million for the six months ended June 30, 2021, and 2020, respectively.

The following table summarizes estimated future amortization expense of finite-lived intangible assets—net:

Year Ending December 31, (unaudited) (in thousands) Remainder of 2021 $ 982 2022 1,947 2023 1,947 2024 1,952 2025 1,705 2026 and thereafter 5,056 Total $ 13,589

8. Debt

Convertible Senior Notes

In November 2020, the Company issued $1.15 billion principal amount of its 0% Convertible Senior Notes due 2027 (the “2027 Notes”). The 2027 Notes do not bear interest, and the principal amount of the Notes will not accrete. However, special interest and additional interest may accrue on the 2027 Notes at a rate per annum not exceeding 0.50% (subject to certain exceptions) upon the occurrence of certain events such as the failure to file certain reports to the Securities and Exchange Commission, or to remove certain restrictive legends from the Notes. The Notes will mature on November 15, 2027, unless repurchased, redeemed or converted earlier.

Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:

• during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on March 31, 2021, if the last reported sale price of the Company's common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter (the “sale price condition”);

• during the five consecutive business days immediately after any ten consecutive trading day period (the “measurement period”) if the trading price per $1,000 principal amount of the Notes for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on such trading day; or

• upon the occurrence of specified corporate events

From and after August 15, 2027, holders of the 2027 Notes may convert their 2027 Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date.

The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.

The Company may not redeem the 2027 Notes at its option at any time before November 20, 2024. The Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after November 20, 2024 and on or before the 25th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.

If certain corporate events that constitute a “Fundamental Change” occur, then, subject to a limited exception for certain cash mergers, holders of Notes may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company’s common stock.

In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings.

Since the 2027 Notes were not convertible as of June 30, 2021, the net carrying amount of the 2027 Notes was classified as a long-term liability.

The following table sets forth the components of the 2027 Notes as of June 30, 2021, and December 31, 2020:

December 31, June 30, 2021 2020

(unaudited) (in thousands) Liability component: Principal $ 1,150,000 $ 1,150,000 Less: debt discount, net of amortization — (331,074) Less: debt issuance costs, net of amortization (16,461) (12,634) Net carrying amount $ 1,133,539 $ 806,292

Equity component recorded at issuance: 2027 Notes $ — $ 335,667 Less: issuance costs — (5,264) Net amount recorded in equity $ — $ 330,403

The total estimated fair value of the 2027 Notes was $1.3 billion and $1.3 billion as of June 30, 2021, and December 31, 2020, respectively. The fair value was determined based on the closing trading price per $100 of the 2027 Notes as of the last day of trading for the period.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The interest expense recognized in relation to amortization of debt issuance costs was $0.6 million and $1.3 million for the three and six months ended June 2021, which represented an effective interest rate of 0.2% and 0.2% and for the three and six months ended June 2021.

Note Hedges

To minimize the impact of potential economic dilution upon conversion of the 2027 Notes, the Company entered into convertible note hedge transactions (the "2027 Note Hedges") with respect to its common stock concurrent with the issuance of the Notes. The 2027 Note Hedges cover, subject to customary adjustments, the number of shares of common stock initially underlying the Notes. The strike price of the 2027 Note Hedges will initially be approximately $182.60 per share, which represents a premium of 75% over the last reported sale price of the

Company’s common stock of $104.34 per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.

As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders’ equity and are not accounted for as derivatives. The Company paid an aggregate amount of $90.0 million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.

9. Leases

The Company has entered into various operating lease agreements for office space, data center, lab and warehouse use, with remaining terms ranging from 1 year to 12 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement. In July 2020, the Company entered into two lease agreements for additional office space in Palo Alto, California ("Palo Alto Lease") and in San Diego, California ("San Diego Lease"). The San Diego Lease has a term of 8 years with rent payments commencing in May 2022. The Palo Alto Lease has a term of 12 years with an option to renew the lease term for an additional ten years which has not been considered in the determination of ROU or the lease liability as the Company does not consider it reasonably certain of exercising the renewal option. Rent payments for the Palo Alto Lease will commence in October 2021. Both leases consist of fixed and variable payments and are being accounting for as operating leases. The Company took possession of these facilities in March 2021. The Company estimated the incremental borrowing rate to determine the present value of lease payments for the San Diego and Palo Alto leases using trading data of the Company's convertible debt adjusted for credit rating and market yield curves.

Operating lease expense was $6.9 million and $1.9 million for the three months ended June 30, 2021, and 2020, respectively, and $10.8 million and $3.4 million for the six months ended June 30, 2021, and 2020, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).

June 30, 2021 December 31, 2020

(unaudited) Weighted-average remaining lease term (in years) 10.3 5.5 Weighted-average discount rate 4.14 % 8.07 %

The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of June 30, 2021:

Year Ending December 31, (unaudited) (in thousands) Remainder of 2021 $ 5,398 2022 21,454 2023 28,976 2024 31,529 2025 32,084 2026 and thereafter 177,402 Total operating lease payments $ 296,843 Less: imputed interest (54,792) Less: lease incentives (22,721) Total operating lease liabilities $ 219,330

Finance leases are not material to the Company's condensed consolidated financial statements.

10. Commitments and Contingencies

Legal Proceedings

In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, the Company has received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. The Company has also instituted, and may in the future institute, additional legal proceedings to enforce its rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. The Company cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on the Company because of diversion of management time and attention as well as the financial costs related to resolving such disputes.

The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.

Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.

Patent Disputes

In November 2017, the Company filed a lawsuit against Foundation Medicine, Inc. (“Foundation Medicine”) in the United States District Court for the District of Delaware. The Company has alleged that Foundation Medicine has infringed four of the Company’s digital sequencing technology patents. Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license and noninfringement. The parties are seeking damages, injunctive relief and attorneys’ fees. Discovery in the lawsuit has closed, and a number of pre-trial motions were filed in September and October 2020.

Foundation Medicine also filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company. The PTAB denied institution of inter partes review for four of the six petitions filed by Foundation Medicine and instituted inter partes review for the remaining two petitions. In November 2020, the Company filed a lawsuit against Foundation Medicine in the United States District Court for the District of Delaware, wherein the Company alleged that Foundation Medicine infringes seven of the Company’s patents. Foundation Medicine has asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, license, non-infringement, and that the Company has violated Section 2 of Sherman Act. In December 2020, the Company filed a Motion for a Preliminary Injunction to prohibit Foundation Medicine from practicing two of the asserted patents.

In March 2021, the Company filed two lawsuits against Foundation Medicine GmbH in the District Court of Munich I in Germany, wherein the Company alleged that Foundation Medicine GmbH infringes two of the Company’s patents. Final hearings on this matter are scheduled for December 2021.

In May 2021, the Company entered into a binding term sheet with Foundation Medicine, which upon execution of a definitive settlement agreement, will result in the dismissal of all pending patent litigation worldwide between the parties.

In August 2020, the Company and Personal Genome Diagnostics, Inc. settled the patent infringement lawsuit brought by the Company. Under the terms of the confidential settlement, the lawsuit and counterclaims, as well as other challenges to the Company’s patents, have been dismissed.

In August 2021, TwinStrand Biosciences, Inc. and the University of Washington filed a patent infringement suit in the United States District Court for the District of Delaware alleging that the Company infringes U.S. Patent Nos. 10,287,631; 10,689,699; 10,752,951; and 10,760,127. The Company will respond to the complaint and present its defenses to the allegations.

False Advertising Dispute

In May 2021, the Company also filed a lawsuit against Natera, Inc. (“Natera”) in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company’s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera’s Signatera assay. The Company is seeking a Preliminary Injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition.

11. Common Stock

The Company’s common stockholders are entitled to dividends if and when declared by the Company’s Board of Directors (the “Board of Directors”). As of June 30, 2021 and December 31, 2020, no dividends on the Company's common stock had been declared by the Board of Directors.

The Company’s common stock has been reserved for the following potential future issuances:

June 30, 2021 December 31, 2020

(unaudited) Shares underlying outstanding stock options 2,703,906 3,101,181 Shares underlying unvested restricted stock units 1,155,370 1,118,655 Market-based restricted stock units 2,260,764 3,391,148 Performance-based restricted stock units 415,535 377,922 Shares available for issuance under the 2018 Incentive Award Plan 5,928,052 1,819,223 Shares available for issuance under the 2018 Employee Stock Purchase Plan 1,475,593 1,536,491 Total 13,939,220 11,344,620

Follow-on Public Offering

In June 2020, the Company completed an underwritten public offering, in which it issued and sold 4,312,500 shares of its common stock at a price of $84.00 per share. The Company received net proceeds of $354.6 million after deducting underwriting discounts and commissions and offering expenses payable by the Company.

12. Stock-Based Compensation

Stock Option Activity

A summary of the Company’s stock option activity under the 2012 Stock Plan (as amended and restated, the “2012 Plan”) and the 2018 Incentive Award Plan (the “2018 Plan”) and related information is as follows:

Weighted- Average Shares Shares Subject to Weighted- Remaining Available for Options Average Contractual Life Aggregate Intrinsic Grant Outstanding Exercise Price (Years) Value

(unaudited) (in thousands) Balance as of December 31, 2020 1,819,223 3,101,181 $ 15.80 6.9 $ 350,670

2018 Plan annual increase(1) 3,689,000 — Granted (60,677) 60,677 142.73 Exercised — (371,711) 14.34 Canceled 42,956 (86,241) 47.02 Restricted stock units granted (177,166) — — Restricted stock units canceled 94,075 — — Market-based restricted stock units canceled 558,254 — — Performance-based restricted stock units granted (52,917) — — Performance-based restricted stock units canceled 15,304 — — Balance as of June 30, 2021 5,928,052 2,703,906 $ 17.86 6.5 $ 288,749 Vested and Exercisable as of June 30, 2021 2,091,339 $ 9.16 6.1 $ 240,569

(1) Effective as of January 1, 2021, an additional 3,689,000 shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $11.1 million and $33.1 million for the three months ended June 30, 2021 and 2020, respectively, and $49.4 million and $50.3 million for the six months ended June 30, 2021 and 2020, respectively.

The weighted-average grant date fair value of options granted was $81.79 and $44.61 per share for the three months ended June 30, 2021 and 2020, respectively, and $84.02 and $45.52 per share for the six months ended June 30, 2021 and 2020, respectively.

Future stock-based compensation for unvested options as of June 30, 2021 was $19.7 million, which is expected to be recognized over a weighted-average period of 2.7 years.

Restricted Stock Units

A summary of the Company’s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:

Weighted-Average Restricted Stock Grant Date Fair Units Outstanding Value

(unaudited) Balance as of December 31, 2020 1,118,655 $ 92.89 Granted 177,166 154.94 Vested and released (46,376) 80.32 Canceled (94,075) 92.67 Balance as of June 30, 2021 1,155,370 $ 102.93

Future stock-based compensation for unvested restricted stock units as of June 30, 2021, was $98.1 million, which is expected to be recognized over a weighted-average period of 3.1 years.

Performance-based Restricted Stock Units

Since November 2020, the Compensation Committee of the Board of Directors started to approve, and the Company started to grant performance-based restricted stock units (“PSUs”) under the 2018 Plan. The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of 4 years and an additional service period requirement of six months after the performance metrics are met. The PSUs granted to a consultant consistent of operational metrics to be met over a performance period of 4 years. The PSUs are expected to be expensed over a period of approximately 4 years to 4.5 years subject to meeting the respective performance metrics and service requirements. As of June 30, 2021, a significant portion of these PSUs are not expected to achieve the related performance metrics, and therefore, no stock-based compensation expense was recorded for the PSUs that were not probable to vest.

A summary of the Company’s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:

Performance-based Weighted-Average Restricted Stock Grant Date Fair Units Outstanding Value

(unaudited) Balance as of December 31, 2020 377,922 $ 113.40 Granted 52,917 135.94 Canceled (15,304) 113.40 Balance as of June 30, 2021 415,535 $ 116.27

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-based compensation recorded for the PSUs for the three and six months ended June 30, 2021 was $0.3 million and $0.7 million, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of June 30, 2021 was $4.9 million, which is expected to be recognized over a weighted-average period of 3.6 years.

Market-based Restricted Stock Units

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of six to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. The following table presents additional information relating to each MSU award:

Number of Tranche Price Goal RSUs Tranche 1 $120 per share 565,192 Tranche 2 $150 per share 565,191 Tranche 3 $200 per share 565,191

The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model. The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU. The weighted average grant date fair value of the MSUs was $67.00 and the weighted average derived service period was estimated to be in the range of 0.83 – 2.07 years.

On January 1, 2021, Tranche 1 of the MSUs became vested because it has met both service requirement and market-based performance metrics as the predetermined share price goal of $120 per share was achieved for a period of 30 consecutive calendar days. A summary of the Company’s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:

Market-based Weighted-Average Restricted Stock Grant Date Fair Units Outstanding Value

(unaudited) Balance as of December 31, 2020 3,391,148 $ 67.00 Vested and released (572,130) 70.58 Canceled (1) (558,254) 70.58 Balance as of June 30, 2021 2,260,764 $ 65.20

(1) Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.

For the three and six months ended June 30, 2021, stock-based compensation for the MSUs was $22.3 million and $66.3 million, respectively, which was recorded in general and administrative expenses on the condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of June 30, 2021 was $49.0 million, which is expected to be recognized over a weighted- average period of 0.8 years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration.

AMEA 2020 Equity Incentive Plan

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan (the “AMEA 2020 Plan”), under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to employees of the Joint Venture or its affiliates. Nonstatutory stock options may be granted to employees, directors and non-employee consultants. Stock options may be granted at an exercise price of not less than the fair market value of the Joint Venture's common stock on the date of grant, determined by the board of directors of the Joint Venture. Options generally vest over 4 years and expire as determined by the board of directors

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents of the Joint Venture, provided that the term of options may not exceed 10 years from the date of grant. For individuals holding more than 10% of the total combined voting power of all classes of stock of the Joint Venture, the exercise price of an option will not be less than 110% of the fair market value of the Joint Venture's common stock on the date of grant, and the term of the option will not exceed 5 years. A total of 4,595,555 shares of the Joint Venture's Class B common stock are initially reserved for issuance under the AMEA 2020 Plan, and the number of shares may be increased in accordance with the terms of the AMEA 2020 Plan.

A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:

Options Outstanding

Weighted- Average Shares Shares Subject to Weighted- Remaining Available for Options Average Contractual Life Aggregate Intrinsic Grant Outstanding Exercise Price (Years) Value

(unaudited) (in thousands) Balance as of December 31, 2020 542,220 4,053,335 $ 0.58 9.6 $ — Granted (382,223) 382,223 0.58 Exercised — (91,109) 0.58 Canceled 92,412 (92,412) 0.58 Balance as of June 30, 2021 252,409 4,252,037 $ 0.58 9.2 $ — Vested and Exercisable as of June 30, 2021 2,352,180 $ 0.58 9.1 $ —

The weighted-average grant date fair value of options granted was $0.33 per share for the three and six months ended June 30, 2021. Future stock-based compensation for unvested options as of June 30, 2021 was $0.6 million, which is expected to be recognized over a weighted-average period of 2.2 years.

Stock-Based Compensation Expense

The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:

2021 2020 2021 2020

(unaudited) (in thousands) Cost of precision oncology testing $ 873 $ 407 $ 1,640 $ 710 Research and development expense 4,564 2,622 8,864 4,986 Sales and marketing expense 3,438 2,167 6,318 3,965 General and administrative expense 25,632 20,619 72,754 22,492 Total stock-based compensation expense $ 34,507 $ 25,815 $ 89,576 $ 32,153

Valuation of Stock Options

The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) Expected term (in years) 5.49 – 6.04 5.50 – 6.10 5.49 – 6.04 5.50 – 6.10 Expected volatility 63.6% – 66.7% 66.5% – 68.5% 63.6% – 66.7% 66.5% – 73.3% Risk-free interest rate 0.3% – 1.1% 0.4% – 0.4% 0.3% – 1.1% 0.4% – 1.6% Expected dividend yield —% —% —% —%

The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of common stock of the Company and the Joint Venture, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:

Fair Value of Common Stock

The fair value of the Company’s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market. The grant date fair value of the Joint Venture's common stock has been determined by the board of directors of the Joint Venture. The grant date fair value of the Joint Venture’s common stock was determined using valuation methodologies which utilize certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the Joint Venture’s common stock, the methodologies used to estimate the enterprise value of the Joint Venture were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.

Expected Term

The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.

Expected Volatility

Prior to the commencement of trading of the Company’s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company’s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.

The Joint Venture derived the expected volatility from the average historical volatility over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Joint Venture does not have any trading history for its common stock. The Joint Venture will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Risk-Free Interest Rate

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.

Expected Dividend Yield

The Company and the Joint Venture does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.

Valuation of MSUs

The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following:

Expected Volatility

Due to limited historical data for the trading of the Company’s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.

Expected Term

The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model.

Risky Rate

The risky rate represents the Company's cost of equity.

Discount for Lack of Marketability

The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.

The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of 0.83 – 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.53%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% – 14.5%.

2018 Employee Stock Purchase Plan

In September 2018, the Company’s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”). A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional 942,614 shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.

Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to 10% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company’s common stock on the first or last day of the offering period, whichever is lower. The ESPP provides for separate six-month offering periods beginning on May 15 and November 15 of each year.

Shares of common stock purchased under the ESPP were 60,898 and 58,164 for the three and six months ended June 30, 2021 and 2020, respectively. The total compensation expense related to the ESPP was $0.8 million and

$1.1 million for the three months ended June 30, 2021 and 2020, respectively, and $1.6 million and $1.6 million for the six months ended June 30, 2021 and 2020, respectively.

The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black- Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period.

The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

Three and Six Months Ended June 30,

2021 2020

(unaudited) Expected term (in years) 0.5 0.5 Expected volatility 50.8% 73.2% Risk-free interest rate —% 0.2% Expected dividend yield —% —%

As of June 30, 2021, the unrecognized stock-based compensation expense related to the ESPP was $1.4 million, which is expected to be recognized over the remaining term of the offering period of 0.4 years.

13. Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) (in thousands, except per share data) Net loss $ (97,575) $ (49,739) $ (204,933) $ (81,568) Adjustment of redeemable noncontrolling interest — (4,900) (2,300) (800) Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted $ (97,575) $ (54,639) $ (207,233) $ (82,368) Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted $ (0.96) $ (0.57) $ (2.05) $ (0.87) Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted 101,172 96,011 101,064 95,196

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) (in thousands) Stock options issued and outstanding (1) 2,720 4,056 2,816 4,200 Restricted stock units 1,147 542 1,133 519 MSUs 2,261 1,342 2,453 671 PSUs 409 — 408 — ESPP obligation 43 37 45 40 Common stock subject to repurchase 8 20 10 21 Convertible senior notes 8,225 — 8,225 — Total 14,813 5,997 15,090 5,451

(1) Excludes stock options of 4,252,037 shares outstanding under the AMEA 2020 Plan as of June 30, 2021.

14. Income Taxes

The income tax expense for the three and six months ended June 30, 2021 was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. The difference between the Company’s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.

The income tax expense for the three and six months ended June 30, 2021 and 2020 relates primarily to state minimum income tax and income tax on the Company’s earnings in foreign jurisdictions.

15. Segment and Geographic Information

The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) (in thousands) United States $ 87,868 $ 61,422 $ 160,168 $ 126,035

International (1) 4,233 4,913 10,598 7,810 Total revenue $ 92,101 $ 66,335 $ 170,766 $ 133,845

(1) No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June 30, 2021 and 2020, respectively.

As of June 30, 2021 and December 31, 2020, 98% and 94%, respectively, of the Company’s long-lived assets and right-of-use assets are located in the United States.

16. Related Party Transactions

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document As discussed in Note 3, Investment in Joint Venture, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.

The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company’s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved.

Pursuant to a shares subscription agreement entered into in June 2021, the Company acquired $26 million of non-marketable securities in July 2021.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, beliefs, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2020 and in Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.

Overview

We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a liquid and tissue biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we provide our Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy- based tests for advanced stage cancer. Our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration, or the FDA, to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, or NSCLC patients who may benefit from treatment with osimertinib (EGFR exon 19 deletions, exon 20 T790M or exon 21 L858R mutations), amivantamab-vmjw (EGFR exon 20 insertion mutations), and sotorasib (KRAS G12C mutations), which have been developed by our biopharmaceutical customers AstraZeneca, Janssen Biotech and Amgen respectively. In February 2021, we launched our Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, we launched Guardant360 TissueNext, our first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. We are developing tests under our LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening, and individuals at a higher risk for developing cancer with early detection. We have also developed our GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.

We perform our tests in our clinical laboratory located in Redwood City, California. Our laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states.

We generated total revenue of $92.1 million and $66.3 million for the three months ended June 30, 2021 and 2020, respectively, and $170.8 million and $133.8 million for the six months ended June 30, 2021 and 2020, respectively. We also incurred net losses of $97.6 million and $49.7 million for the three months ended June 30, 2021 and 2020, respectively, and $204.9 million and $81.6 million for the six months ended June 30, 2021 and 2020, respectively. We have funded our operations to date principally from the sale of our stock, convertible senior notes, and revenue from our precision oncology testing and development services and other. As of June 30, 2021, we had cash, cash equivalents and marketable securities of $1.8 billion.

Factors affecting our performance

We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document • Testing volume, pricing and customer mix. Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect

our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average reimbursement for clinical tests because we are not a contracted provider for, or our tests are not covered by clinical patients’ insurance for, the majority of the tests that we perform for patients on behalf of clinicians. Revenue from clinical tests for patients covered by Medicare represented approximately 44% and 38% of our precision oncology revenue from clinical customers during the three months ended June 30, 2021, and 2020, respectively, and approximately 42% and 36% of our precision oncology revenue from clinical customers during the six months ended June 30, 2021, and 2020, respectively.

• Payer coverage and reimbursement. Our revenue depends on achieving broad coverage and reimbursement for our tests from third- party payers, including both commercial and government payers. Precision oncology revenue from tests for clinical customers is calculated based on our expected cash collections, using the estimated variable consideration. The variable consideration is estimated based on historical collection patterns as well as the potential for changes in future reimbursement behavior by one or more payers. Estimation of the impact of the potential for changes in reimbursement requires significant judgment and considers payer' past patterns of changes in reimbursement as well as any stated plans to implement changes. Any cash collections over the expected reimbursement period exceeding the estimated variable consideration is recorded in future periods based on actual cash received. Payment from commercial payers can vary depending on whether we have entered into a contract with the payers as a “participating provider” or do not have a contract and are considered a “non-participating provider”. Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. Because we are not contracted with these payers, they determine the amount that they are willing to reimburse us for any of our tests and they can prospectively and retrospectively adjust the amount of reimbursement, adding to the complexity in estimating the variable consideration. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our tests and, potentially, no reimbursement for non-covered uses identified under the payer’s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. Current Procedural Terminology, or CPT, coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. In addition, Z-Code Identifiers are used by certain payers, including under Medicare's Molecular Diagnostic Services Program, or MolDx, to supplement CPT codes for molecular diagnostics tests such as our Guardant360 test. Changes to the codes used to report the Guardant360 test to payers may result in significant changes in its reimbursement. Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore adopted policies that cover our Guardant360 test for the majority of NSCLC patients we test. If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In March 2020, we began to receive reimbursement from Medicare for claims submitted, with respect to Guardant360 clinical tests performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin other than NSCLC. In May 2020, Noridian issued a coverage article and confirmed limited Medicare coverage for our Guardant360 test for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin who meet the criteria of Medicare’s National Coverage Determination for Next Generation Sequencing established in March 2018. Following the FDA approval of our Guardant360 CDx test, a new Z-Code Identifier was issued in August 2020. In January 2021, a proprietary laboratory analyses, or PLA code was issued for our Guardant360 CDx with an effective date in April 2021. Additionally, based on this new PLA code, we applied to the Centers for Medicare and Medicaid Services or CMS for our Guardant360 CDx test to become an advanced diagnostic laboratory test, or ADLT. In March 2021, CMS approved ADLT status to the Guardant360 CDx test, which would allow us to bill Medicare at the lowest available commercial rate for the first three quarters from April 1, 2021. After the initial three quarters, we can bill Medicare for Guardant360 CDx services at the median rate of claims paid by commercial payers. We are in the process of negotiating reimbursement for our Guardant Reveal, Guardant Response and Guardant360 TissueNext tests from commercial and governmental payers. Due to the inherent variability and unpredictability of the reimbursement landscape, including related to the amount that payers reimburse us for any of our tests, previously recorded revenue adjustments are not indicative of future revenue adjustments from actual cash collections, which may fluctuate significantly. Additionally, if coding changes were to occur, payments for certain uses of our tests could be reduced, put on hold, or eliminated. This variability and unpredictability could increase the risk of future revenue reversal and result in our failing to meet any previously publicly stated guidance we may provide.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document • Biopharmaceutical customers. Our revenue also depends on our ability to attract, maintain and expand relationships with biopharmaceutical customers. As we continue to develop these relationships, we expect to

support a growing number of clinical trials globally and continue to have opportunities to offer our platform to such customers for development services, including companion diagnostic development, novel target discovery and validation, as well as clinical trial enrollment. For example, our tests are being developed as companion diagnostics under collaborations with biopharmaceutical companies, including AstraZeneca, Amgen, Daiichi Sankyo, Janssen Biotech, and Radius Health.

• Research and development. A significant aspect of our business is our investment in research and development, including the development of new products. In particular, we have invested heavily in clinical studies as we believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers. With respect to our LUNAR program, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, aiming to recruit approximately 13,000 patients and evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults. In addition, we are investing very heavily in establishing clinical utility of our Guardant Reveal test in adjuvant treatment settings. In 2020, we launched three trials in collaboration with key cancer researchers: COBRA, a randomized controlled study, comprising over 1,400 low-risk stage-II colon cancer patients, ACT-3, comprising over 500 stage-III colorectal cancer patients, and PEGASUS for the de-escalation of therapy, encompassing over 140 high-risk stage-II and stage-III colon cancer patients. We have expended considerable resources, and expect to increase such expenditures over the next few years, to support our research and development programs with the goal of fueling further innovation.

• International expansion. A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals or partnerships with research organizations. In May 2018, we formed and capitalized a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the Americas and Europe. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa.

• Sales and marketing expense. Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our sales and marketing expense, increase in headcount, and in particular, our various marketing programs around existing and new product introductions.

• General and administrative expense. Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our general and administrative expense, and in particular, our stock-based compensation expense. Our equity awards, including market-based and performance-based restricted stock units, are intended to retain and incentivize employees to lead us to sustained, long-term superior financial and operational performance.

• COVID-19 Global Pandemic. The global outbreak of coronavirus 2019, or COVID-19, has disrupted, and we expect will continue to disrupt, our operations. To protect the health and well-being of our workforce, partners, vendors and customers, we have provided free COVID-19 testing for all of our employees, contractors and their dependents, implemented social distance and building entry policies at work, and followed California’s public health orders and the guidance from the Centers for Disease Control and Prevention. The COVID-19 global pandemic has negatively affected, and we expect will continue to negatively affect, our revenue and our clinical studies. For example, our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. The severity of the impact on our business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including the duration and severity of the pandemic and the impact of any variants of the virus. In August 2020, we launched our Guardant-19 test and received the FDA’s emergency use authorization for use in the detection of the novel coronavirus. The test was being offered to our employees and to select partner organizations via our CLIA-certified clinical laboratory. We do not expect out Guardant-19 test to be used extensively by third parties following June 30, 2021, due to our decision to discontinue offering the test to third parties.

While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020, and Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q, for more information.

Components of results of operations

Revenue

We derive our revenue from two sources: (i) precision oncology testing and (ii) development services and other.

Precision oncology testing. Precision oncology testing revenue is generated from sales of our tests to clinical and biopharmaceutical customers. In the United States, through June 30, 2021, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. We submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin and for Guardant360 CDx clinical testing performed for qualifying patients diagnosed with solid tumor cancers who meet the criteria of Medicare’s National Coverage Determination for Next Generation Sequencing established in March 2018. Revenue from clinical tests for patients covered by Medicare represented approximately 44% and 38% of our precision oncology revenue from clinical customers during the three months ended June 30, 2021, and 2020, respectively, and 42% and 36% of our precision oncology revenue from clinical customers during the six months ended June 30, 2021, and 2020, respectively.

Development services and other. Development services and other revenue primarily represents services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions. It includes companion diagnostic development and regulatory approval services, clinical trial setup, monitoring and maintenance, referrals, liquid biopsy testing development and support, as well as GuardantConnect, GuardantINFORM, Guardant-19, and kits fulfillment related revenues. We collaborate with biopharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings to support companion diagnostic device submissions for our liquid biopsy panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. Development services and other revenue can vary over time as different projects start and complete.

Costs and operating expenses

Cost of precision oncology testing. Cost of precision oncology testing generally consists of cost of materials, inventory write-downs, direct labor, including employee benefits, bonus, and stock-based compensation; equipment and infrastructure expenses associated with processing liquid biopsy test samples such as sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples; freight; curation of test results for physicians; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, depreciation of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors.

We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.

Cost of development services and other. Cost of development services and other primarily includes costs incurred for the performance of development services requested by our customers comprising of direct labor and material costs including any inventory write-downs. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services and other will vary depending on the nature, timing and scope of customer projects.

Research and development expense. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits including stock-based compensation, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.

We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical trials.

Sales and marketing expense. Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses and stock-based compensation, as well as marketing, sales incentives, and educational activities and allocated overhead expenses.

We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our tests.

General and administrative expense. Our general and administrative expenses include costs for our executive, accounting and finance, information technology, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.

We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased stock- based compensation expense, including resulting from the market-based restricted stock units granted to our Chief Executive Officer and our President and Chief Operating Officer in May 2020. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses being incurred.

Interest income

Interest income consists of interest earned on our cash, cash equivalents and marketable securities.

Interest expense

Interest expense consists primarily of charges relating to amortization of debt issuance costs.

Other income (expense), net

Other income (expense), net consists of foreign currency exchange gains and losses, payments due and received in relation to the settlement of a patent dispute, net of credit losses, and the relief fund grant from the Department of Health and Human Services, or HHS, under the U.S. Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.

Results of operations

The following table set forth the significant components of our results of operations for the periods presented.

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) (in thousands) Revenue: Precision oncology testing $ 72,604 $ 50,991 $ 136,333 $ 111,237 Development services and other 19,497 15,344 34,433 22,608 Total revenue 92,101 66,335 170,766 133,845 Costs and operating expenses: Cost of precision oncology testing(1) 24,887 17,809 48,477 36,000 Cost of development services and other 5,040 4,626 10,197 6,941 Research and development expense(1) 63,724 36,319 119,232 73,335 Sales and marketing expense(1) 47,716 25,015 82,054 50,130 General and administrative expense(1) 48,376 37,186 116,311 56,971 Total costs and operating expenses 189,743 120,955 376,271 223,377 Loss from operations (97,642) (54,620) (205,505) (89,532) Interest income 1,037 2,640 2,588 5,958 Interest expense (644) (10) (1,290) (22) Other income (expense), net (243) 2,285 (533) 2,076 Loss before provision for income taxes (97,492) (49,705) (204,740) (81,520) Provision for income taxes 83 34 193 48 Net loss $ (97,575) $ (49,739) $ (204,933) $ (81,568)

(1) Amounts include stock-based compensation expense as follows:

2021 2020 2021 2020

Comparison of the Three Months Ended June 30, 2021 and 2020

Revenue

Three Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Precision oncology testing $ 72,604 $ 50,991 $ 21,613 42 % Development services and other 19,497 15,344 4,153 27 % Total revenue $ 92,101 $ 66,335 $ 25,766 39 %

Total revenue was $92.1 million for the three months ended June 30, 2021 compared to $66.3 million for the three months ended June 30, 2020, an increase of $25.8 million, or 39%.

Precision oncology testing revenue increased to $72.6 million for the three months ended June 30, 2021 from $51.0 million for the three months ended June 30, 2020, an increase of $21.6 million, or 42%. This increase in precision oncology testing revenue was primarily due to an increase in sample volume.

Precision oncology revenue from tests for clinical customers was $61.1 million in the three months ended June 30, 2021, and $39.6 million in the three months ended June 30, 2020, respectively. Tests for clinical customers increased to 20,830 for the three months ended June 30, 2021 from 13,694 for the three months ended June 30, 2020 mainly due to an increase in the number of physicians ordering Guardant360 tests.

Precision oncology revenue from tests for biopharmaceutical customers was $11.6 million in the three months ended June 30, 2021, and $11.4 million in the three months ended June 30, 2020, respectively. Tests for biopharmaceutical customers increased to 3,653 for the three months ended June 30, 2021, from 2,805 for the three months ended June 30, 2020, primarily due to an increase in the number of biopharmaceutical customers and their contracted projects. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we began receiving fewer samples for testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Our future sample volumes and precision oncology revenue may be adversely impacted by the COVID-19 pandemic depending on the duration and severity of the pandemic.

Development services and other revenue increased to $19.5 million for the three months ended June 30, 2021 from $15.3 million for the three months ended June 30, 2020, an increase of $4.2 million, or 27%. This increase in development services and other revenue was primarily due to new collaboration projects from biopharmaceutical customers for companion diagnostic development services and receipt of regulatory approval for two of our companion diagnostic programs during the three months ended June 30, 2021. Our development services arrangements with biopharmaceutical customers and development services revenue may be adversely impacted by the COVID-19 pandemic in future periods.

Costs and operating expenses

Cost of revenue

2021 2020 $ %

(unaudited) (in thousands) Cost of revenue $ 29,927 $ 22,435 $ 7,492 33 % Gross profit $ 62,174 $ 43,900 Gross margin 68 % 66 %

Cost of revenue was $29.9 million for the three months ended June 30, 2021, compared to $22.4 million for the three months ended June 30, 2020, an increase of $7.5 million, or 33%.

Cost of precision oncology testing revenue was $24.9 million for the three months ended June 30, 2021, compared to $17.8 million for the three months ended June 30, 2020, an increase of $7.1 million, or 40%. This increase in cost of precision oncology testing was primarily due to a $5.3 million increase in material costs, $1.4 million increase in

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents labor and manufacturing overhead costs, a $0.7 million increase in other costs including costs related to freight and curation of test results for physicians, partially offset by a $0.3 million decrease in royalties.

Cost of development services and other was $5.0 million for the three months ended June 30, 2021, compared to $4.6 million for the three months ended June 30, 2020, an increase of $0.4 million, or 9%. This increase in cost of development services and other was primarily due to an increase in material and labor costs related to companion diagnostic development and regulatory approval service contracts.

Gross margin for the three months ended June 30, 2021, was 68% compared to 66% for the three months ended June 30, 2020. Gross margin improvement primarily relates to higher revenues from our biopharmaceutical customers due to the receipt of regulatory approval for two of our companion diagnostic programs. Our gross margin may be adversely impacted by the COVID-19 pandemic for the affected periods.

Research and development expense

Three Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Research and development $ 63,724 $ 36,319 $ 27,405 75 %

Research and development expenses were $63.7 million for the three months ended June 30, 2021 compared to $36.3 million for the three months ended June 30, 2020, an increase of $27.4 million, or 75%. This increase in research and development expense was primarily due to an increase of $11.8 million in personnel-related costs for employees in our research and development group, including a $1.9 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology and clinical studies. The increase is also attributable to an increase of $6.6 million in outside service costs, an increase of $5.1 million in material costs, and an increase of $2.3 million related to allocated facilities and information technology infrastructure costs. Our research and development expenses are expected to increase in absolute dollars in coming years as the Company continues to innovate and invest in new product initiatives with a particular focus on LUNAR program.

Sales and marketing expense

Three Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Sales and marketing $ 47,716 $ 25,015 $ 22,701 91 %

Selling and marketing expenses were $47.7 million for the three months ended June 30, 2021 compared to $25.0 million for the three months ended June 30, 2020, an increase of $22.7 million, or 91%. This increase was primarily due to an increase of $15.5 million in personnel-related costs, including a $1.3 million increase in stock-based compensation, associated with the expansion of our commercial organization. The increase is also attributable to an increase of $3.4 million related to allocated facilities and information technology infrastructure costs, and an increase of $2.6 million related to marketing activities. We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our tests.

General and administrative expense

2021 2020 $ %

(unaudited) (in thousands) General and administrative $ 48,376 $ 37,186 $ 11,190 30 %

General and administrative expenses were $48.4 million for the three months ended June 30, 2021 compared to $37.2 million for the three months ended June 30, 2020, an increase of $11.2 million, or 30%. This increase was primarily due to an increase of $7.2 million in personnel-related costs, including a $5.0 million increase in stock-based compensation primarily in connection with the issuance of market-based restricted stock units to our Chief

Executive Officer and our President and Chief Operating Officer as well as an increase in our headcount, an increase of $1.4 million in professional service expenses related to outside legal, accounting, consulting and IT services, an increase of $2.0 million related to allocated facilities and information technology infrastructure cost, and an increase of $0.3 million in office administrative costs. Our general and administrative expenses may increase in the near term due to increase in stock-based compensation expense associated with increase headcount as well as expense recognition associated with the market-based restricted stock units.

Interest income

Three Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Interest income $ 1,037 $ 2,640 $ (1,603) (61)%

Interest income was $1.0 million for the three months ended June 30, 2021 compared to $2.6 million for the three months ended June 30, 2020, a decrease of $1.6 million, or 61%. This decrease was primarily due to a significant decrease in interest rate as the U.S. Federal Reserve lowered the risk-free interest rate to nearly zero, offset by a significant increase in cash, cash equivalents and marketable securities related to the receipt of cash proceeds from our follow-on public offering completed in June 2020 and borrowings on our convertible senior notes issued in November 2020.

Interest expense

Three Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Interest expense $ (644) $ (10) $ (634) 6,340 %

Interest expense was $0.6 million for the three months ended June 30, 2021, primarily due to the amortization of debt issuance costs. Interest expense was immaterial for the three months ended June 30, 2020.

Other income (expense), net

Three Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Other income (expense), net $ (243) $ 2,285 $ (2,528) *

Other income (expense), net included foreign currency exchange losses of $0.1 million for the three months ended June 30, 2021. For the three months ended June 30, 2020, other income (expense), net included receipt of $1.8 million from HHS’s relief fund under the CARES Act and foreign currency exchange gains of $0.2 million.

Provision for income taxes

2021 2020 $ %

(unaudited) (in thousands) Provision for income taxes $ 83 $ 34 $ 49 *

* Not meaningful

Provision for income taxes was immaterial for the three months ended June 30, 2021 and 2020.

Comparison of the Six Months Ended June 30, 2021 and 2020

Revenue

Six Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Precision oncology testing $ 136,333 $ 111,237 $ 25,096 23 % Development services and other 34,433 22,608 11,825 52 % Total revenue $ 170,766 $ 133,845 $ 36,921 28 %

Total revenue was $170.8 million for the six months ended June 30, 2021 compared to $133.8 million for the six months ended June 30, 2020, an increase of $36.9 million, or 28%.

Precision oncology testing revenue increased to $136.3 million for the six months ended June 30, 2021 from $111.2 million for the six months ended June 30, 2020, an increase of $25.1 million, or 23%. This increase in precision oncology testing revenue was primarily due to an increase in tests performed.

Precision oncology revenue from tests for clinical customers was $110.9 million in the six months ended June 30, 2021 and $77.6 million in the six months ended June 30, 2020, respectively. Tests for clinical customers increased to 39,220 for the six months ended June 30, 2021 from 28,951 for the six months ended June 30, 2020 mainly due to an increase in the number of physicians ordering Guardant360 tests.

Precision oncology revenue from tests for biopharmaceutical customers was $25.4 million in the six months ended June 30, 2021 and $33.6 million in the six months ended June 30, 2020, respectively. Tests for biopharmaceutical customers decreased to 7,175 for the six months ended June 30, 2021 from 8,071 for the six months ended June 30, 2020, primarily due to the timing and progression of clinical trials and studies which resulted in fluctuation in the number of samples received for testing. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we began receiving fewer samples for testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Our future sample volumes and precision oncology revenue may be adversely impacted by the COVID-19 pandemic for the affected periods.

Development services and other revenue increased to $34.4 million for the six months ended June 30, 2021 from $22.6 million for the six months ended June 30, 2020, an increase of $11.8 million, or 52%. This increase in development services and other revenue was primarily due to progression of collaboration projects from biopharmaceutical customers for companion diagnostic development services and receipt of regulatory approval of two of our companion diagnostic programs during the six months ended June 30, 2021. Our development services arrangements with biopharmaceutical customers and development services revenue may be adversely impacted by the COVID-19 pandemic in future periods.

Cost of Revenue and Gross Margin

2021 2020 $ %

(unaudited) (dollars in thousands) Cost of revenue $ 58,674 $ 42,941 $ 15,733 37 % Gross profit $ 112,092 $ 90,904 Gross margin 66 % 68 %

Cost of revenue was $58.7 million for the six months ended June 30, 2021 compared to $42.9 million for the six months ended June 30, 2020, an increase of $15.7 million, or 37%.

Cost of precision oncology testing revenue was $48.5 million for the six months ended June 30, 2021 compared to $36.0 million for the six months ended June 30, 2020, an increase of $12.5 million, or 35%. This increase in cost of precision oncology testing was attributable to an increase in sample volumes and was primarily due to a $8.1 million increase in material costs, a $3.2 million increase in production labor and overhead costs, and a $1.7 million increase

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents in other costs including costs related to freight and curation of test results for physicians, offset by a $0.5 million decrease in royalties.

Cost of development services and other was $10.2 million for the six months ended June 30, 2021 compared to $6.9 million for the six months ended June 30, 2020, an increase of $3.3 million, or 47%. This increase in cost of development services and other was primarily due to an increase in labor costs related to companion diagnostic development and regulatory approval service contracts.

Gross margin for the six months ended June 30, 2021 was 66% compared to 68% for the six months ended June 30, 2020. The decrease in gross margin is primarily due to higher average cost per test resulting from varied product mix. Our gross margin may be adversely impacted by the COVID-19 pandemic depending on how long the pandemic lasts and the severity of the situation in coming quarters.

Operating Expenses

Research and development expense

Six Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Research and development $ 119,232 $ 73,335 $ 45,897 63 %

Research and development expenses were $119.2 million for the six months ended June 30, 2021 compared to $73.3 million for the six months ended June 30, 2020, an increase of $45.9 million, or 63%. This increase in research and development expense was primarily due to an increase of $23.8 million in personnel-related costs for employees in our research and development group, including a $3.9 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology and clinical studies, an increase of $13.7 million in material costs related to various programs, an increase of $7.9 million in outside service costs, and an increase of $6.5 million related to allocated facility and information technology infrastructure costs offset by a decrease of $8.5 million relating to in-process research and development (IPR&D) technology expensed in connection with a patent license acquisition that occurred in March 2020.

Sales and marketing expense

Six Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Sales and marketing $ 82,054 $ 50,130 $ 31,924 64 %

Selling and marketing expenses were $82.1 million for the six months ended June 30, 2021 compared to $50.1 million for the six months ended June 30, 2020, an increase of $31.9 million, or 64%. This increase was primarily due to an increase of $20.0 million in personnel-related costs, including a $2.4 million increase in stock-based compensation, associated with the expansion of our commercial organization, an increase of $5.6 million related to allocated facility and information technology infrastructure costs and an increase of $5.1 million related to marketing activities.

General and administrative expense

2021 2020 $ %

(unaudited) (in thousands) General and administrative $ 116,311 $ 56,971 $ 59,340 104 %

General and administrative expenses were $116.3 million for the six months ended June 30, 2021 compared to $57.0 million for the six months ended June 30, 2020, an increase of $59.3 million, or 104%. This increase was primarily due to an increase of $55.4 million in personnel-related costs, including a $50.3 million increase in stock-based compensation primarily in connection with the issuance of market-based restricted stock units to our Chief

Executive Officer and our President and Chief Operating Officer as well as an increase in our headcount, an increase of $2.3 million related to allocated facilities and information technology infrastructure costs, and an increase of $2.2 million in professional service expenses related to outside legal, accounting, consulting and IT services, offset by a decrease of $1.2 million related to settlement costs in connection with a patent license acquisition that occurred in March 2020. Our general and administrative expenses may increase in the near term due to increase in stock-based compensation expense associated with increase headcount as well as expense recognition associated with the market-based restricted stock units.

Interest income

Six Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Interest income $ 2,588 $ 5,958 $ (3,370) (57)%

Interest income was $2.6 million for the six months ended June 30, 2021 compared to $6.0 million for the six months ended June 30, 2020, a decrease of $3.4 million, or (57)%. This decrease was primarily due to a significant decrease in interest rate as the U.S. Federal Reserve lowered the risk-free interest rate to nearly zero, offset by a significant increase in cash, cash equivalents and marketable securities related to the receipt of cash proceeds from our follow-on public offering completed in June 2020 and borrowings on our convertible senior notes issued in November 2020.

Interest expense

Six Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Interest expense $ (1,290) $ (22) $ (1,268) 5,764 %

Interest expense was $1.3 million for the six months ended June 30, 2021, primarily due to the amortization of debt issuance costs. Interest expense was immaterial for the six months ended June 30, 2020.

Other income (expense), net

Six Months Ended June 30, Change

2021 2020 $ %

(unaudited) (in thousands) Other income (expense), net $ (533) $ 2,076 $ (2,609) *

Other income (expense), net included foreign currency exchange losses of $0.1 million for the six months ended June 30, 2021. For the six months ended June 30, 2020, other income (expense), net included receipt of $1.8 million received from HHS’s relief fund under the CARES Act.

Provision for income taxes

2021 2020 $ %

(unaudited) (in thousands) Provision for income taxes $ 193 $ 48 $ 145 *

* Not meaningful

Provision for income taxes was immaterial for the six months ended June 30, 2021 and 2020.

Liquidity and capital resources

We have incurred losses and negative cash flows from operations since our inception, and as of June 30, 2021, we had an accumulated deficit of $809.4 million. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical trials and develop new products, expand our sales organization, and increase our marketing efforts to drive market adoption of our tests. As demand for our tests are expected to continue to increase from physicians and biopharmaceutical companies, we anticipate that our capital expenditure requirements could also increase if we require additional laboratory capacity.

We have funded our operations to date principally from the sale of stock, convertible debt and through revenue from precision oncology testing and development services and other. As of June 30, 2021, we had cash and cash equivalents of $938.6 million and marketable securities of $908.4 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to provide liquidity while ensuring capital preservation. Currently, our investments are held in marketable securities consisting of United States treasury securities and non-marketable securities in the form of private equity investments.

Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flows from operations, will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this report. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development services and other is expected to grow long-term, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.

If our available cash, cash equivalents and marketable securities and anticipated cash flows from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in our Form 10-K for the year ended December 31, 2020, we may seek to sell additional common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all.

Cash flows

The following table summarizes our cash flows for the periods presented:

Six Months Ended June 30,

2021 2020

(unaudited) (in thousands) Net cash used in operating activities $ (78,884) $ (36,647) Net cash provided by (used in) investing activities $ 250,936 $ (304,745) Net cash (used in) provided by financing activities $ (65,044) $ 362,786

Operating activities

Cash used in operating activities during the six months ended June 30, 2021 was $78.9 million, which resulted from a net loss of $204.9 million, partially offset by non-cash charges of $119.7 million and net change in our operating assets and liabilities of $6.3 million. Non-

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document cash charges primarily consisted of $89.6 million of stock-based compensation, $10.6 million of depreciation and amortization, $10.8 million of non-cash operating lease costs, $6.5 million of amortization of premium on investment, and $1.3 million of amortization of debt issuance costs. The net change in our operating assets and liabilities was primarily the result of a $7.1 million increase in accounts payable, a $6.5 million increase in accrued compensation due to increased personnel and a $7.3 million increase in accrued expenses and other liabilities, partially offset by a $4.3 million increase in other assets, net, a $3.8 million increase in

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents inventory due to higher testing volumes and a $3.0 million payment of operating lease liabilities net of receipt of tenant improvement allowance.

Cash used in operating activities during the six months ended June 30, 2020 was $36.6 million, which resulted from a net loss of $81.6 million and net change in our operating assets and liabilities of $7.1 million, partially offset by non-cash charges of $52.0 million. Non-cash charges primarily consisted of $32.2 million of stock-based compensation, $8.5 million of charge of in-process research and development costs with no alternative future use, $7.1 million of depreciation and amortization, $3.4 million of non-cash operating lease costs, and $1.1 million of amortization of premium on investment. The net change in our operating assets and liabilities was primarily the result of a $5.2 million increase in inventory due to higher testing volumes, a $3.9 million payment of operating lease liabilities, a $2.5 million decrease in accounts payable, a $1.8 million decrease in accrued expenses and other liabilities, and a $0.8 million decrease in deferred revenue, partially offset by a $6.9 million decrease in accounts receivables.

Investing activities

Cash provided by investing activities during the six months ended June 30, 2021 was $250.9 million, which resulted primarily from maturities of marketable securities of $418.1 million, partially offset by purchases of marketable securities of $126.2 million, purchases of property and equipment of $28.3 million and purchase of non-marketable equity and other related investments of $12.8 million.

Cash used in investing activities during the six months ended June 30, 2020 was $304.7 million, which resulted primarily from purchases of marketable securities of $465.3 million, purchases of property and equipment of $19.1 million and purchases of intangible assets and capitalized license obligations of $17.9 million, partially offset by maturities of marketable securities of $197.5 million.

Financing activities

Cash used in financing activities during the six months ended June 30, 2021 was $65.0 million, which was primarily due to taxes paid related to net share settlement of restricted stock units of $75.0 million, partially offset by proceeds from issuances of common stock under employee stock purchase plan of $5.4 million and proceeds from exercise of stock options of $5.4 million.

Cash provided by financing activities during the six months ended June 30, 2020 was $362.8 million, which was primarily due to proceeds from a follow-on offering of our common stock, net of underwriting discounts and commissions and offering expenses payable by us, of $354.6 million, proceeds from issuances of common stock under employee stock purchase plan of $4.0 million and proceeds from exercise of stock options of $3.5 million.

Contractual obligations and commitments

Except as set forth in Note 10, Commitments and Contingencies, of the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.

As of June 30, 2021, we have not had any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

Critical accounting policies and estimates

We have prepared our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the consolidated financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are described in more detail in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and in Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations”, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. During the three and six months ended June 30, 2021, there were no material changes to our critical accounting policies from those discussed previously.

Recent accounting pronouncements

See Note 2, Summary of Significant Accounting Policies, to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.

Interest rate risk

We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness. As of June 30, 2021, we had cash and cash equivalents of $938.6 million held primarily in cash deposits and money market funds. Our marketable securities are held in U.S. government debt securities. As of June 30, 2021, we had short-term marketable securities of $853.1 million and long-term marketable securities of $55.4 million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of June 30, 2021, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate $4.5 million decline of the fair value of our available-for- sale securities and a hypothetical 100 basis point decrease in interest rates would have resulted in an approximate $0.5 million increase of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.

Foreign currency risk

The majority of our revenue is generated in the United States. Through June 30, 2021, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. As of June 30, 2021, the effect of a hypothetical 10% change in foreign currency exchange rates would not be material to our financial condition or results of operations. To date, we have not entered into

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our Chief Executive Officer, or CEO, and our Chief Financial Officer, or CFO with the participation of other members of our management, have evaluated the effectiveness of our “disclosure controls and procedures” (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of June 30, 2021, and our CEO and our CFO have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.

Changes in internal control

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that a number of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

Limitations on effectiveness of controls and procedures

Our management, including our CEO and our CFO, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

The information under the caption “Commitments and Contingencies – Legal Proceedings” in Note 10 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.

Item 1A. Risk Factors

Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021. The risks and uncertainties disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. During the first quarter of fiscal 2021, there were no material changes to our previously disclosed risk factors. Besides risk factors disclosed in the Annual Report and this Quarterly Report, additional risks and uncertainties not currently known or we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.

These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Not applicable.

Exhibit Filed/Furnished Number Description Form File No. Exhibit Filing Date Herewith

3.1 Amended and Restated Certificate of Incorporation 8-K 001-38683 3.1 10/9/2018 3.2 Amended and Restated Bylaws 8-K 001-38683 3.2 10/9/2018 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 31.1 302 of the Sarbanes-Oxley Act of 2002 * Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 31.2 302 of the Sarbanes-Oxley Act of 2002 * Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 32.1 906 of the Sarbanes-Oxley Act of 2002 ** Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 32.2 906 of the Sarbanes-Oxley Act of 2002 ** Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL 101.INS document * 101.SCH Inline XBRL Taxonomy Extension Schema Document * Inline XBRL Taxonomy Extension Calculation 101.CAL Linkbase Document * Inline XBRL Taxonomy Extension Definition Linkbase 101.DEF Document * Inline XBRL Taxonomy Extension Label Linkbase 101.LAB Document * Inline XBRL Taxonomy Extension Presentation 101.PRE Linkbase Document * Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information 104 contained in Exhibits 101) *

______

* Filed herewith. ** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized

GUARDANT HEALTH, INC.

Dated: August 5, 2021 By: /s/ Helmy Eltoukhy Name: Helmy Eltoukhy Title: Chief Executive Officer (Principal Executive Officer)

Dated: August 5, 2021 By: /s/ Michael Bell Name: Michael Bell Title: Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Helmy Eltoukhy, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Date: August 5, 2021 /s/ Helmy Eltoukhy Helmy Eltoukhy Chief Executive Officer (Principal Executive Officer)

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Bell, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Michael Bell Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Guardant Health, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 5, 2021 /s/ Helmy Eltoukhy Helmy Eltoukhy Chief Executive Officer (Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 5, 2021 /s/ Michael Bell Michael Bell Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Cover Page - shares Jun. 30, 2021 Jul. 30, 2021 Cover [Abstract] Document Type 10-Q Document Quarterly Report true Document Period End Date Jun. 30, 2021 Document Transition Report false Entity File Number 001-38683 Entity Registrant Name GUARDANT HEALTH, INC. Entity Incorporation, State or Country Code DE Entity Tax Identification Number 45-4139254 Entity Address, Address Line One 505 Penobscot Dr. Entity Address, City or Town Redwood City Entity Address, State or Province CA Entity Address, Postal Zip Code 94063 City Area Code 855 Local Phone Number 698-8887 Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Large Accelerated Filer Entity Small Business false Entity Emerging Growth Company false Entity Shell Company false Title of 12(b) Security Common Stock, par value $0.00001 Trading Symbol GH Security Exchange Name NASDAQ Entity Common Stock, Shares Outstanding 101,298,669 Amendment Flag false Document Fiscal Year Focus 2021 Document Fiscal Period Focus Q2 Entity Central Index Key 0001576280 Current Fiscal Year End Date --12-31

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated Balance Sheets (unaudited) - Jun. 30, Dec. 31, USD ($) 2021 2020 $ in Thousands Current assets: Cash and cash equivalents $ 938,590$ 832,977 Short-term marketable securities 853,072 961,903 Accounts receivable, net 53,667 53,299 Inventory 26,494 22,716 Prepaid expenses and other current assets, net 19,236 17,466 Total current assets 1,891,0591,888,361 Long-term marketable securities 55,368 246,597 Property and equipment, net 89,737 62,782 Right-of-use assets 200,958 37,343 Intangible assets, net 15,189 16,155 Goodwill 3,290 3,290 Other assets, net 36,284 17,253 Total Assets [1] 2,291,8852,271,781 Current liabilities: Accounts payable 21,399 7,340 Accrued compensation 34,735 28,280 Accrued expenses 31,998 22,639 Deferred revenue 8,480 8,550 Total current liabilities 96,612 66,809 Convertible senior notes, net 1,133,539806,292 Long-term operating lease liabilities 211,783 41,565 Other long-term liabilities 2,486 1,520 Total Liabilities [1] 1,444,420916,186 Redeemable noncontrolling interest 59,400 57,100 Stockholders’ equity: Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 101,265,100 and 100,213,985 shares issued and 1 1 outstanding as of June 30, 2021 and December 31, 2020, respectively Additional paid-in capital 1,597,4191,902,389 Accumulated other comprehensive income 33 2,697 Accumulated deficit (809,388) (606,592) Total Stockholders’ Equity 788,065 1,298,495 Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity $ $ 2,291,8852,271,781 [1]As of June 30, 2021 and December 31, 2020, this balance includes $27.5 million and $35.0 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $3.8 million and $4.9 million, respectively, of liabilities of the consolidated VIE and VIE’s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See Note 3, Investment in Joint Venture.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated Balance Sheets (unaudited) Dec. 31, Jun. 30, 2021 (Parenthetical) - USD ($) 2020 $ in Thousands Common stock, par value (in usd per share) $ 0.00001 $ 0.00001 Common stock, shares authorized (in shares) 350,000,000 350,000,000 Common stock, shares outstanding (in shares) 101,265,100 100,213,985 Common stock, shares issued (in shares) 101,265,100 100,213,985 Assets [1] $ 2,291,885 $ 2,271,781 Liabilities [1] 1,444,420 916,186 Variable Interest Entity Assets 27,500 35,000 Liabilities $ 3,800 $ 4,900 [1]As of June 30, 2021 and December 31, 2020, this balance includes $27.5 million and $35.0 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $3.8 million and $4.9 million, respectively, of liabilities of the consolidated VIE and VIE’s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See Note 3, Investment in Joint Venture.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 3 Months 6 Months Ended Statements of Operations Ended (unaudited) - USD ($) Jun. 30, Jun. 30, Jun. 30, Jun. 30, shares in Thousands, $ in 2021 2020 2021 2020 Thousands Revenue: Precision oncology testing $ $ $ $ 72,604 50,991 136,333 111,237 Development services and other 19,497 15,344 34,433 22,608 Total revenue 92,101 66,335 170,766 133,845 Costs and operating expenses: Cost of precision oncology testing 24,887 17,809 48,477 36,000 Cost of development services and other 5,040 4,626 10,197 6,941 Research and development expense 63,724 36,319 119,232 73,335 Sales and marketing expense 47,716 25,015 82,054 50,130 General and administrative expense 48,376 37,186 116,311 56,971 Total costs and operating expenses 189,743 120,955 376,271 223,377 Loss from operations (97,642)(54,620)(205,505)(89,532) Interest income 1,037 2,640 2,588 5,958 Interest expense (644) (10) (1,290) (22) Other income (expense), net (243) 2,285 (533) 2,076 Loss before provision for income taxes (97,492)(49,705)(204,740)(81,520) Provision for income taxes 83 34 193 48 Net loss (97,575)(49,739)(204,933)(81,568) Adjustment of redeemable noncontrolling interest 0 (4,900) (2,300) (800) Net loss attributable to Guardant Health, Inc. common stockholders (97,575)(54,639)(207,233)(82,368) Net loss attributable to Guardant Health, Inc. common stockholders $ $ $ $ (97,575)(54,639)(207,233)(82,368) Net loss per share attributable to Guardant Health, Inc. common $ (0.96) $ (0.57) $ (2.05) $ (0.87) stockholders, basic (in usd per share) Net loss per share attributable to Guardant Health, Inc. common $ (0.96) $ (0.57) $ (2.05) $ (0.87) stockholders, diluted (in usd per share) Weighted-average shares used in computing net loss per share attributable to 101,172 96,011 101,064 95,196 Guardant Health, Inc. common stockholders, basic (in shares) Weighted-average shares used in computing net loss per share attributable to 101,172 96,011 101,064 95,196 Guardant Health, Inc. common stockholders, diluted (in shares)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 3 Months Ended 6 Months Ended Statements of Comprehensive Loss Jun. 30, Jun. 30, Jun. 30, Jun. 30, (unaudited) - USD ($) 2021 2020 2021 2020 $ in Thousands Statement of Comprehensive Income [Abstract] Net loss $ $ (97,575) $ (49,739) $ (81,568) (204,933) Other comprehensive income (loss), net of tax impact: Unrealized gain (loss) on available-for-sale securities (878) (2,338) (1,584) 4,233 Foreign currency translation adjustments 7 25 (1,080) 48 Other comprehensive income (loss) (871) (2,313) (2,664) 4,281 Comprehensive loss (98,446) (52,052) (207,597) (77,287) Comprehensive income (loss) attributable to redeemable 0 (4,900) (2,300) (800) noncontrolling interest Comprehensive loss attributable to Guardant Health, Inc. $ $ (98,446) $ (56,952) $ (78,087) (209,897)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Additional Paid-in Accumulated Condensed Consolidated Cumulative Capital Deficit Statements of Redeemable effect Accumulated Redeemable AdditionalCumulative Cumulative Noncontrolling Interest and adjustment Other Total NoncontrollingCommon Stock Paid-in effect Accumulated effect Stockholders’ Equity for ASU Comprehensive Interest Capital adjustment Deficit adjustment (unaudited) - USD ($) 2020-06 Income (Loss) for ASU for ASU $ in Thousands adoption 2020-06 2020-06 adoption adoption Beginning balance at Dec. 31, $ 49,600 2019 Increase (Decrease) in Temporary Equity [Roll Forward] Adjustment of redeemable $ (800) 800 $ (800) noncontrolling interest Ending balance at Jun. 30, 50,400 2020 Beginning balance (in shares) 94,261,414 at Dec. 31, 2019 Beginning balance at Dec. 31, $ 798,393 $ 1 $ 1,111 (352,809) 2019 1,150,090 Increase (Decrease) in Stockholders' Equity [Roll Forward] Issuance of common stock in public offering, net of offering 4,312,500 costs (in shares) Issuance of common stock in public offering, net of offering 354,600 354,600 costs Issuance of common stock upon exercise of stock options 654,557 (in shares) Issuance of common stock 3,548 3,548 upon exercise of stock options Vesting of restricted stock 25,602 units (in shares) Vesting of common stock 26 26 exercised early Common stock issued under employee stock purchase plan 58,164 (in shares) Common stock issued under 3,956 3,956 employee stock purchase plan Stock-based compensation 32,153 32,153 Other comprehensive gain 4,281 4,281 (loss), net of tax impact Net loss (81,568) (81,568) Ending balance (in shares) at 99,312,237 Jun. 30, 2020 Ending balance at Jun. 30, 1,114,589 $ 1 1,544,373 5,392 (435,177) 2020 Beginning balance at Mar. 31, 45,500 2020 Increase (Decrease) in Temporary Equity [Roll Forward] Adjustment of redeemable (4,900) 4,900 (4,900) noncontrolling interest Ending balance at Jun. 30, 50,400 2020 Beginning balance (in shares) 94,509,011 at Mar. 31, 2020 Beginning balance at Mar. 31, 785,113 $ 1 1,157,945 7,705 (380,538) 2020 Increase (Decrease) in Stockholders' Equity [Roll Forward] Issuance of common stock in public offering, net of offering 4,312,500 costs (in shares) Issuance of common stock in public offering, net of offering 354,600 354,600 costs Issuance of common stock upon exercise of stock options 412,554 (in shares) Issuance of common stock 2,044 2,044 upon exercise of stock options

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Vesting of restricted stock 20,008 units (in shares) Vesting of common stock 13 13 exercised early Common stock issued under employee stock purchase plan 58,164 (in shares) Common stock issued under 3,956 3,956 employee stock purchase plan Stock-based compensation 25,815 25,815 Other comprehensive gain (2,313) (2,313) (loss), net of tax impact Net loss (49,739) (49,739) Ending balance (in shares) at 99,312,237 Jun. 30, 2020 Ending balance at Jun. 30, 1,114,589 $ 1 1,544,373 5,392 (435,177) 2020 Beginning balance at Dec. 31, 57,100 2020 Increase (Decrease) in Temporary Equity [Roll Forward] Adjustment of redeemable (2,300) 2,300 (2,300) noncontrolling interest Ending balance at Jun. 30, 59,400 2021 Beginning balance (in shares) 100,213,985 at Dec. 31, 2020 Beginning balance at Dec. 31, $ 1,298,495 $ (325,966) $ 1 1,902,389 $ (330,403) 2,697 (606,592) $ 4,437 2020 Increase (Decrease) in Stockholders' Equity [Roll Forward] Accounting Standards Update gh:AccountingStandardsUpdate202006Member [Extensible List] Issuance of common stock upon exercise of stock options 371,711 371,711 (in shares) Issuance of common stock $ 5,388 5,388 upon exercise of stock options Vesting of restricted stock 618,506 units (in shares) Vesting of common stock 26 26 exercised early Common stock issued under employee stock purchase plan 60,898 (in shares) Common stock issued under 5,401 5,401 employee stock purchase plan Taxes paid related to net share settlement of restricted stock (74,958) (74,958) units Stock-based compensation 89,576 89,576 Other comprehensive gain (2,664) (2,664) (loss), net of tax impact Net loss (204,933) (204,933) Ending balance (in shares) at 101,265,100 Jun. 30, 2021 Ending balance at Jun. 30, 788,065 $ 1 1,597,419 33 (809,388) 2021 Beginning balance at Mar. 31, 59,400 2021 Ending balance at Jun. 30, $ 59,400 2021 Beginning balance (in shares) 101,085,653 at Mar. 31, 2021 Beginning balance at Mar. 31, 847,046 $ 1 1,557,954 904 (711,813) 2021 Increase (Decrease) in Stockholders' Equity [Roll Forward] Issuance of common stock upon exercise of stock options 88,832 (in shares) Issuance of common stock 926 926 upon exercise of stock options Vesting of restricted stock 29,717 units (in shares) Vesting of common stock 13 13 exercised early

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Common stock issued under employee stock purchase plan 60,898 (in shares) Common stock issued under 5,401 5,401 employee stock purchase plan Taxes paid related to net share settlement of restricted stock (1,382) (1,382) units Stock-based compensation 34,507 34,507 Other comprehensive gain (871) (871) (loss), net of tax impact Net loss (97,575) (97,575) Ending balance (in shares) at 101,265,100 Jun. 30, 2021 Ending balance at Jun. 30, $ $ 788,065 $ 1 $ 33 $ (809,388) 2021 1,597,419

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 3 Months Ended6 Months Ended Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity Jun. 30, 2020 Jun. 30, 2020 (unaudited) (Parenthetical) - USD ($) $ in Thousands Statement of Stockholders' Equity [Abstract] Adjustments to additional paid in capital, stock issued, issuance costs $ 1,130 $ 1,130

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 6 Months Ended Statements of Cash Flows Jun. 30, Jun. 30, (unaudited) - USD ($) 2021 2020 $ in Thousands OPERATING ACTIVITIES: Net loss $ $ (204,933)(81,568) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 10,637 7,109 Non-cash operating lease costs 10,839 3,386 Charge of in-process research and development costs with no alternative future use 0 8,500 Re-valuation of contingent consideration 875 (190) Non-cash stock-based compensation 89,576 32,153 Amortization of debt issuance costs 1,282 0 Amortization of premium (discount) on marketable securities 6,528 1,065 Other 8 (19) Changes in operating assets and liabilities: Accounts receivable, net (368) 6,894 Inventory (3,778) (5,173) Prepaid expenses and other current assets (3,036) 438 Other assets (4,282) (242) Accounts payable 7,112 (2,476) Accrued compensation 6,455 (31) Accrued expenses and other liabilities 7,304 (1,820) Operating lease liabilities (3,033) (3,881) Deferred revenue (70) (792) Net cash used in operating activities (78,884) (36,647) INVESTING ACTIVITIES: Purchases of marketable securities (126,163)(465,302) Maturity of marketable securities 418,110 197,548 Purchase of non-marketable equity and other related investments (12,750) 0 Purchases of property and equipment (28,261) (19,105) Purchase of intangible assets and capitalized license obligations 0 (17,886) Net cash provided by (used in) investing activities 250,936 (304,745) FINANCING ACTIVITIES: Payments made on finance lease obligations (91) (79) Proceeds from issuance of common stock upon exercise of stock options 5,388 3,548 Proceeds from issuances of common stock under employee stock purchase plan 5,401 3,956 Taxes paid related to net share settlement of restricted stock units (74,958) 0 Proceeds from public offering, net of underwriting discounts and commissions 0 355,730 Payment of offering costs related to public offering 0 (369) Payment of offering costs related to borrowings on convertible senior notes (784) 0 Net cash (used in) provided by financing activities (65,044) 362,786 Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash (1,080) 49

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Net increase in cash, cash equivalents and restricted cash 105,928 21,443 Cash and cash equivalents—Beginning of period 832,977 143,228 Cash, cash equivalents and restricted cash—End of period 938,905 164,671 Supplemental Disclosures of Cash Flow Information: Operating lease liabilities arising from obtaining right-of-use assets 170,911 11,373 Supplemental Disclosures of Noncash Investing and Financing Activities: Purchases of property and equipment included in accounts payable and accrued expenses 10,289 5,396 Issuance costs related to purchase of non-marketable equity and other related investments 587 0 included in accounts payable and accrued expenses Follow-on public offering issuance costs included in accounts payable and accrued expenses 0 761 Property and equipment acquired under finance leases 236 0 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents 938,590 164,671 Restricted cash – included in other assets, net 315 0 Total cash, cash equivalents and restricted cash $ $ 938,905 164,671

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Description of Business Jun. 30, 2021 Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Description of BusinessGuardant Health, Inc. (the “Company”) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a liquid or tissue biopsy. The Guardant Health Oncology Platform is designed to leverage the Company’s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company provides its Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. In February 2021, the Company launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to first address the need in Stage II-III colorectal cancer. In June 2021, the Company launched Guardant360 TissueNext, the Company's first tissue-based test which will be used to identify patients with advanced cancer who may benefit from biomarker-informed treatment, and Guardant360 Response which will be used to measure early indications to patients' response to treatment up to eight weeks earlier than response evaluation criteria in solid tumors. The Company is also developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's tests, the Company has also developed the GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker- driven cancers.The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the “Joint Venture”) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (“SoftBank”). Under the terms of the joint venture agreement, the Company holds a 50% ownership interest in the Joint Venture. As of June 30, 2021, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, Investment in Joint Venture) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Summary of Significant 6 Months Ended Accounting Policies Jun. 30, 2021 Accounting Policies [Abstract] Summary of Significant Summary of Significant Accounting Policies Accounting Policies Basis of Presentation

Use of Estimates

marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

Unaudited Interim Condensed Financial Statements

The accompanying condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations for the three and six months ended June 30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders’ equity for the three and six months ended June 30, 2021, and 2020, and cash flows for the six months ended June 30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with GAAP. Interim- period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.

Foreign Currency

Restricted Cash

Non-Marketable Securities

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The Company acquires certain equity investments in private companies to promote business and strategic objectives. The Company's investments in non-marketable equity securities do not give the Company the ability to control or exercise significant influence over the investee. The Company's non-marketable equity and other related investments totaled $13.3 million as of June 30, 2021, and are included in other assets, net on the accompanying condensed consolidated balance sheets. The Company did not have such non-marketable equity and other related investments as of December 31, 2020. Non-marketable securities are subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions. The Company's evaluation of impairment of such non-marketable securities is based on adverse changes in market conditions and the regulatory or economic environment, qualitative and quantitative analysis of the operating performance of the investee; changes in operating structure or management of the investee; additional funding requirements; and the investee’s ability to remain in business.

Concentration of Risk

Revenue Accounts Receivable, Net

Three Months Ended June 30, Six Months Ended June 30,

2021 2020 2021 2020 June 30, 2021 December 31, 2020

(unaudited) (unaudited) Customer A * * * 14 % * 11 % Customer B 29 % 23 % 27 % 21 % * 13 % Customer C * 10 % * * * 12 % Customer D * * * * 16 % 11 %

* less than 10%

The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third- party in relation to the settlement of a patent dispute reached in August 2020 for $8.0 million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0 million. The Company has evaluated and recorded a credit loss for the remaining $7.0 million considering the third-party's credit worthiness and lack of financial history. The following table presents the receivable and the related credit loss amounts:

Three and Six Months Ended June 30, 2021

Charged to (Reversed from) December 31, Beginning Other Income December 31, June 30, 2021 2020 Balance (Expense), Net Reclassi-fication Ending Balance June 30, 2021 2020

(unaudited) (unaudited) (unaudited)

(in thousand) Prepaid expenses and other current assets $ 1,100 $ — $ — $ — $ (1,100) $ (1,100) $ — $ — Other assets 5,900 7,000 (7,000) — 1,100 (5,900) — $ —

Accounts Receivable, Net

Asset Acquisition

Goodwill and Intangible Assets, net

Intangible assets related to in-process research and development costs (“IPR&D”) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.

Leases

Convertible Senior Notes

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net.

Revenue Recognition

Precision oncology testing

Development services and other

Contracts with multiple performance obligations

Deferred revenue

Transaction price allocated to the remaining performance obligations

Costs of Precision Oncology Testing

Cost of Development Services and Other

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Cost of development service and other primarily includes costs incurred for the performance of development services requested by the Company’s biopharmaceutical customers and other revenues included as noted above. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services and other.

Research and Development Expenses

Stock-Based Compensation

For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.

Net Loss Per Share Attributable to Common Stockholders

Accounting Pronouncements Adopted

Convertible Instruments and Contracts in an Entity’s Own Equity

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Investment in Joint Venture Jun. 30, 2021 Equity Method Investments and Joint Ventures [Abstract] Investment in Joint Venture Investment in Joint Venture Variable Interest Entity (“VIE”)

Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to 89,000,000 shares consisting of 80,000,000 shares of Class A common stock and 9,000,000 shares of Class B (non- voting) common stock; and authorized 80,000,000 shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for 1,000 shares of Series A preferred stock. As a result, each of the Company and the affiliate of

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document over the Company’s general credit or assets. Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of June 30, 2021, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.

Put-call arrangements

The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration. The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company’s control and has been classified outside of permanent equity in the consolidated balance sheets.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company’s initial public offering (the “IPO”) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 6 Months Ended Balance Sheet Components Jun. 30, 2021 Balance Sheet Related Disclosures [Abstract] Condensed Consolidated Condensed Consolidated Balance Sheet Components Balance Sheet Components Property and Equipment, Net

Property and equipment, net consist of the following:

June 30, 2021 December 31, 2020

Accrued Expenses

Accrued expenses consist of the following:

June 30, 2021 December 31, 2020

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value Measurements, 6 Months Ended Cash Equivalents and Jun. 30, 2021 Marketable Securities Fair Value Disclosures [Abstract] Fair Value Measurements, Fair Value Measurements, Cash Equivalents and Marketable Securities Cash Equivalents and Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued Marketable Securities expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

June 30, 2021

Fair Value Level 1 Level 2 Level 3

(unaudited) (in thousands) Financial Assets: Money market funds $ 838,114 $ 838,114 $ — $ — Total cash equivalents $ 838,114 $ 838,114 $ — $ —

U.S. government debt securities $ 853,072 $ — $ 853,072 $ — Total short-term marketable securities $ 853,072 $ — $ 853,072 $ —

U.S. government debt securities $ 55,368 $ — $ 55,368 $ — Total long-term marketable securities $ 55,368 $ — $ 55,368 $ — Total $ 1,746,554 $ 838,114 $ 908,440 $ —

Financial Liabilities: Contingent consideration $ 2,120 $ — $ — $ 2,120 Total $ 2,120 $ — $ — $ 2,120

Fair Value Level 1 Level 2 Level 3

(in thousands) Financial Assets: Money market funds $ 620,630 $ 620,630 $ — $ — Total cash equivalents $ 620,630 $ 620,630 $ — $ —

U.S. government debt securities $ 961,902 $ — $ 961,902 $ — Total short-term marketable securities $ 961,902 $ — $ 961,902 $ —

U.S. government debt securities $ 246,597 $ — $ 246,597 $ — Total long-term marketable securities $ 246,597 $ — $ 246,597 $ — Total $ 1,829,129 $ 620,630 $ 1,208,499 $ —

Financial Liabilities: Contingent consideration $ 1,245 $ — $ — $ 1,245 Total $ 1,245 $ — $ — $ 1,245

The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/ dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.

Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations. As of June 30, 2021, and December 31, 2020, contingent consideration liability of $2.1 million and $1.2 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets.

The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June 30, 2021, and 2020:

Redeemable Noncontrolling Interest Contingent Consideration

Three Months Ended June 30, Six Months Ended June 30, Three Months Ended June 30, Six Months Ended June 30,

2021 2020 2021 2020 2021 2020 2021 2020

(unaudited)

Fair value — end of period $ 59,400 $ 50,400 $ 59,400 $ 50,400 $ 2,120 $ 1,175 $ 2,120 $ 1,175

Cash Equivalents and Marketable Securities

Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value

(unaudited) (in thousands) Money market fund $ 838,114 $ — $ — $ 838,114 U.S. government debt securities 907,832 613 (5) 908,440 Total $ 1,745,946 $ 613 $ (5) $ 1,746,554

December 31, 2020

Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value

(in thousands) Money market fund $ 620,630 $ — $ — $ 620,630 U.S. government debt securities 1,206,195 2,339 (35) 1,208,499 Total $ 1,826,825 $ 2,339 $ (35) $ 1,829,129

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Patent License Acquisition Jun. 30, 2021 Business Combinations [Abstract] Patent License Acquisition Patent License Acquisition In January 2017, the Company entered into a license agreement with a biotechnology company, KeyGene N.V. (“KeyGene”). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the “SPLA”) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene’s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $18.5 million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $0.6 million of certain capitalizable transaction costs, was allocated to various components of the SPLA.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Intangible Assets, Net and 6 Months Ended Goodwill Jun. 30, 2021 Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, Net and Intangible Assets, Net and Goodwill Goodwill The following table presents details of purchased intangible assets as of June 30, 2021, and December 31, 2020:

June 30, 2021

Gross Carrying Accumulated Remaining Weighted Amount Amortization Net Carrying Amount Average Useful Life

December 31, 2020

Gross Carrying Accumulated Remaining Weighted Amount Amortization Net Carrying Amount Average Useful Life

The following table summarizes estimated future amortization expense of finite-lived intangible assets—net:

Year Ending December 31, (unaudited) (in thousands) Remainder of 2021 $ 982 2022 1,947 2023 1,947 2024 1,952 2025 1,705 2026 and thereafter 5,056 Total $ 13,589

Convertible Senior Notes

Before August 15, 2027, holders of the 2027 Notes will have the right to convert their 2027 Notes only under the following circumstances:

• upon the occurrence of specified corporate events

The Company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election.

The initial conversion rate is 7.1523 shares of common stock per $1,000 principal amount of 2027 Notes, which represents an initial conversion price of approximately $139.82 per share of common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.

of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.

Since the 2027 Notes were not convertible as of June 30, 2021, the net carrying amount of the 2027 Notes was classified as a long-term liability.

The following table sets forth the components of the 2027 Notes as of June 30, 2021, and December 31, 2020:

Equity component recorded at issuance: 2027 Notes $ — $ 335,667 Less: issuance costs — (5,264) Net amount recorded in equity $ — $ 330,403

The interest expense recognized in relation to amortization of debt issuance costs was $0.6 million and $1.3 million for the three and six months ended June 2021, which represented an effective interest rate of 0.2% and 0.2% and for the three and six months ended June 2021.

Note Hedges

Company’s common stock of $104.34 per share on November 16, 2020, and is subject to certain adjustments under the terms of the 2027 Note Hedges.

The 2027 Note Hedges will expire upon maturity of the 2027 Notes. The 2027 Note Hedges are separate transactions and are not part of the terms of the 2027 Notes. Holders of the 2027 Notes will not have any rights with respect to the 2027 Note Hedges. The shares receivable related to the 2027 Note Hedges are excluded from the calculation of diluted earnings per share as they are anti-dilutive. As these transactions meet certain accounting criteria, the 2027 Note Hedges are recorded in stockholders’ equity and are not accounted for as derivatives. The Company paid an aggregate amount of $90.0 million for the 2027 Note Hedges, which has been recorded as a reduction to additional paid-in capital and will not be remeasured.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Leases Jun. 30, 2021 Leases [Abstract] Leases Leases The Company has entered into various operating lease agreements for office space, data center, lab and warehouse use, with remaining terms ranging from 1 year to 12 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement. In July 2020, the Company entered into two lease agreements for additional office space in Palo Alto, California ("Palo Alto Lease") and in San Diego, California ("San Diego Lease"). The San Diego Lease has a term of 8 years with rent payments commencing in May 2022. The Palo Alto Lease has a term of 12 years with an option to renew the lease term for an additional ten years which has not been considered in the determination of ROU or the lease liability as the Company does not consider it reasonably certain of exercising the renewal option. Rent payments for the Palo Alto Lease will commence in October 2021. Both leases consist of fixed and variable payments and are being accounting for as operating leases. The Company took possession of these facilities in March 2021. The Company estimated the incremental borrowing rate to determine the present value of lease payments for the San Diego and Palo Alto leases using trading data of the Company's convertible debt adjusted for credit rating and market yield curves.

June 30, 2021 December 31, 2020

(unaudited) Weighted-average remaining lease term (in years) 10.3 5.5 Weighted-average discount rate 4.14 % 8.07 %

The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of June 30, 2021:

Finance leases are not material to the Company's condensed consolidated financial statements.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Commitments and 6 Months Ended Contingencies Jun. 30, 2021 Commitments and Contingencies Disclosure [Abstract] Commitments and Commitments and Contingencies Contingencies Legal Proceedings

Patent Disputes

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document parties are seeking damages, injunctive relief and attorneys’ fees. Discovery in the lawsuit has closed, and a number of pre-trial motions were filed in September and October 2020.

False Advertising Dispute In May 2021, the Company also filed a lawsuit against Natera, Inc. (“Natera”) in the United States District Court for the Northern District of California, wherein the Company alleged that Natera is misleading healthcare providers about the performance of the Company’s new oncology test, Guardant Reveal, by suggesting the test is inaccurate and/or insensitive, and inferior to Natera’s Signatera assay. The Company is seeking a Preliminary Injunction to prevent Natera from continuing to make false and misleading statements and to require Natera to take corrective actions. Natera has asserted counterclaims of false and misleading statements, false advertising, unlawful trade practices and unfair competition.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Common Stock Jun. 30, 2021 Equity [Abstract] Common Stock Common StockThe Company’s common stockholders are entitled to dividends if and when declared by the Company’s Board of Directors (the “Board of Directors”). As of June 30, 2021 and December 31, 2020, no dividends on the Company's common stock had been declared by the Board of Directors. The Company’s common stock has been reserved for the following potential future issuances:

June 30, 2021 December 31, 2020

Follow-on Public Offering

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Stock-Based Compensation Jun. 30, 2021 Share-based Payment Arrangement [Abstract] Stock-Based Compensation Stock-Based Compensation Stock Option Activity

Options Outstanding

Weighted-Average Remaining Shares Shares Subject to Weighted-Average Contractual Life Aggregate Intrinsic Available for Grant Options Outstanding Exercise Price (Years) Value

(unaudited) (in thousands) Balance as of December 31, 2020 1,819,223 3,101,181 $ 15.80 6.9 $ 350,670

Vested and Exercisable as of June 30, 2021 2,091,339 $ 9.16 6.1 $ 240,569

Future stock-based compensation for unvested options as of June 30, 2021 was $19.7 million, which is expected to be recognized over a weighted-average period of 2.7 years.

Restricted Stock Units

Restricted Stock Units Weighted-Average Grant Outstanding Date Fair Value

(unaudited) Balance as of December 31, 2020 1,118,655 $ 92.89 Granted 177,166 154.94 Vested and released (46,376) 80.32 Canceled (94,075) 92.67 Balance as of June 30, 2021 1,155,370 $ 102.93

Future stock-based compensation for unvested restricted stock units as of June 30, 2021, was $98.1 million, which is expected to be recognized over a weighted-average period of 3.1 years.

A summary of the Company’s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:

Performance-based Restricted Stock Units Weighted-Average Grant Outstanding Date Fair Value

(unaudited) Balance as of December 31, 2020 377,922 $ 113.40 Granted 52,917 135.94 Canceled (15,304) 113.40 Balance as of June 30, 2021 415,535 $ 116.27

Stock-based compensation recorded for the PSUs for the three and six months ended June 30, 2021 was $0.3 million and $0.7 million, respectively. Future stock-based compensation for unvested PSUs that are probable to vest as of June 30, 2021 was $4.9 million, which is expected to be recognized over a weighted-average period of 3.6 years.

Market-based Restricted Stock Units

In May 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units (“MSUs”) under the 2018 Plan to each of the Company's Chief Executive Officer and the Company's President and Chief Operating Officer, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of six to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. The following table presents additional information relating to each MSU award:

Tranche Price Goal Number of RSUs Tranche 1 $120 per share 565,192 Tranche 2 $150 per share 565,191 Tranche 3 $200 per share 565,191

Market-based Restricted Weighted-Average Grant Stock Units Outstanding Date Fair Value

(unaudited) Balance as of December 31, 2020 3,391,148 $ 67.00 Vested and released (572,130) 70.58 Canceled (1) (558,254) 70.58 Balance as of June 30, 2021 2,260,764 $ 65.20

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document (1) Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.

For the three and six months ended June 30, 2021, stock-based compensation for the MSUs was $22.3 million and $66.3 million, respectively, which was recorded in general and administrative expenses on the condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of June 30, 2021 was $49.0 million, which is expected to be recognized over a weighted-average period of 0.8 years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration.

AMEA 2020 Equity Incentive Plan

In August 2020, the board of directors of the Joint Venture approved its 2020 Equity Incentive Plan (the “AMEA 2020 Plan”), under which the Joint Venture may grant equity incentive awards such as stock options, restricted stock, restricted stock units, stock appreciation rights and cash-based awards to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to employees of the Joint Venture or its affiliates. Nonstatutory stock options may be granted to employees, directors and non-employee consultants. Stock options may be granted at an exercise price of not less than the fair market value of the Joint Venture's common stock on the date of grant, determined by the board of directors of the Joint Venture. Options generally vest over 4 years and expire as determined by the board of directors of the Joint Venture, provided that the term of options may not exceed 10 years from the date of grant. For individuals holding more than 10% of the total combined voting power of all classes of stock of the Joint Venture, the exercise price of an option will not be less than 110% of the fair market value of the Joint Venture's common stock on the date of grant, and the term of the option will not exceed 5 years. A total of 4,595,555 shares of the Joint Venture's Class B common stock are initially reserved for issuance under the AMEA 2020 Plan, and the number of shares may be increased in accordance with the terms of the AMEA 2020 Plan.

A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:

Options Outstanding

Weighted-Average Remaining Shares Shares Subject to Weighted-Average Contractual Life Aggregate Intrinsic Available for Grant Options Outstanding Exercise Price (Years) Value

Vested and Exercisable as of June 30, 2021 2,352,180 $ 0.58 9.1 $ —

Stock-Based Compensation Expense

The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

Valuation of Stock Options

The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Venture:

2021 2020 2021 2020

Fair Value of Common Stock

Expected Term

Expected Volatility

Risk-Free Interest Rate

The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.

Expected Dividend Yield

The Company and the Joint Venture does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.

Valuation of MSUs

Expected Volatility

Expected Term

The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model.

Risky Rate

The risky rate represents the Company's cost of equity.

Discount for Lack of Marketability

The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of 0.83 – 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.53%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% – 14.5%.

2018 Employee Stock Purchase Plan

$1.1 million for the three months ended June 30, 2021 and 2020, respectively, and $1.6 million and $1.6 million for the six months ended June 30, 2021 and 2020, respectively.

The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period.

The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

Three and Six Months Ended June 30,

2021 2020

(unaudited) Expected term (in years) 0.5 0.5 Expected volatility 50.8% 73.2% Risk-free interest rate —% 0.2% Expected dividend yield —% —%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Net Loss Per Share 6 Months Ended Attributable to Guardant Health, Inc. Common Jun. 30, 2021 Stockholders Earnings Per Share [Abstract] Net Loss Per Share Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders Attributable to Guardant The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders: Health, Inc. Common Stockholders Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been antidilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Income Taxes Jun. 30, 2021 Income Tax Disclosure [Abstract] Income Taxes Income Taxes The income tax expense for the three and six months ended June 30, 2021 was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. The difference between the Company’s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.

The income tax expense for the three and six months ended June 30, 2021 and 2020 relates primarily to state minimum income tax and income tax on the Company’s earnings in foreign jurisdictions.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Segment and Geographic 6 Months Ended Information Jun. 30, 2021 Segment Reporting [Abstract] Segment and Geographic Segment and Geographic Information Information The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations:

Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) (in thousands) United States $ 87,868 $ 61,422 $ 160,168 $ 126,035

International (1) 4,233 4,913 10,598 7,810 Total revenue $ 92,101 $ 66,335 $ 170,766 $ 133,845

(1) No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June 30, 2021 and 2020, respectively.

As of June 30, 2021 and December 31, 2020, 98% and 94%, respectively, of the Company’s long-lived assets and right-of-use assets are located in the United States.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Related Party Transactions Jun. 30, 2021 Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions As discussed in Note 3, Investment in Joint Venture, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Subsequent Events Jun. 30, 2021 Subsequent Events [Abstract] Subsequent Events Subsequent EventsPursuant to a shares subscription agreement entered into in June 2021, the Company acquired $26 million of non-marketable securities in July 2021.

Use of Estimates Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock- based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non- marketable securities, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. The extent to which the coronavirus 2019, or COVID-19 pandemic will ultimately impact the Company’s business, results of operations, financial conditions, or cash flows continues to be highly uncertain. The severity of the impact on the Company's business for the remainder of calendar year 2021 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted. Unaudited Interim Condensed Unaudited Interim Condensed Financial Statements Financial Statements The accompanying condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations for the three and six months ended June 30, 2021, and 2020, the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021, and 2020, the condensed consolidated statements of redeemable noncontrolling interest and stockholders’ equity for the three and six months ended June 30, 2021, and 2020, and cash flows for the six months ended June 30, 2021, and 2020, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company’s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.

Foreign Currency Foreign Currency The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders’ equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June 30, 2021, and 2020, foreign currency transaction gains and losses were immaterial. Concentration of Risk Concentration of Risk

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.

The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount. The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached in August 2020 for $8.0 million payable over a period of 6 years. In December 2020, the Company received the first installment payment of $1.0 million. The Company has evaluated and recorded a credit loss for the remaining $7.0 million considering the third-party's credit worthiness and lack of financial history. Accounts Receivable, Net Accounts Receivable, Net

Asset Acquisition Asset Acquisition

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.

Goodwill and Intangible Goodwill and Intangible Assets, net Assets, net Intangible assets related to in-process research and development costs (“IPR&D”) acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we

become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.

Leases Leases

The Company determines if an arrangement contains a lease at inception. Operating lease right- of-use (“ROU”) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received or receivable. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company’s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.

Convertible Senior Notes Convertible Senior Notes

In accounting for the issuance of the convertible senior notes, the Company separates the notes into liability and equity components. The carrying amount of the liability component is calculated by

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document measuring the fair value of a similar liability that does not have an associated convertible feature, using a discounted cash flow model with a risk adjusted yield. The carrying amount of the equity component representing the conversion option is determined by deducting the fair value of the liability component from the par value of the notes as a whole. This difference represents a debt discount that is amortized to interest expense using the effective interest method over the term of the notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. In accounting for the transaction costs related to the issuance of the notes, the Company allocated the total amount incurred to the liability and equity components based on their relative fair values. Transaction costs attributable to the liability component are netted with the liability component and amortized to interest expense using the effective interest method over the term of the notes. Transaction costs attributable to the equity component are netted with the equity component of the notes in additional paid-in capital in the condensed consolidated balance sheets. Starting January 1, 2021, upon early adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, the carrying amount of the equity component of the cash conversion feature including the allocated debt issuance costs were reclassified from additional paid-in capital to convertible senior notes, net. In accounting for the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated using a Black-Scholes model by measuring the fair value of a similar instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes as a whole. This difference represents a debt discount that is amortized as interest expense using an effective interest over the term of the 2027 Notes. Effective January 1, 2021, the Company early adopted ASU 2020-06 which resulted in the re-classification of the equity component representing the associated convertible feature and the related debt issuance costs into long-term liabilities with a corresponding impact to retained earnings. Revenue Recognition Revenue Recognition

Precision oncology testing

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2021, and 2020, the Company recorded $9.6 million and $9.1 million as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments. For the six months ended June 30, 2021, and 2020, the Company recorded $14.6 million and $16.5 million as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration related to samples processed in previous periods, including revenue received from successful appeals of reimbursement denials, net of recoupments.

Development services and other

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is assessed and updated at each reporting period as a revision to the estimated transaction price.

Contracts with multiple performance obligations

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.

Deferred revenue

Transaction price allocated to the remaining performance obligations

Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months. Costs of Precision Oncology Costs of Precision Oncology Testing Testing Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document and information technology costs. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.

Cost of Development Services Cost of Development Services and Other

Research and Development Research and Development Expenses Expenses Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company’s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.

Stock-Based Compensation Stock-Based Compensation

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document service period, the stock-based compensation expense will be accelerated, and a cumulative catch- up expense will be recorded during the period in which the market condition is met. The Company measures the grant date fair value of its service-based and performance-based restricted stock units issued to employees based on the closing market price of the common stock on the date of grant. For restricted stock units with only service-based vesting conditions, compensation expense is recognized in the Company’s condensed consolidated statement of operations on a straight-line basis over the requisite service period. Compensation expense for restricted stock units with performance metrics is calculated based upon expected achievement of the metrics specified in the grant, and is recognized in the Company’s condensed consolidated statement of operations using an accelerated attribution model over the requisite service period for each separately vesting portion of the award. Net Loss Per Share Net Loss Per Share Attributable to Common Stockholders Attributable to Common Shareholders The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method or the as-if converted method, as appropriate. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares under the convertible senior notes are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.

Accounting Pronouncements Accounting Pronouncements Adopted Adopted Convertible Instruments and Contracts in an Entity’s Own Equity

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document feature including the allocated debt issuance costs as of December 31, 2020 from additional paid- in capital to convertible senior notes, net.

Fair Value Measurements Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, net, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, net, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Summary of Significant 6 Months Ended Accounting Policies (Tables) Jun. 30, 2021 Accounting Policies [Abstract] Schedules of Concentration of A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company’s total revenue or accounts receivable balance. Risk, by Risk Factor Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:

Revenue Accounts Receivable, Net

Three Months Ended June 30, Six Months Ended June 30,

2021 2020 2021 2020 June 30, 2021 December 31, 2020

(unaudited) (unaudited) Customer A * * * 14 % * 11 % Customer B 29 % 23 % 27 % 21 % * 13 % Customer C * 10 % * * * 12 % Customer D * * * * 16 % 11 %

* less than 10%

Schedule of Contractual The following table presents the receivable and the related credit loss amounts: Receivables and Related Gross Amount Allowance for Credit Losses Net Amount Credit Loss Three and Six Months Ended June 30, 2021

Charged to (Reversed from) December 31, Beginning Other Income December 31, June 30, 2021 2020 Balance (Expense), Net Reclassi-fication Ending Balance June 30, 2021 2020

(unaudited) (unaudited) (unaudited)

(in thousand) Prepaid expenses and other current assets $ 1,100 $ — $ — $ — $ (1,100) $ (1,100) $ — $ — Other assets 5,900 7,000 (7,000) — 1,100 (5,900) — $ —

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 6 Months Ended Balance Sheet Components Jun. 30, 2021 (Tables) Balance Sheet Related Disclosures [Abstract] Schedule of Property, Plant Property and equipment, net consist of the following: and Equipment June 30, 2021 December 31, 2020

Schedule of Accrued Accrued expenses consist of the following: Liabilities June 30, 2021 December 31, 2020

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value Measurements, 6 Months Ended Cash Equivalents and Marketable Securities Jun. 30, 2021 (Tables) Fair Value Disclosures [Abstract] Schedule of Fair Value The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such Measurements, Recurring and measurements were as follows: Nonrecurring June 30, 2021

Fair Value Level 1 Level 2 Level 3

(unaudited) (in thousands) Financial Assets: Money market funds $ 838,114 $ 838,114 $ — $ — Total cash equivalents $ 838,114 $ 838,114 $ — $ —

U.S. government debt securities $ 853,072 $ — $ 853,072 $ — Total short-term marketable securities $ 853,072 $ — $ 853,072 $ —

U.S. government debt securities $ 55,368 $ — $ 55,368 $ — Total long-term marketable securities $ 55,368 $ — $ 55,368 $ — Total $ 1,746,554 $ 838,114 $ 908,440 $ —

Financial Liabilities: Contingent consideration $ 2,120 $ — $ — $ 2,120 Total $ 2,120 $ — $ — $ 2,120

December 31, 2020

Fair Value Level 1 Level 2 Level 3

(in thousands) Financial Assets: Money market funds $ 620,630 $ 620,630 $ — $ — Total cash equivalents $ 620,630 $ 620,630 $ — $ —

U.S. government debt securities $ 961,902 $ — $ 961,902 $ — Total short-term marketable securities $ 961,902 $ — $ 961,902 $ —

U.S. government debt securities $ 246,597 $ — $ 246,597 $ — Total long-term marketable securities $ 246,597 $ — $ 246,597 $ — Total $ 1,829,129 $ 620,630 $ 1,208,499 $ —

Financial Liabilities: Contingent consideration $ 1,245 $ — $ — $ 1,245 Total $ 1,245 $ — $ — $ 1,245

Schedule of Level 3 Activity The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June 30, 2021, and 2020:

Three Months Ended June 30, Six Months Ended June 30, Three Months Ended June 30, Six Months Ended June 30,

2021 2020 2021 2020 2021 2020 2021 2020

(unaudited)

Fair value — end of period $ 59,400 $ 50,400 $ 59,400 $ 50,400 $ 2,120 $ 1,175 $ 2,120 $ 1,175

Schedule of Debt Securities, The following tables summarizes the Company’s cash equivalents and marketable securities’ amortized costs, gross unrealized gains, gross unrealized losses and estimated Available-for-sale fair values by significant investment category:

June 30, 2021

Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value

(unaudited) (in thousands) Money market fund $ 838,114 $ — $ — $ 838,114 U.S. government debt securities 907,832 613 (5) 908,440 Total $ 1,745,946 $ 613 $ (5) $ 1,746,554

December 31, 2020

Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value

(in thousands) Money market fund $ 620,630 $ — $ — $ 620,630 U.S. government debt securities 1,206,195 2,339 (35) 1,208,499 Total $ 1,826,825 $ 2,339 $ (35) $ 1,829,129

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Intangible Assets, Net and 6 Months Ended Goodwill (Tables) Jun. 30, 2021 Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived The following table presents details of purchased intangible assets as of June 30, 2021, and December 31, 2020: Intangible Assets June 30, 2021

Gross Carrying Accumulated Remaining Weighted Amount Amortization Net Carrying Amount Average Useful Life

December 31, 2020

Gross Carrying Accumulated Remaining Weighted Amount Amortization Net Carrying Amount Average Useful Life

Schedule of Indefinite-Lived The following table presents details of purchased intangible assets as of June 30, 2021, and December 31, 2020: Intangible Assets June 30, 2021

Gross Carrying Accumulated Remaining Weighted Amount Amortization Net Carrying Amount Average Useful Life

Schedule of Finite-Lived The following table summarizes estimated future amortization expense of finite-lived intangible assets—net: Intangible Assets, Future Amortization Expense Year Ending December 31, (unaudited) (in thousands) Remainder of 2021 $ 982 2022 1,947 2023 1,947 2024 1,952 2025 1,705 2026 and thereafter 5,056 Total $ 13,589

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Debt (Tables) Jun. 30, 2021 Debt Disclosure [Abstract] Schedule of Long-term Debt The following table sets forth the components of the 2027 Notes as of June 30, 2021, and December 31, 2020: Instrument Components June 30, 2021 December 31, 2020

Equity component recorded at issuance: 2027 Notes $ — $ 335,667 Less: issuance costs — (5,264) Net amount recorded in equity $ — $ 330,403

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Leases (Tables) Jun. 30, 2021 Leases [Abstract] Lease Information June 30, 2021 December 31, 2020

(unaudited) Weighted-average remaining lease term (in years) 10.3 5.5 Weighted-average discount rate 4.14 % 8.07 %

Schedule of Operating Lease The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of June 30, 2021: Liability Maturities Year Ending December 31, (unaudited) (in thousands) Remainder of 2021 $ 5,398 2022 21,454 2023 28,976 2024 31,529 2025 32,084 2026 and thereafter 177,402 Total operating lease payments $ 296,843 Less: imputed interest (54,792) Less: lease incentives (22,721) Total operating lease liabilities $ 219,330

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Common Stock (Tables) Jun. 30, 2021 Equity [Abstract] Schedule of Stock by Class The Company’s common stock has been reserved for the following potential future issuances:

June 30, 2021 December 31, 2020

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-Based Compensation 6 Months Ended (Tables) Jun. 30, 2021 Share-based Payment Arrangement [Abstract] Schedule of Share-based A summary of the Company’s stock option activity under the 2012 Stock Plan (as amended and restated, the “2012 Plan”) and the 2018 Incentive Award Plan (the “2018 Compensation, Stock Options, Plan”) and related information is as follows: Activity Options Outstanding

Weighted-Average Remaining Shares Shares Subject to Weighted-Average Contractual Life Aggregate Intrinsic Available for Grant Options Outstanding Exercise Price (Years) Value

(unaudited) (in thousands) Balance as of December 31, 2020 1,819,223 3,101,181 $ 15.80 6.9 $ 350,670

Vested and Exercisable as of June 30, 2021 2,091,339 $ 9.16 6.1 $ 240,569

A summary of the Joint Venture's stock option activity under the AMEA 2020 Plan and related information is as follows:

Options Outstanding

Weighted-Average Remaining Shares Shares Subject to Weighted-Average Contractual Life Aggregate Intrinsic Available for Grant Options Outstanding Exercise Price (Years) Value

Vested and Exercisable as of June 30, 2021 2,352,180 $ 0.58 9.1 $ —

Schedule of Restricted Stock A summary of the Company’s restricted stock unit activity excluding the performance-based and market-based restricted stock units under the 2012 Plan and the 2018 Plan Activity and related information is as follows:

(unaudited) Balance as of December 31, 2020 1,118,655 $ 92.89 Granted 177,166 154.94 Vested and released (46,376) 80.32 Canceled (94,075) 92.67 Balance as of June 30, 2021 1,155,370 $ 102.93

A summary of the Company’s performance-based restricted stock unit activity under the 2018 Plan and related information is as follows:

Performance-based Restricted Stock Units Weighted-Average Grant Outstanding Date Fair Value

(unaudited) Balance as of December 31, 2020 377,922 $ 113.40 Granted 52,917 135.94 Canceled (15,304) 113.40 Balance as of June 30, 2021 415,535 $ 116.27

A summary of the Company’s market-based restricted stock unit activity under the 2018 Plan and related information is as follows:

Market-based Restricted Weighted-Average Grant Stock Units Outstanding Date Fair Value

(unaudited) Balance as of December 31, 2020 3,391,148 $ 67.00 Vested and released (572,130) 70.58 Canceled (1) (558,254) 70.58 Balance as of June 30, 2021 2,260,764 $ 65.20

(1) Represented shares withheld by the Company for MSU holders' tax obligation upon release of vested MSUs.

Schedule of Performance- Tranche Price Goal Number of RSUs based Restricted Stock Units Tranche 1 $120 per share 565,192 Vesting Conditions Tranche 2 $150 per share 565,191 Tranche 3 $200 per share 565,191 The following table presents additional information relating to each MSU award: Schedule of Compensation The following table presents the effect of employee and non-employee related stock-based compensation expense including the Joint Venture: Cost for Share-based Payment Arrangements, Allocation of Three Months Ended Six Months Ended Share-based Compensation June 30, June 30, Costs by Plan 2021 2020 2021 2020

Schedule of Share-based Payment Award, Employee The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions including the Joint Stock Purchase Plan, Valuation Venture: Assumptions

2021 2020 2021 2020

The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

Three and Six Months Ended June 30,

2021 2020

(unaudited) Expected term (in years) 0.5 0.5 Expected volatility 50.8% 73.2% Risk-free interest rate —% 0.2% Expected dividend yield —% —%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Net Loss Per Share 6 Months Ended Attributable to Guardant Health, Inc. Common Jun. 30, 2021 Stockholders (Tables) Earnings Per Share [Abstract] Schedule of Earnings Per The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders: Share, Basic and Diluted Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

Schedule of Antidilutive The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Securities Excluded from Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect: Computation of Earnings Per Three Months Ended Six Months Ended Share June 30, June 30,

2021 2020 2021 2020

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Segment and Geographic 6 Months Ended Information (Tables) Jun. 30, 2021 Segment Reporting [Abstract] Schedule of Segment The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations: Reporting Information, by Segment Three Months Ended Six Months Ended June 30, June 30,

2021 2020 2021 2020

(unaudited) (in thousands) United States $ 87,868 $ 61,422 $ 160,168 $ 126,035

International (1) 4,233 4,913 10,598 7,810 Total revenue $ 92,101 $ 66,335 $ 170,766 $ 133,845

(1) No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June 30, 2021 and 2020, respectively.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Description of Business May 31, 2018 (Details) Guardant Health AMEA, Inc Subsidiary, Sale of Stock [Line Items] Ownership interest in joint venture 50.00%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 1 Months Ended 3 Months Ended 6 Months Ended Summary of Significant Jun. 30, Accounting Policies - Dec. 31, Aug. 31, Jun. 30, Jun. 30, Jun. 30, 2021 Narrative (Details) 2020 2020 2021 2020 2020 USD ($) $ in Thousands USD ($) USD ($) USD ($) USD ($) USD ($) segment Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Restricted cash – included in other assets, net $ 315 $ 0 $ 315 $ 0 Restricted cash $ 0 Non-marketable equity and other investments 0 13,300 13,300 Impairment or adjustments of non-marketable securities 0 Other receivables and other assets due from a third-party $ 8,000 Other receivables and other assets, term 6 years Contractual receivables, installment payment 1,000 Contractual receivables, credit loss 7,000 0 0 Contract asset 15,600 24,800 $ 24,800 Number of operating segments | segment 1 Impairment of goodwill 0 $ 0 Impairment of intangible assets 0 Revenue from cash collections exceeding estimated 9,600 $ 9,100 14,600 16,500 variable consideration Deferred revenue 8,600 8,500 8,500 Deferred revenue recognized 6,400 $ 7,600 Guardant360CDx Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Contract asset 8,400 Collaborative Arrangement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Deferred revenue $ 3,000 $ 2,900 2,900 Deferred revenue recognized $ 3,000 Minimum Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Useful life (years) 6 years Maximum Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Useful life (years) 12 years

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Summary of Significant 12 Months 3 Months Ended 6 Months Ended Accounting Policies - Ended Schedule of Concentration Jun. 30, Jun. 30, Jun. 30, Jun. 30, Risk (Details) - Credit Dec. 31, 2020 2021 2020 2021 2020 Concentration Risk Customer A | Revenue Concentration Risk [Line Items] Concentration risk, percentage 14.00% Customer A | Accounts Receivable, Net Concentration Risk [Line Items] Concentration risk, percentage 11.00% Customer B | Revenue Concentration Risk [Line Items] Concentration risk, percentage 29.00% 23.00% 27.00% 21.00% Customer B | Accounts Receivable, Net Concentration Risk [Line Items] Concentration risk, percentage 13.00% Customer C | Revenue Concentration Risk [Line Items] Concentration risk, percentage 10.00% Customer C | Accounts Receivable, Net Concentration Risk [Line Items] Concentration risk, percentage 12.00% Customer D | Accounts Receivable, Net Concentration Risk [Line Items] Concentration risk, percentage 16.00% 11.00%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Summary of Significant 1 Months 3 Months 6 Months Accounting Policies - Ended Ended Ended Receivable and Related Credit Loss (Details) - USD Dec. 31, 2020 Jun. 30, 2021 Jun. 30, 2021 ($) $ in Thousands Accounting Policies [Abstract] Financing receivable, gross amount, current $ 0 $ 1,100 $ 1,100 Financing receivable, net amount, noncurrent 7,000 5,900 5,900 Allowance for Credit Losses Beginning balance, financing receivable, allowance for credit loss, 0 0 current Additions: charged to other income (expense), net, allowance for 0 0 credit loss, current Reclassification, allowance for credit loss, current (1,100) (1,100) Ending balance, financing receivable, allowance for credit loss, 0 (1,100) (1,100) current Beginning balance, financing receivable, allowance for credit loss, (7,000) (7,000) noncurrent Additions: charged to other income (expense), net, allowance for (7,000) 0 0 credit loss, noncurrent Reclassification, allowance for credit loss, noncurrent 1,100 1,100 Ending balance, financing receivable, allowance for credit loss, (7,000) (5,900) (5,900) noncurrent Financing receivable, net amount, current 0 0 0 Financing receivable, net amount, noncurrent $ 0 $ 0 $ 0

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Investment in Joint Venture 6 Months 1 Months Ended (Details) - USD ($) Ended $ / shares in Units, $ in Jun. 30, May 31, Dec. 31, Jun. 30, 2021 Thousands 2020 2018 2020 Schedule of Equity Method Investments [Line Items] Common stock, shares authorized (in shares) 350,000,000 350,000,000 Common stock, shares reserved for future issuance (in 13,939,220 11,344,620 shares) Common stock, shares issued (in shares) 101,265,100 100,213,985 Common stock, shares outstanding (in shares) 101,265,100 100,213,985 Assets [1] $ 2,291,885 $ 2,271,781 Threshold percentage of fair value that is no less than 20.00% internal rate of return Fair value of joint venture threshold 40.00% Variable Interest Entity Schedule of Equity Method Investments [Line Items] Assets $ 27,500 $ 35,000 Guardant Health AMEA, Inc Schedule of Equity Method Investments [Line Items] Payments to acquire interest in joint venture $ 9,000 Equity method investment, shares purchased (in shares) 40,000 Equity method investment, ownership percentage 50.00% Common stock, shares authorized (in shares) 89,000,000 Guardant Health AMEA, Inc | Class A Schedule of Equity Method Investments [Line Items] Common stock, shares authorized (in shares) 80,000,000 Common stock, shares issued (in shares) 0 0 Common stock, shares outstanding (in shares) 0 0 Guardant Health AMEA, Inc | Class B Schedule of Equity Method Investments [Line Items] Common stock, shares authorized (in shares) 9,000,000 Common stock, shares issued (in shares) 91,109 0 Common stock, shares outstanding (in shares) 91,109 0 Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan Schedule of Equity Method Investments [Line Items] Common stock, shares reserved for future issuance (in 4,595,555 shares) Guardant Health AMEA, Inc | Series A Schedule of Equity Method Investments [Line Items] Preferred stock, shares authorized (in shares) 80,000,000 Preferred stock issued (in shares) 80,000,000 80,000,000 Preferred stock dividend rate (in usd per share) $ 0.05 Preferred stock outstanding (in shares) 80,000,000 80,000,000 Guardant Health AMEA, Inc | Series A | SoftBank

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Schedule of Equity Method Investments [Line Items] Preferred stock issued (in shares) 40,000,000 Guardant Health AMEA, Inc | Series A | Guardant Health, Inc. Schedule of Equity Method Investments [Line Items] Preferred stock issued (in shares) 40,000,000 Guardant Health AMEA, Inc | SoftBank Schedule of Equity Method Investments [Line Items] Equity method investment, shares purchased (in shares) 40,000 Equity method investment, ownership percentage 50.00% Redeemable noncontrolling interest, redemption value $ 41,000 Guardant Health AMEA, Inc | SoftBank | Series A Schedule of Equity Method Investments [Line Items] Common stock reclassified and converted into preferred 1,000 stock (in shares) [1]As of June 30, 2021 and December 31, 2020, this balance includes $27.5 million and $35.0 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $3.8 million and $4.9 million, respectively, of liabilities of the consolidated VIE and VIE’s subsidiaries, for which their creditors do not have recourse to the general credit of the Company. See Note 3, Investment in Joint Venture.

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated Balance Sheet Components - Property, Plant and Jun. 30, 2021Dec. 31, 2020 Equipment (Details) - USD ($) $ in Thousands Property, Plant and Equipment [Line Items] Property and equipment, gross $ 134,008 $ 97,127 Less: accumulated depreciation (44,271) (34,345) Property and equipment, net 89,737 62,782 Machinery and equipment Property, Plant and Equipment [Line Items] Property and equipment, gross 50,960 40,216 Leasehold improvements Property, Plant and Equipment [Line Items] Property and equipment, gross 35,542 34,037 Computer hardware Property, Plant and Equipment [Line Items] Property and equipment, gross 15,929 10,862 Construction in progress Property, Plant and Equipment [Line Items] Property and equipment, gross 26,892 7,833 Furniture and fixtures Property, Plant and Equipment [Line Items] Property and equipment, gross 3,591 3,043 Computer software Property, Plant and Equipment [Line Items] Property and equipment, gross $ 1,094 $ 1,136

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated 3 Months Ended 6 Months Ended Balance Sheet Components - Narrative (Details) - USD ($) Jun. 30, 2021Jun. 30, 2020Jun. 30, 2021Jun. 30, 2020 $ in Millions Balance Sheet Related Disclosures [Abstract] Depreciation and amortization expense $ 5.1 $ 3.2 $ 9.6 $ 6.2

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) - Jun. 30, 2021Dec. 31, 2020 USD ($) $ in Thousands Balance Sheet Related Disclosures [Abstract] Operating lease liabilities $ 7,547 $ 6,632 Accrued tax liabilities 4,500 4,634 Accrued professional services 6,564 3,397 Accrued clinical trials and studies 2,625 1,264 Accrued legal expenses 2,081 2,875 Purchases of property and equipment included in accrued expenses 2,383 1,156 Accrued royalty obligations 179 146 Others 6,119 2,535 Total accrued expenses $ 31,998 $ 22,639

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Jun. 30, Dec. 31, Basis (Details) - Fair Value, 2021 2020 Measurements, Recurring - USD ($) $ in Thousands Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents $ 838,114 $ 620,630 Debt securities, short-term 853,072 961,902 Debt securities, long-term 55,368 246,597 Total assets 1,746,554 1,829,129 Initial fair value of contingent consideration at acquisition date 2,120 1,245 Financial and nonfinancial liabilities, fair value disclosure 2,120 1,245 Level 1 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 838,114 620,630 Debt securities, short-term 0 0 Debt securities, long-term 0 0 Total assets 838,114 620,630 Initial fair value of contingent consideration at acquisition date 0 0 Financial and nonfinancial liabilities, fair value disclosure 0 0 Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 0 0 Debt securities, short-term 853,072 961,902 Debt securities, long-term 55,368 246,597 Total assets 908,440 1,208,499 Initial fair value of contingent consideration at acquisition date 0 0 Financial and nonfinancial liabilities, fair value disclosure 0 0 Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 0 0 Debt securities, short-term 0 0 Debt securities, long-term 0 0 Total assets 0 0 Initial fair value of contingent consideration at acquisition date 2,120 1,245 Financial and nonfinancial liabilities, fair value disclosure 2,120 1,245 U.S. government debt securities

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt securities, short-term 853,072 961,902 Debt securities, long-term 55,368 246,597 U.S. government debt securities | Level 1 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt securities, short-term 0 0 Debt securities, long-term 0 0 U.S. government debt securities | Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt securities, short-term 853,072 961,902 Debt securities, long-term 55,368 246,597 U.S. government debt securities | Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt securities, short-term 0 0 Debt securities, long-term 0 0 Money market funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 838,114 620,630 Money market funds | Level 1 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 838,114 620,630 Money market funds | Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents 0 0 Money market funds | Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents $ 0 $ 0

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value Measurements, 6 Months Ended Cash Equivalents and Marketable Securities - Dec. 31, Jun. 30, 2021 Narrative (Details) - USD ($) 2020 $ in Thousands Minimum Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long term maturity period (years) 1 year 3 months 18 days Maximum Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long term maturity period (years) 2 years Fair Value, Measurements, Recurring Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Contingent liability from business acquisition $ 2,120 $ 1,245 Level 3 | Fair Value, Measurements, Recurring Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Contingent liability from business acquisition $ 2,120 $ 1,245

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value Measurements, 3 Months Ended 6 Months Ended Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details) - Fair Jun. 30, Jun. 30, Jun. 30, Jun. 30, Value, Measurements, 2021 2020 2021 2020 Recurring - Level 3 - USD ($) $ in Thousands Redeemable Noncontrolling Interest Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value — beginning of period $ $ $ $ 59,400 45,500 57,100 49,600 Increase (decrease) in fair value 1,645 6,186 5,932 3,159 Net loss for the period (1,645) (1,286) (3,632) (2,359) Fair value — end of period 59,400 50,400 59,400 50,400 Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value — beginning of period 1,245 1,175 1,245 1,365 Increase (decrease) in fair value 875 0 875 (190) Net loss for the period 0 0 0 0 Fair value — end of period $ 2,120 $ 1,175 $ 2,120 $ 1,175

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Jun. 30, Dec. 31, Jun. 30, Equivalents and Marketable 2021 2020 2020 Securities (Details) - USD ($) $ in Thousands Debt Securities, Available-for-sale [Line Items] Cash and cash equivalents $ 938,590 $ 832,977 $ 164,671 Amortized cost, cash and cash equivalents and debt securities available- 1,745,946 1,826,825 for-sale Gross Unrealized Gain 613 2,339 Gross Unrealized Loss (5) (35) Cash, cash equivalents and debt securities, fair value 1,746,554 1,829,129 Money market funds Debt Securities, Available-for-sale [Line Items] Cash and cash equivalents 838,114 620,630 Gross Unrealized Gain 0 0 Gross Unrealized Loss 0 0 Estimated fair value, cash and cash equivalents 838,114 620,630 U.S. government debt securities Debt Securities, Available-for-sale [Line Items] Amortized cost, debt securities, available-for-sale 907,832 1,206,195 Gross Unrealized Gain 613 2,339 Gross Unrealized Loss (5) (35) Estimated fair value, debt securities $ 908,440 $ 1,208,499

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 1 Months Patent License Acquisition 6 Months Ended Ended (Details) - USD ($) Jun. 30, Jun. 30, Dec. 31, $ in Thousands Mar. 31, 2020 2021 2020 2020 Business Acquisition [Line Items] Finite-lived intangible assets $ 16,986 $ 16,986 In process research and development expensed $ 0 $ 8,500 Minimum Business Acquisition [Line Items] Useful life (years) 6 years Maximum Business Acquisition [Line Items] Useful life (years) 12 years Patent and Covenant Rights | Minimum Business Acquisition [Line Items] Useful life (years) 6 years Patent and Covenant Rights | Maximum Business Acquisition [Line Items] Useful life (years) 12 years KeyGene Patent License Acquisition Business Acquisition [Line Items] Payment in connection with a license agreement $ 18,500 Asset acquisition, transaction costs 600 In process research and development expensed 8,500 Settlement of prior dispute between parties $ 1,200 KeyGene Patent License Acquisition | Patent and Covenant Rights Business Acquisition [Line Items] Finite-lived intangible assets $ 9,400

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Intangible Assets, Net and 6 Months Ended 12 Months Ended Goodwill - Schedule of Intangible Assets by Class Jun. 30, 2021 Dec. 31, 2020 (Details) - USD ($) $ in Thousands Finite-Lived Intangible Assets [Line Items] Intangible assets subject to amortization, gross carrying $ 16,986 $ 16,986 amount Intangible assets subject to amortization, accumulated (3,397) (2,431) amortization Intangible assets subject to amortization, net 13,589 14,555 Goodwill 3,290 3,290 Gross Carrying Amount 21,876 21,876 Net Carrying Amount 18,479 19,445 IPR&D Finite-Lived Intangible Assets [Line Items] IPR&D 1,600 1,600 Acquired license Finite-Lived Intangible Assets [Line Items] Intangible assets subject to amortization, gross carrying 11,886 11,886 amount Intangible assets subject to amortization, accumulated (1,915) (1,367) amortization Intangible assets subject to amortization, net $ 9,971 $ 10,519 Remaining Weighted Average Useful Life 9 years 3 months 18 9 years 9 months 18 days days Non-compete agreements and other covenant rights Finite-Lived Intangible Assets [Line Items] Intangible assets subject to amortization, gross carrying $ 5,100 $ 5,100 amount Intangible assets subject to amortization, accumulated (1,482) (1,064) amortization Intangible assets subject to amortization, net $ 3,618 $ 4,036 Remaining Weighted Average Useful Life 4 years 4 months 24 4 years 10 months 24 days days

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Intangible Assets, Net and 3 Months Ended 6 Months Ended Goodwill - Narrative Jun. 30, Jun. 30, Jun. 30, Jun. 30, (Details) - USD ($) 2021 2020 2021 2020 $ in Millions Goodwill and Intangible Assets Disclosure [Abstract] Amortization of intangible assets $ 0.5 $ 0.5 $ 1.0 $ 0.8

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Intangible Assets, Net and Goodwill - Schedule of Future Amortization Jun. 30, 2021Dec. 31, 2020 (Details) - USD ($) $ in Thousands Goodwill and Intangible Assets Disclosure [Abstract] Remainder of 2021 $ 982 2022 1,947 2023 1,947 2024 1,952 2025 1,705 2026 and thereafter 5,056 Intangible assets subject to amortization, net $ 13,589 $ 14,555

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 1 Months 3 Months 6 Months Ended Ended Ended Debt - Narrative (Details) Nov. 30, Nov. 16, $ / shares in Units, $ in 2020 Jun. 30, Jun. 30, Jun. 30, Dec. 31, 2020 Thousands USD ($) 2021 2021 2020 2020 $ / d USD ($) USD ($) USD ($) USD ($) shares $ / shares Debt Instrument [Line Items] Amortization of debt issuance costs | $ $ 1,282 $ 0 Notes Hedges, strike price (in dollars per $ 182.60 share) | $ / shares Share price, premium 75.00% Common stock share price (in dollars per $ 104.34 share) | $ / shares Purchase of convertible senior note hedges | $ $ 90,000 Senior Notes Due 2027 | Conversion Period Three Debt Instrument [Line Items] Threshold percentage of common stock price 130.00% trigger Threshold of common stock trading days 20 Threshold of consecutive common stock 30 trading days Senior Notes Due 2027 | Convertible Debt Debt Instrument [Line Items] Principal amount | $ $ $ 1,150,000 $ 1,150,000 1,150,000 1,150,000 Stated interest rate 0.00% Maximum special interest rate percentage 0.50% Conversion ratio 0.0071523 Conversion price (in dollars per share) | $ / $ 139.82 shares Estimated fair value | $ $ 1,300,000 1,300,000 1,300,000 Senior Notes Due 2027 | Convertible Debt | Conversion Period One Debt Instrument [Line Items] Threshold percentage of common stock price 130.00% trigger Threshold of common stock trading days 20 Threshold of consecutive common stock 30 trading days Senior Notes Due 2027 | Convertible Debt | Conversion Period Two Debt Instrument [Line Items]

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Threshold of common stock trading days 5 Threshold of consecutive common stock 10 trading days Minimum percentage of common stock price 98.00% trigger Senior Notes Due 2027 | Convertible senior notes Debt Instrument [Line Items] Amortization of debt issuance costs | $ $ 600 $ 1,300 Effective interest rate of the liability 0.20% 0.20% component

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Debt - Components of Convertible Senior Notes (Details) - Convertible Debt - Jun. 30, 2021Dec. 31, 2020Nov. 30, 2020 Senior Notes Due 2027 - USD ($) $ in Thousands Debt Instrument [Line Items] Principal $ 1,150,000 $ 1,150,000 $ 1,150,000 Less: debt discount, net of amortization 0 (331,074) Less: debt issuance costs, net of amortization (16,461) (12,634) Net carrying amount 1,133,539 806,292 2027 Notes 0 335,667 Less: issuance costs 0 (5,264) Net amount recorded in equity $ 0 $ 330,403

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 1 Months 3 Months Ended 6 Months Ended Ended Leases - Narrative (Details) Jun. 30, Jun. 30, Jun. 30, Jun. 30, $ in Millions Jul. 31, 2020 2021 2020 2021 2020 segment USD ($) USD ($) USD ($) USD ($) Lessee, Lease, Description [Line Items] Operating lease expense | $ $ 6.9 $ 1.9 $ 10.8 $ 3.4 Office and laboratory space Lessee, Lease, Description [Line Items] Number lease agreements, not yet commenced | 2 segment Renewal lease term, lease not yet commenced 10 years Office and laboratory space | San Diego, California Lessee, Lease, Description [Line Items] Lease not yet commenced, term 8 years Office and laboratory space | Palo Alto, California Lessee, Lease, Description [Line Items] Lease not yet commenced, term 12 years Minimum Lessee, Lease, Description [Line Items] Lease term 1 year 1 year Maximum Lessee, Lease, Description [Line Items] Lease term 12 years 12 years

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Leases - Lease Information Jun. 30, 2021 Dec. 31, 2020 (Details) Leases [Abstract] Weighted-average remaining lease term (in years) 10 years 3 months 18 days5 years 6 months Weighted-average discount rate 4.14% 8.07%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Leases - Schedule of Operating Liability Jun. 30, 2021 Maturities (Details) USD ($) $ in Thousands Leases [Abstract] Remainder of 2021 $ 5,398 2022 21,454 2023 28,976 2024 31,529 2025 32,084 2026 and thereafter 177,402 Total operating lease payments 296,843 Less: imputed interest (54,792) Less: lease incentives (22,721) Total operating lease liabilities $ 219,330

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 1 Months Ended Commitments and Jul. 31, Mar. 31, Dec. 31, Nov. 30, Nov. 30, Contingencies - Narrative 2018 2021 2020 2020 2017 (Details) segment patent patent patent patent petition Other Commitments [Line Items] Gain contingency, patents allegedly infringed upon, 4 4 number Foundation Medicine, Inc. vs. Guardant Health, Inc. Other Commitments [Line Items] Gain contingency, patents allegedly infringed upon, 2 2 7 number | patent Number of petitions filed 6 Number of petitions denied | segment 4 Number of petitions remaining 2

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 12 1 Months 3 Months 6 Months Ended Months Ended Ended Common Stock (Details) - Ended USD ($) Dec. Jun. 30, Jun. 30, Jun. 30, Jun. 30, Dec. 31, 31, 2020 2020 2021 2020 2020 2018 Class of Stock [Line Items] Dividends on common stock $ 0 $ 0 Common stock, shares reserved for future 13,939,220 11,344,620 issuance (in shares) Issuance of common stock in public 4,312,500 offering, net of offering costs (in shares) Share price of stock issued (in usd per $ 84.00 $ 84.00 $ 84.00 share) Issuance of common stock in public $ $ $ offering, net of offering costs 354,600,000354,600,000 354,600,000 Shares underlying outstanding stock options Class of Stock [Line Items] Common stock, shares reserved for future 2,703,906 3,101,181 issuance (in shares) Shares underlying unvested restricted stock units Class of Stock [Line Items] Common stock, shares reserved for future 1,155,370 1,118,655 issuance (in shares) Market-based restricted stock units Class of Stock [Line Items] Common stock, shares reserved for future 2,260,764 3,391,148 issuance (in shares) Performance-based restricted stock units Class of Stock [Line Items] Common stock, shares reserved for future 415,535 377,922 issuance (in shares) Shares available for issuance under the 2018 Incentive Award Plan Class of Stock [Line Items] Common stock, shares reserved for future 5,928,052 1,819,223 issuance (in shares) Shares available for issuance under the 2018 Employee Stock Purchase Plan Class of Stock [Line Items] Common stock, shares reserved for future 1,475,593 1,536,491 922,250 issuance (in shares)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Stock-Based Compensation - 12 Months Ended Ended Stock Option Activity Jun. 30, 2021 Dec. 31, 2020 (Details) USD ($) USD ($) $ / shares in Units, $ in $ / shares $ / shares Thousands shares shares Shares Available for Grant Beginning number of shares, available for grant (in shares) 1,819,223 2018 plan annual increase (in shares) 3,689,000 Ending number of shares, available for grant (in shares) 5,928,052 1,819,223 Shares Subject to Options Outstanding Beginning number of shares, outstanding (in shares) 3,101,181 Granted (in shares) 60,677 Exercised (in shares) (371,711) Canceled (in shares) (86,241) Ending number of shares, outstanding (in shares) 2,703,906 3,101,181 Options vested and exercisable, number of options (in shares) 2,091,339 Weighted-Average Exercise Price Beginning balance of options outstanding (in usd per share) | $ / shares $ 15.80 Granted (in usd per share) | $ / shares 142.73 Exercised (in usd per share) | $ / shares 14.34 Canceled (in usd per share) | $ / shares 47.02 Ending balance of options outstanding (in usd per share) | $ / shares 17.86 $ 15.80 Options vested and exercisable, weighted average exercise price per share $ 9.16 (in usd per share) | $ / shares Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Options outstanding, weighted average remaining contractual term (in 6 years 10 months 6 years 6 months years) 24 days Options outstanding, aggregate intrinsic value | $ $ 288,749 $ 350,670 Options vested and exercisable, weighted average remaining contractual 6 years 1 month term (in years) 6 days Options vested and exercisable, aggregate intrinsic value | $ $ 240,569 Equity Option Shares Available for Grant Granted (in shares) (60,677) Canceled (in shares) 42,956 Restricted Stock Units Shares Available for Grant Granted (in shares) (177,166) Canceled (in shares) 94,075 Market-based restricted stock units Shares Available for Grant Canceled (in shares) 558,254

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Risky rate, cost of equity 0.16 Performance-based restricted stock units Shares Available for Grant Granted (in shares) (52,917) Canceled (in shares) 15,304

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 1 Stock-Based Compensation - Months 3 Months Ended 6 Months Ended Narrative (Details) - USD ($) Ended $ / shares in Units, $ in Jan. Nov. Dec. May 26, Jun. 30, Jun. 30, Jun. 30, Jun. 30, Dec. 31, Thousands 01, 30, 31, 2020 2021 2020 2021 2020 2020 2020 2020 2018 Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Weighted average grant date fair value, grants in period (in $ 81.79 $ 44.61 $ 84.02 $ 45.52 usd per share) Stock based compensation not $ 19,700 $ 19,700 recognized, options Stock based compensation not 2 years 8 recognized, period for months 12 recognition (years) days Stock-based compensation $ 34,507 $ 25,815 $ 89,576 $ 32,153 Common stock, shares reserved for future issuance (in 13,939,220 13,939,220 11,344,620 shares) Class B | AMEA 2020 Plan Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Weighted average grant date fair value, grants in period (in $ 0.33 $ 0.33 usd per share) Stock based compensation not $ 600 $ 600 recognized, options Stock based compensation not 2 years 2 recognized, period for months 12 recognition (years) days Total market-based restricted stock units approved and 382,223 granted (in shares) Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Common stock, shares reserved for future issuance (in 4,595,555 4,595,555 shares) Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan | Tranche One

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Market-based stock unit 4 years vesting period Option term, expiration period 10 years Guardant Health AMEA, Inc | Class B | AMEA 2020 Plan | Tranche Two Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Option term, expiration period 5 years Threshold percentage for individual's combined voting 10.00% power triggering five year option term Purchase price of common stock (as a percent of the fair 110.00% value of common stock) Stock options issued and outstanding Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Exercises in period, intrinsic $ 11,100 $ 33,100 $ 49,400 $ 50,300 value Common stock, shares reserved for future issuance (in 2,703,906 2,703,906 3,101,181 shares) Expected dividend yield 0.00% 0.00% 0.00% 0.00% Stock options issued and outstanding | Minimum Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Expected volatility 63.60% 66.50% 63.60% 66.50% Risk-free interest rate 0.30% 0.40% 0.30% 0.40% Stock options issued and outstanding | Maximum Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Expected volatility 66.70% 68.50% 66.70% 73.30% Risk-free interest rate 1.10% 0.40% 1.10% 1.60%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Shares underlying unvested restricted stock units Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Stock based compensation not 3 years 1 recognized, period for month 6 recognition (years) days Stock based compensation not $ 98,100 $ 98,100 recognized, other than options Weighted average grant date fair value of MSU (in usd per $ 154.94 share) Common stock, shares reserved for future issuance (in 1,155,370 1,155,370 1,118,655 shares) Performance-based restricted stock units Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Stock based compensation not 3 years 7 recognized, period for months 6 recognition (years) days Stock based compensation not $ 4,900 $ 4,900 recognized, other than options Additional service period 6 requirement months Weighted-average derivative 4 years service period Stock-based compensation $ 300 $ 700 Total market-based restricted stock units approved and 52,917 granted (in shares) Weighted average grant date fair value of MSU (in usd per $ 135.94 share) Common stock, shares reserved for future issuance (in 415,535 415,535 377,922 shares) Performance-based restricted stock units | Minimum Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Market-based stock unit 4 years vesting period

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Performance-based restricted stock units | Maximum Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Market-based stock unit 4 years vesting period 6 months MSUs Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Stock based compensation not 9 months recognized, period for 18 days recognition (years) Stock based compensation not $ 49,000 $ 49,000 recognized, other than options Market-based stock unit 7 years vesting period Stock-based compensation $ 22,300 $ 66,300 Market-based restricted stock 30 days share price goal Weighted average grant date fair value of MSU (in usd per $ 67.00 share) Common stock, shares reserved for future issuance (in 2,260,764 2,260,764 3,391,148 shares) Expected dividend yield 0.00% Expected volatility 65.50% Risk-free interest rate 0.53% Risky rate, cost of equity 0.16 MSUs | Chief Executive Officer Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Total market-based restricted stock units approved and 1,695,574 granted (in shares) MSUs | President and Chief Operating Officer Share-based Compensation Arrangement by Share- based Payment Award [Line Items]

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Total market-based restricted stock units approved and 1,695,574 granted (in shares) MSUs | Minimum Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Weighted-average derivative 9 months service period 29 days Market-based stock units 6 months holding period during vesting Discount for post-vesting 10.40% restrictions MSUs | Maximum Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Weighted-average derivative 2 years 25 service period days Market-based stock units 12 holding period during vesting months Discount for post-vesting 14.50% restrictions Shares available for issuance under the 2018 Employee Stock Purchase Plan Share-based Compensation Arrangement by Share- based Payment Award [Line Items] Stock based compensation not 4 months recognized, period for 24 days recognition (years) Stock based compensation not $ 1,400 $ 1,400 recognized, other than options Stock-based compensation $ 800 $ 1,100 $ 1,600 $ 1,600 Purchase price of common stock (as a percent of the fair 85.00% value of common stock) Common stock, shares reserved for future issuance (in 1,475,593 1,475,593 1,536,491 922,250 shares) Expected dividend yield 0.00% 0.00% 0.00% 0.00% Expected volatility 50.80% 73.20% 50.80% 73.20% Risk-free interest rate 0.00% 0.20% 0.00% 0.20% Shares authorized (in shares) 942,614 Maximum employee 10.00% 10.00% subscription rate, ESPP

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Purchase period 6 months Common stock issued under employee stock purchase plan 60,898 58,164 60,898 58,164 (in shares)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document 6 Months Ended Stock-Based Compensation - Jun. 30, 2021 Restricted Stock Activity $ / shares (Details) shares Shares underlying unvested restricted stock units Restricted Stock Units Outstanding Beginning unvested balance (in shares) | shares 1,118,655 Granted (in shares) | shares 177,166 Vested and released (in shares) | shares (46,376) Canceled (in shares) | shares (94,075) Ending unvested balance (in shares) | shares 1,155,370 Weighted-Average Grant Date Fair Value Beginning balance of options outstanding (in usd per share) $ 92.89 Granted (in usd per share) 154.94 Vested and released (in usd per share) 80.32 Canceled (in usd per share) 92.67 Ending balance of options outstanding (in usd per share) $ 102.93 Performance-based restricted stock units Restricted Stock Units Outstanding Beginning unvested balance (in shares) | shares 377,922 Granted (in shares) | shares 52,917 Canceled (in shares) | shares (15,304) Ending unvested balance (in shares) | shares 415,535 Weighted-Average Grant Date Fair Value Beginning balance of options outstanding (in usd per share) $ 113.40 Granted (in usd per share) 135.94 Canceled (in usd per share) 113.40 Ending balance of options outstanding (in usd per share) $ 116.27 MSUs Restricted Stock Units Outstanding Beginning unvested balance (in shares) | shares 3,391,148 Vested and released (in shares) | shares (572,130) Canceled (in shares) | shares (558,254) Ending unvested balance (in shares) | shares 2,260,764 Weighted-Average Grant Date Fair Value Beginning balance of options outstanding (in usd per share) $ 67.00 Granted (in usd per share) 67.00 Vested and released (in usd per share) 70.58 Canceled (in usd per share) 70.58 Ending balance of options outstanding (in usd per share) $ 65.20

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-Based Compensation - 6 Months Ended Market-based Restricted Jun. 30, 2021 Stock Units (Details) - MSUs shares Tranche 1 - $120 per share Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of MSUs (in shares) 565,192 Tranche 2 - $150 per share Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of MSUs (in shares) 565,191 Tranche 3 - $200 per share Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of MSUs (in shares) 565,191

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-Based Compensation - 6 Months Ended 12 Months Ended AMEA 2020 Equity Jun. 30, 2021 Dec. 31, 2020 Incentive Plan (Details) USD ($) USD ($) $ / shares in Units, $ in $ / shares $ / shares Thousands shares shares Shares Available for Grant Beginning number of shares, available for grant (in shares) 1,819,223 Ending number of shares, available for grant (in shares) 5,928,052 1,819,223 Shares Subject to Options Outstanding Beginning number of shares, outstanding (in shares) 3,101,181 Granted (in shares) 60,677 Exercised (in shares) (371,711) Canceled (in shares) (86,241) Ending number of shares, outstanding (in shares) 2,703,906 3,101,181 Options vested and exercisable, number of options (in shares) 2,091,339 Weighted-Average Exercise Price Beginning balance of options outstanding (in usd per share) | $ / shares $ 15.80 Granted (in usd per share) | $ / shares 142.73 Exercised (in usd per share) | $ / shares 14.34 Canceled (in usd per share) | $ / shares 47.02 Ending balance of options outstanding (in usd per share) | $ / shares 17.86 $ 15.80 Options vested and exercisable, weighted average exercise price per share $ 9.16 (in usd per share) | $ / shares Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Options outstanding, weighted average remaining contractual term (in 6 years 10 months 6 years 6 months years) 24 days Options outstanding, aggregate intrinsic value | $ $ 288,749 $ 350,670 Options vested and exercisable, weighted average remaining contractual 6 years 1 month 6 term (in years) days Options vested and exercisable, aggregate intrinsic value | $ $ 240,569 AMEA 2020 Plan | Class B Shares Available for Grant Beginning number of shares, available for grant (in shares) 542,220 Granted (in shares) (382,223) Canceled (in shares) 92,412 Ending number of shares, available for grant (in shares) 252,409 542,220 Shares Subject to Options Outstanding Beginning number of shares, outstanding (in shares) 4,053,335 Granted (in shares) 382,223 Exercised (in shares) (91,109) Canceled (in shares) (92,412) Ending number of shares, outstanding (in shares) 4,252,037 4,053,335 Options vested and exercisable, number of options (in shares) 2,352,180

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Weighted-Average Exercise Price Beginning balance of options outstanding (in usd per share) | $ / shares $ 0.58 Granted (in usd per share) | $ / shares 0.58 Exercised (in usd per share) | $ / shares 0.58 Canceled (in usd per share) | $ / shares 0.58 Ending balance of options outstanding (in usd per share) | $ / shares 0.58 $ 0.58 Options vested and exercisable, weighted average exercise price per share $ 0.58 (in usd per share) | $ / shares Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value Options outstanding, weighted average remaining contractual term (in 9 years 2 months 9 years 7 months 6 years) 12 days days Options outstanding, aggregate intrinsic value | $ $ 0 $ 0 Options vested and exercisable, weighted average remaining contractual 9 years 1 month 6 term (in years) days Options vested and exercisable, aggregate intrinsic value | $ $ 0

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-Based Compensation - 3 Months Ended 6 Months Ended Stock Based Compensation Jun. 30, Jun. 30, Jun. 30, Jun. 30, Expense (Details) - USD ($) 2021 2020 2021 2020 $ in Thousands Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense $ 34,507 $ 25,815 $ 89,576 $ 32,153 Cost of precision oncology testing Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense 873 407 1,640 710 Research and development expense Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense 4,564 2,622 8,864 4,986 Sales and marketing expense Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense 3,438 2,167 6,318 3,965 General and administrative expense Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense $ 25,632 $ 20,619 $ 72,754 $ 22,492

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-Based Compensation - 3 Months Ended 6 Months Ended Valuation of Stock Options Jun. 30, Jun. 30, (Details) - Stock options Jun. 30, 2021 Jun. 30, 2021 2020 2020 issued and outstanding Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected dividend yield 0.00% 0.00% 0.00% 0.00% Minimum Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected term (in years) 5 years 5 5 years 5 5 years 6 5 years 6 months 26 months 26 months months days days Expected volatility 63.60% 66.50% 63.60% 66.50% Risk-free interest rate 0.30% 0.40% 0.30% 0.40% Maximum Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected term (in years) 6 years 14 6 years 1 6 years 14 6 years 1 days month 6 days days month 6 days Expected volatility 66.70% 68.50% 66.70% 73.30% Risk-free interest rate 1.10% 0.40% 1.10% 1.60%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Stock-Based Compensation - 3 Months Ended 6 Months Ended Employee Stock Purchase Plan (Details) - Shares Jun. 30, Jun. 30, Jun. 30, Jun. 30, available for issuance under 2021 2020 2021 2020 the 2018 Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected term (in years) 6 months 6 months 6 months 6 months Expected volatility 50.80% 73.20% 50.80% 73.20% Risk-free interest rate 0.00% 0.20% 0.00% 0.20% Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Net Loss Per Share 3 Months 6 Months Ended Attributable to Guardant Ended Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) Jun. 30, Jun. 30, Jun. 30, Jun. 30, - USD ($) 2021 2020 2021 2020 $ / shares in Units, shares in Thousands, $ in Thousands Earnings Per Share [Abstract] Net loss $ $ $ $ (97,575)(49,739)(204,933)(81,568) Adjustment of redeemable noncontrolling interest 0 (4,900) (2,300) (800) Net loss attributable to Guardant Health, Inc. common stockholders, basic (97,575)(54,639)(207,233)(82,368) Net loss attributable to Guardant Health, Inc. common stockholders $ $ $ $ (97,575)(54,639)(207,233)(82,368) Net loss per share attributable to Guardant Health, Inc. common $ (0.96) $ (0.57) $ (2.05) $ (0.87) stockholders, basic (in usd per share) Net loss per share attributable to Guardant Health, Inc. common $ (0.96) $ (0.57) $ (2.05) $ (0.87) stockholders, diluted (in usd per share) Weighted-average shares used in computing net loss per share attributable to 101,172 96,011 101,064 95,196 Guardant Health, Inc. common stockholders, basic (in shares) Weighted-average shares used in computing net loss per share attributable to 101,172 96,011 101,064 95,196 Guardant Health, Inc. common stockholders, diluted (in shares)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Net Loss Per Share 3 Months Ended 6 Months Ended Attributable to Guardant Health, Inc. Common Jun. 30, Jun. 30, Jun. 30, Jun. 30, Dec. 31, Stockholders - Schedule of 2021 2020 2021 2020 2020 Antidilutive Securities (Details) - shares Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 14,813,0005,997,00015,090,0005,451,000 earnings per share (in shares) Stock options outstanding (in shares) 2,703,906 2,703,906 3,101,181 AMEA 2020 Plan | Class B Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock options outstanding (in shares) 4,252,037 4,252,037 4,053,335 Stock options issued and outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 2,720,000 4,056,0002,816,000 4,200,000 earnings per share (in shares) Restricted stock units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 1,147,000 542,000 1,133,000 519,000 earnings per share (in shares) MSUs Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 2,261,000 1,342,0002,453,000 671,000 earnings per share (in shares) PSUs Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 409,000 0 408,000 0 earnings per share (in shares) ESPP obligation Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 43,000 37,000 45,000 40,000 earnings per share (in shares) Common stock subject to repurchase Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 8,000 20,000 10,000 21,000 earnings per share (in shares)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Convertible senior notes Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of 8,225,000 0 8,225,000 0 earnings per share (in shares)

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Segment and Geographic 12 Months 3 Months Ended 6 Months Ended Information (Details) - USD Ended ($) Jun. 30, Jun. 30, Jun. 30, Jun. 30, Dec. 31, 2020 $ in Thousands 2021 2020 2021 2020 Segment Reporting Information [Line Items] Total revenue $ 92,101 $ 66,335 $ 170,766 $ 133,845 Assets | Geographic Concentration Risk | Net Assets, Geographic Area Segment Reporting Information [Line Items] Concentration risk, percentage 98.00% 94.00% United States Segment Reporting Information [Line Items] Total revenue 87,868 61,422 $ 160,168 126,035 International Segment Reporting Information [Line Items] Total revenue $ 4,233 $ 4,913 $ 10,598 $ 7,810

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Subsequent Events (Details) 1 Months Ended 6 Months Ended - USD ($) Jul. 31, 2021 Jun. 30, 2021Jun. 30, 2020 $ in Thousands Subsequent Event [Line Items] Non-marketable equity and other investments $ 12,750 $ 0 Subsequent Event Subsequent Event [Line Items] Non-marketable equity and other investments $ 26,000

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document { "instance": { "gh-20210630.htm": { "axisCustom": 3, "axisStandard": 32, "contextCount": 316, "dts": { "calculationLink": { "local": [ "gh-20210630_cal.xml" ] }, "definitionLink": { "local": [ "gh-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "gh-20210630.htm" ] }, "labelLink": { "local": [ "gh-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "gh-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "gh-20210630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 613, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 2, "http://guardanthealth.com/20210630": 1, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 8 }, "keyCustom": 72, "keyStandard": 374, "memberCustom": 25, "memberStandard": 54, "nsprefix": "gh", "nsuri": "http://guardanthealth.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://guardanthealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109103 - Disclosure - Investment in Joint Venture", "role": "http://guardanthealth.com/role/InvestmentinJointVenture", "shortName": "Investment in Joint Venture", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Condensed Consolidated Balance Sheet Components", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents", "shortName": "Condensed Consolidated Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities", "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities", "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Patent License Acquisition", "role": "http://guardanthealth.com/role/PatentLicenseAcquisition", "shortName": "Patent License Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Intangible Assets, Net and Goodwill", "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill", "shortName": "Intangible Assets, Net and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129108 - Disclosure - Debt", "role": "http://guardanthealth.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - Leases", "role": "http://guardanthealth.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138110 - Disclosure - Commitments and Contingencies", "role": "http://guardanthealth.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140111 - Disclosure - Common Stock", "role": "http://guardanthealth.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143112 - Disclosure - Stock-Based Compensation", "role": "http://guardanthealth.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153113 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders", "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders", "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157114 - Disclosure - Income Taxes", "role": "http://guardanthealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158115 - Disclosure - Segment and Geographic Information", "role": "http://guardanthealth.com/role/SegmentandGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161116 - Disclosure - Related Party Transactions", "role": "http://guardanthealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2162117 - Disclosure - Subsequent Events", "role": "http://guardanthealth.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables", "shortName": "Condensed Consolidated Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)", "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables", "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)", "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables", "shortName": "Intangible Assets, Net and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330305 - Disclosure - Debt (Tables)", "role": "http://guardanthealth.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334306 - Disclosure - Leases (Tables)", "role": "http://guardanthealth.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341307 - Disclosure - Common Stock (Tables)", "role": "http://guardanthealth.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344308 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://guardanthealth.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)", "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2359310 - Disclosure - Segment and Geographic Information (Tables)", "role": "http://guardanthealth.com/role/SegmentandGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i4b51e4645e2c40c6a91c611fcecbd85a_I20180531", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Description of Business (Details)", "role": "http://guardanthealth.com/role/DescriptionofBusinessDetails", "shortName": "Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9d1d3f3b81014cb7bda36e0a91465fb3_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i307f9901221147f68ce3e30fabff5c00_D20200101-20200630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)", "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i307f9901221147f68ce3e30fabff5c00_D20200101-20200630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "gh:RevenuefromPrecisionOncologyTesting", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)", "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "shortName": "Condensed Consolidated Statements of Operations (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "gh:RevenuefromPrecisionOncologyTesting", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9d1d3f3b81014cb7bda36e0a91465fb3_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)", "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails", "shortName": "Summary of Significant Accounting Policies - Receivable and Related Credit Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9d1d3f3b81014cb7bda36e0a91465fb3_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gh:ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Investment in Joint Venture (Details)", "role": "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "shortName": "Investment in Joint Venture (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "INF", "lang": "en-US", "name": "gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails", "shortName": "Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails", "shortName": "Condensed Consolidated Balance Sheet Components - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)", "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails", "shortName": "Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i4da1c6a6acef4f31af44870bb2784a55_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)", "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i4da1c6a6acef4f31af44870bb2784a55_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i619dcd41ec464e10aa0951e5b11fd9cf_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "gh:LongTermMarketableSecuritiesMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)", "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails", "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i619dcd41ec464e10aa0951e5b11fd9cf_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "gh:LongTermMarketableSecuritiesMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ica4ceb6c94404256804b5f53fbb1b913_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)", "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ica4ceb6c94404256804b5f53fbb1b913_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)", "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails", "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gh:DebtSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "lang": "en-US", "name": "gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Patent License Acquisition (Details)", "role": "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails", "shortName": "Patent License Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i4dd6786226b846edb2e894f72d595565_D20200301-20200331", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)", "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails", "shortName": "Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)", "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails", "shortName": "Intangible Assets, Net and Goodwill - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)", "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails", "shortName": "Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Debt - Narrative (Details)", "role": "http://guardanthealth.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ia18e36062fc548c8aff73f348045e91e_I20201116", "decimals": "2", "lang": "en-US", "name": "gh:ConvertibleDebtHedgeStrikePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "id9adbe6af2f44278b01a82a320bdbe83_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - Debt - Components of Convertible Senior Notes (Details)", "role": "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "shortName": "Debt - Components of Convertible Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "id9adbe6af2f44278b01a82a320bdbe83_I20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435419 - Disclosure - Leases - Narrative (Details)", "role": "http://guardanthealth.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Leases - Lease Information (Details)", "role": "http://guardanthealth.com/role/LeasesLeaseInformationDetails", "shortName": "Leases - Lease Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)", "role": "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails", "shortName": "Leases - Schedule of Operating Liability Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i743ef2d72d754e72ba5313d0a1efe460_I20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ia6050eb13ba4413bb35048a35ca8eda5_D20180701-20180731", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ia6050eb13ba4413bb35048a35ca8eda5_D20180701-20180731", "decimals": "INF", "first": true, "lang": "en-US",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - Common Stock (Details)", "role": "http://guardanthealth.com/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic6a43ce57a7d485fa4d92a8b0b3e3d8b_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited)", "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited", "shortName": "Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic6a43ce57a7d485fa4d92a8b0b3e3d8b_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9d1d3f3b81014cb7bda36e0a91465fb3_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "INF", "lang": "en-US", "name": "gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i065d45136b354cb0a40b8aacc20702da_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i065d45136b354cb0a40b8aacc20702da_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9f9ae112a2f24482aac3313eefcf76bf_D20210101-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails", "shortName": "Stock-Based Compensation - Market-based Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9f9ae112a2f24482aac3313eefcf76bf_D20210101-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9d1d3f3b81014cb7bda36e0a91465fb3_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "shortName": "Stock-Based Compensation - AMEA 2020 Equity Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9c947db1efaa4451a835d5bdf903965c_D20210101-20210630", "decimals": "INF", "lang": "en-US", "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450429 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "iab6b40437f4f4d24b40ea588b6709b54_D20210401-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i822d98f38d644313a60ca0e8eb76cecf_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451430 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails", "shortName": "Stock-Based Compensation - Valuation of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i9fc7a8a638234872a05cbad63cf425f2_D20210401-20210630", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ib83f20478e094efc8ee55b801081ad4e_D20210401-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452431 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)", "role": "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ib83f20478e094efc8ee55b801081ad4e_D20210401-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)", "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails", "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456433 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)", "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i845773fa86af4147bedd899cc2987306_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited) (Parenthetical)", "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical", "shortName": "Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i845773fa86af4147bedd899cc2987306_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ic533dfe0e51340acb4df300a590b43e3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460434 - Disclosure - Segment and Geographic Information (Details)", "role": "http://guardanthealth.com/role/SegmentandGeographicInformationDetails", "shortName": "Segment and Geographic Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i5fdb63d4b4604603ad87d93a54c097b6_D20210101-20210630", "decimals": "2", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "gh:PaymentsToAcquireEquitySecuritiesFVNI", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463435 - Disclosure - Subsequent Events (Details)", "role": "http://guardanthealth.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "i393a637b63964e989f1d715299b3ebbb_D20210701-20210731", "decimals": "-6", "lang": "en-US", "name": "gh:PaymentsToAcquireEquitySecuritiesFVNI", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Description of Business", "role": "http://guardanthealth.com/role/DescriptionofBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gh-20210630.htm", "contextRef": "ie6aa3ee1720b43edb39d7f8523e17a0f_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 88, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "gh_A2018IncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Incentive Award Plan [Member]", "label": "2018 Incentive Award Plan [Member]", "verboseLabel": "Shares available for issuance under the 2018 Incentive Award Plan" } } }, "localname": "A2018IncentiveAwardPlanMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails" ], "xbrltype": "domainItemType" }, "gh_AMEA2020PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AMEA 2020 Plan", "label": "AMEA 2020 Plan [Member]", "terseLabel": "AMEA 2020 Plan" } } }, "localname": "AMEA2020PlanMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_AccruedClinicalTrialsandStudies": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Trials and Studies", "label": "Accrued Clinical Trials and Studies", "terseLabel": "Accrued clinical trials and studies" } } }, "localname": "AccruedClinicalTrialsandStudies", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gh_AccruedExpensesPropertyandEquipmentCurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expenses, Property and Equipment, Current", "label": "Accrued Expenses, Property and Equipment, Current", "terseLabel": "Purchases of property and equipment included in accrued expenses" } } }, "localname": "AccruedExpensesPropertyandEquipmentCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gh_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Hedges", "terseLabel": "Purchase of convertible senior note hedges" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition And Business Combination Disclosure", "label": "Asset Acquisition And Business Combination Disclosure [Text Block]", "terseLabel": "Patent License Acquisition" } } }, "localname": "AssetAcquisitionAndBusinessCombinationDisclosureTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisition" ], "xbrltype": "textBlockItemType" }, "gh_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "stringItemType" }, "gh_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Asset Acquisition [Axis]", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "domainItemType" }, "gh_AssetAcquisitionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Policy Text Block]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionPolicyTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gh_AssetAcquisitionTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Transaction Costs", "label": "Asset Acquisition, Transaction Costs", "terseLabel": "Asset acquisition, transaction costs" } } }, "localname": "AssetAcquisitionTransactionCosts", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "gh_CashCashEquivalentsandDebtSecuritiesFairValue": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents and Debt Securities, Fair Value", "label": "Cash, Cash Equivalents and Debt Securities, Fair Value", "terseLabel": "Cash, cash equivalents and debt securities, fair value" } } }, "localname": "CashCashEquivalentsandDebtSecuritiesFairValue", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "gh_ChargeOfInProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charge Of In Process Research And Development", "label": "Charge Of In Process Research And Development", "terseLabel": "Charge of in-process research and development costs with no alternative future use", "verboseLabel": "In process research and development expensed" } } }, "localname": "ChargeOfInProcessResearchAndDevelopment", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration [Member]", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" ], "xbrltype": "domainItemType" }, "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, After Allowance For Credit Loss Net, Current", "label": "Contractual Receivables, After Allowance For Credit Loss Net, Current", "totalLabel": "Financing receivable, net amount, current" } } }, "localname": "ContractualReceivablesAfterAllowanceForCreditLossNetCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent", "label": "Contractual Receivables, After Allowance For Credit Loss, Net, Noncurrent", "totalLabel": "Financing receivable, net amount, noncurrent" } } }, "localname": "ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesAllowanceForCreditLossCurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": { "order": 2.0, "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Allowance For Credit Loss, Current", "label": "Contractual Receivables, Allowance For Credit Loss, Current", "negatedPeriodEndLabel": "Ending balance, financing receivable, allowance for credit loss, current", "negatedPeriodStartLabel": "Beginning balance, financing receivable, allowance for credit loss, current" } } }, "localname": "ContractualReceivablesAllowanceForCreditLossCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesAllowanceForCreditLossNoncurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": { "order": 2.0, "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Allowance For Credit Loss, Noncurrent", "label": "Contractual Receivables, Allowance For Credit Loss, Noncurrent", "negatedPeriodEndLabel": "Ending balance, financing receivable, allowance for credit loss, noncurrent", "negatedPeriodStartLabel": "Beginning balance, financing receivable, allowance for credit loss, noncurrent" } } }, "localname": "ContractualReceivablesAllowanceForCreditLossNoncurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesAllowanceForCreditLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Allowance For Credit Loss", "label": "Contractual Receivables, Allowance For Credit Loss [Table Text Block]", "terseLabel": "Schedule of Contractual Receivables and Related Credit Loss" } } }, "localname": "ContractualReceivablesAllowanceForCreditLossTableTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "gh_ContractualReceivablesBeforeAllowanceForCreditLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Before Allowance For Credit Loss", "label": "Contractual Receivables, Before Allowance For Credit Loss", "terseLabel": "Other receivables and other assets due from a third-party" } } }, "localname": "ContractualReceivablesBeforeAllowanceForCreditLoss", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": { "order": 1.0, "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Current", "label": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Current", "terseLabel": "Financing receivable, gross amount, current" } } }, "localname": "ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails": { "order": 1.0, "parentTag": "gh_ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent", "label": "Contractual Receivables, Before Allowance For Credit Loss, Gross, Noncurrent", "terseLabel": "Financing receivable, net amount, noncurrent" } } }, "localname": "ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesCreditLossExpenseReversalCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Credit Loss, Expense (Reversal), Current", "label": "Contractual Receivables, Credit Loss, Expense (Reversal), Current", "negatedTerseLabel": "Additions: charged to other income (expense), net, allowance for credit loss, current" } } }, "localname": "ContractualReceivablesCreditLossExpenseReversalCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesCreditLossExpenseReversalNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent", "label": "Contractual Receivables, Credit Loss, Expense (Reversal), Noncurrent", "negatedTerseLabel": "Additions: charged to other income (expense), net, allowance for credit loss, noncurrent", "terseLabel": "Contractual receivables, credit loss" } } }, "localname": "ContractualReceivablesCreditLossExpenseReversalNoncurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesCreditLossReclassificationCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Credit Loss, Reclassification, Current", "label": "Contractual Receivables, Credit Loss, Reclassification, Current", "negatedTerseLabel": "Reclassification, allowance for credit loss, current" } } }, "localname": "ContractualReceivablesCreditLossReclassificationCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesCreditLossReclassificationNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Credit Loss, Reclassification, Noncurrent", "label": "Contractual Receivables, Credit Loss, Reclassification, Noncurrent", "negatedTerseLabel": "Reclassification, allowance for credit loss, noncurrent" } } }, "localname": "ContractualReceivablesCreditLossReclassificationNoncurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "monetaryItemType" }, "gh_ContractualReceivablesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual Receivables, Term", "label": "Contractual Receivables, Term", "terseLabel": "Other receivables and other assets, term" } } }, "localname": "ContractualReceivablesTerm", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_ConversionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Period One", "label": "Conversion Period One [Member]", "terseLabel": "Conversion Period One" } } }, "localname": "ConversionPeriodOneMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_ConversionPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Period Three", "label": "Conversion Period Three [Member]", "terseLabel": "Conversion Period Three" } } }, "localname": "ConversionPeriodThreeMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_ConversionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Period Two", "label": "Conversion Period Two [Member]", "terseLabel": "Conversion Period Two" } } }, "localname": "ConversionPeriodTwoMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_ConvertibleDebtHedgeSharePricePremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Debt, Hedge, Share Price, Premium Percentage", "label": "Convertible Debt, Hedge, Share Price, Premium Percentage", "terseLabel": "Share price, premium" } } }, "localname": "ConvertibleDebtHedgeSharePricePremiumPercentage", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gh_ConvertibleDebtHedgeStrikePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Debt, Hedge, Strike Price", "label": "Convertible Debt, Hedge, Strike Price", "terseLabel": "Notes Hedges, strike price (in dollars per share)" } } }, "localname": "ConvertibleDebtHedgeStrikePrice", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "gh_ConvertibleSeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes Due 2027", "label": "Convertible Senior Notes Due 2027 [Member]", "terseLabel": "Senior Notes Due 2027" } } }, "localname": "ConvertibleSeniorNotesDue2027Member", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_CostofDevelopmentServices": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of Development Services", "label": "Cost of Development Services", "terseLabel": "Cost of development services and other" } } }, "localname": "CostofDevelopmentServices", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_CostofDevelopmentServicesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of Development Services [Policy Text Block]", "label": "Cost of Development Services [Policy Text Block]", "terseLabel": "Cost of Development Services" } } }, "localname": "CostofDevelopmentServicesPolicyTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gh_CostsofPrecisionOncologyTesting": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of Precision Oncology Testing", "label": "Costs of Precision Oncology Testing", "terseLabel": "Cost of precision oncology testing" } } }, "localname": "CostsofPrecisionOncologyTesting", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_CostsofPrecisionOncologyTestingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs of Precision Oncology Testing [Policy Text Block]", "label": "Costs of Precision Oncology Testing [Policy Text Block]", "terseLabel": "Costs of Precision Oncology Testing" } } }, "localname": "CostsofPrecisionOncologyTestingPolicyTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gh_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "gh_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "gh_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C", "label": "Customer C [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerCMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "gh_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer D", "label": "Customer D [Member]", "terseLabel": "Customer D" } } }, "localname": "CustomerDMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "gh_DebtInstrumentConversionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion", "label": "Debt Instrument, Conversion [Axis]", "terseLabel": "Debt Instrument, Conversion [Axis]" } } }, "localname": "DebtInstrumentConversionAxis", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "gh_DebtInstrumentConversionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion", "label": "Debt Instrument, Conversion [Domain]", "terseLabel": "Debt Instrument, Conversion [Domain]" } } }, "localname": "DebtInstrumentConversionDomain", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Equity Component, Gross", "label": "Debt Instrument, Convertible, Equity Component Before Issuance Costs", "terseLabel": "2027 Notes" } } }, "localname": "DebtInstrumentConvertibleEquityComponentBeforeIssuanceCosts", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "gh_DebtInstrumentConvertibleIssuanceCostsEquityComponent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Issuance Costs, Equity Component", "label": "Debt Instrument, Convertible, Issuance Costs, Equity Component", "negatedTerseLabel": "Less: issuance costs" } } }, "localname": "DebtInstrumentConvertibleIssuanceCostsEquityComponent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "gh_DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate", "label": "Debt Instrument, Convertible, Maximum Percentage Of Product Of Last Reported Sale Price And Conversion Rate", "terseLabel": "Minimum percentage of common stock price trigger" } } }, "localname": "DebtInstrumentConvertibleMaximumPercentageOfProductOfLastReportedSalePriceAndConversionRate", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gh_DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage", "label": "Debt Instrument, Maximum Interest Rate, Special Interest Rate Percentage", "terseLabel": "Maximum special interest rate percentage" } } }, "localname": "DebtInstrumentMaximumInterestRateSpecialInterestRatePercentage", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost", "label": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost", "totalLabel": "Amortized cost, cash and cash equivalents and debt securities available-for-sale" } } }, "localname": "DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "gh_DebtSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities [Table Text Block]", "label": "Debt Securities [Table Text Block]", "terseLabel": "Schedule of Debt Securities, Available-for-sale" } } }, "localname": "DebtSecuritiesTableTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "gh_EquityIncentivePlanTrancheAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan Tranche", "label": "Equity Incentive Plan Tranche [Axis]", "terseLabel": "Equity Incentive Plan Tranche [Axis]" } } }, "localname": "EquityIncentivePlanTrancheAxis", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "gh_EquityIncentivePlanTrancheDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan Tranche", "label": "Equity Incentive Plan Tranche [Domain]", "terseLabel": "Equity Incentive Plan Tranche [Domain]" } } }, "localname": "EquityIncentivePlanTrancheDomain", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_EquityMethodInvestmentSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Shares Purchased", "label": "Equity Method Investment, Shares Purchased", "terseLabel": "Equity method investment, shares purchased (in shares)" } } }, "localname": "EquityMethodInvestmentSharesPurchased", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "gh_EquitySecuritiesFVNIIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Securities, FV-NI Incurred But Not Yet Paid", "label": "Equity Securities, FV-NI Incurred But Not Yet Paid", "terseLabel": "Issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses" } } }, "localname": "EquitySecuritiesFVNIIncurredButNotYetPaid", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value", "label": "Equity Security, FV-NI, Impairment Or Adjustments To Carrying Value", "terseLabel": "Impairment or adjustments of non-marketable securities" } } }, "localname": "EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gh_EstimatedLitigationLiabilityLegalFeesCurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Litigation Liability, Legal Fees, Current", "label": "Estimated Litigation Liability, Legal Fees, Current", "terseLabel": "Accrued legal expenses" } } }, "localname": "EstimatedLitigationLiabilityLegalFeesCurrent", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "terseLabel": "Net loss for the period" } } }, "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four", "label": "Finite Lived Intangible Assets Amortization Expense After Year Four", "terseLabel": "2026 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "gh_FoundationMedicineInc.vs.GuardantHealthInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]", "label": "Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member]", "terseLabel": "Foundation Medicine, Inc. vs. Guardant Health, Inc." } } }, "localname": "FoundationMedicineInc.vs.GuardantHealthInc.Member", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_Guardant360CDxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Guardant360CDx", "label": "Guardant360CDx [Member]", "terseLabel": "Guardant360CDx" } } }, "localname": "Guardant360CDxMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_GuardantHealthAMEAIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Guardant Health AMEA, Inc [Member]", "label": "Guardant Health AMEA, Inc [Member]", "terseLabel": "Guardant Health AMEA, Inc" } } }, "localname": "GuardantHealthAMEAIncMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusinessDetails", "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_GuardantHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Guardant Health, Inc.", "label": "Guardant Health, Inc. [Member]", "terseLabel": "Guardant Health, Inc." } } }, "localname": "GuardantHealthIncMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "gh_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liabilities", "label": "Increase (Decrease) In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_IntangibleAssetsGrossIncludingGoodwill": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intangible Assets, Gross (Including Goodwill)", "label": "Intangible Assets, Gross (Including Goodwill)", "totalLabel": "Gross Carrying Amount" } } }, "localname": "IntangibleAssetsGrossIncludingGoodwill", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "monetaryItemType" }, "gh_KeyGenePatentLicenseAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KeyGene Patent License Acquisition [Member]", "label": "KeyGene Patent License Acquisition [Member]", "terseLabel": "KeyGene Patent License Acquisition" } } }, "localname": "KeyGenePatentLicenseAcquisitionMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "domainItemType" }, "gh_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term of Contract", "terseLabel": "Renewal lease term, lease not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTermOfContract", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_LesseeOperatingLeaseLiabilityLeaseIncentive": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Lease Incentive", "label": "Lessee, Operating Lease, Liability, Lease Incentive", "negatedTerseLabel": "Less: lease incentives" } } }, "localname": "LesseeOperatingLeaseLiabilityLeaseIncentive", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "terseLabel": "2026 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "gh_LongTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Marketable Securities, Maturity Period", "label": "Long Term Marketable Securities, Maturity Period", "terseLabel": "Long term maturity period (years)" } } }, "localname": "LongTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_NonCashOperatingLeaseCosts": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non Cash Operating Lease Costs", "label": "Non Cash Operating Lease Costs", "terseLabel": "Non-cash operating lease costs" } } }, "localname": "NonCashOperatingLeaseCosts", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_NumberOfOperatingLeasesLeaseNotYetCommenced": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operating Leases, Lease Not yet Commenced", "label": "Number Of Operating Leases, Lease Not yet Commenced", "terseLabel": "Number lease agreements, not yet commenced" } } }, "localname": "NumberOfOperatingLeasesLeaseNotYetCommenced", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gh_NumberOfPetitionsFiledRemaining": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Petitions Filed, Remaining", "label": "Number Of Petitions Filed, Remaining", "terseLabel": "Number of petitions remaining" } } }, "localname": "NumberOfPetitionsFiledRemaining", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gh_NumberofPetitionsDenied": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Petitions Denied", "label": "Number of Petitions Denied", "terseLabel": "Number of petitions denied" } } }, "localname": "NumberofPetitionsDenied", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gh_NumberofPetitionsFiled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Petitions Filed", "label": "Number of Petitions Filed", "terseLabel": "Number of petitions filed" } } }, "localname": "NumberofPetitionsFiled", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "gh_OfferingCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering Costs Incurred But Not Yet Paid", "label": "Offering Costs Incurred But Not Yet Paid", "terseLabel": "Follow-on public offering issuance costs included in accounts payable and accrued expenses" } } }, "localname": "OfferingCostsIncurredButNotYetPaid", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_PaloAltoCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palo Alto, California", "label": "Palo Alto, California [Member]", "terseLabel": "Palo Alto, California" } } }, "localname": "PaloAltoCaliforniaMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_PatentandCovenantRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent and Covenant Rights [Member]", "label": "Patent and Covenant Rights [Member]", "terseLabel": "Patent and Covenant Rights" } } }, "localname": "PatentandCovenantRightsMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "domainItemType" }, "gh_PaymentInConnectionWithaLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment In Connection With a License Agreement", "label": "Payment In Connection With a License Agreement", "terseLabel": "Payment in connection with a license agreement" } } }, "localname": "PaymentInConnectionWithaLicenseAgreement", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "gh_PaymentsToAcquireEquitySecuritiesFVNI": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equity Securities, FV-NI", "label": "Payments To Acquire Equity Securities, FV-NI", "negatedTerseLabel": "Purchase of non-marketable equity and other related investments", "verboseLabel": "Non-marketable equity and other investments" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFVNI", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://guardanthealth.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "gh_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Based Restricted Stock Units", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance-based restricted stock units", "verboseLabel": "PSUs" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "gh_PrecisionOncologyTestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Precision Oncology Testing [Member]", "label": "Precision Oncology Testing [Member]", "terseLabel": "Cost of precision oncology testing" } } }, "localname": "PrecisionOncologyTestingMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "gh_PreferredStockSharesIssuedUponConversionOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Shares Issued Upon Conversion Of Common Stock", "label": "Preferred Stock, Shares Issued Upon Conversion Of Common Stock", "terseLabel": "Common stock reclassified and converted into preferred stock (in shares)" } } }, "localname": "PreferredStockSharesIssuedUponConversionOfCommonStock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "gh_ProceedsFromContractualReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Contractual Receivable", "label": "Proceeds From Contractual Receivable", "terseLabel": "Contractual receivables, installment payment" } } }, "localname": "ProceedsFromContractualReceivable", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gh_PropertyPlantAndEquipmentAcquiredUnderFinanceLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property, Plant And Equipment, Acquired Under Finance Leases", "label": "Property, Plant And Equipment, Acquired Under Finance Leases", "terseLabel": "Property and equipment acquired under finance leases" } } }, "localname": "PropertyPlantAndEquipmentAcquiredUnderFinanceLeases", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_RedeemableNoncontrollingInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Noncontrolling Interest [Member]", "label": "Redeemable Noncontrolling Interest [Member]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "localname": "RedeemableNoncontrollingInterestMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" ], "xbrltype": "domainItemType" }, "gh_RevenuefromDevelopmentServices": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from Development Services", "label": "Revenue from Development Services", "terseLabel": "Development services and other" } } }, "localname": "RevenuefromDevelopmentServices", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_RevenuefromPrecisionOncologyTesting": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from Precision Oncology Testing", "label": "Revenue from Precision Oncology Testing", "terseLabel": "Precision oncology testing" } } }, "localname": "RevenuefromPrecisionOncologyTesting", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "gh_SanDiegoCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "San Diego, California", "label": "San Diego, California [Member]", "terseLabel": "San Diego, California" } } }, "localname": "SanDiegoCaliforniaMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Additional Service Period", "terseLabel": "Additional service period requirement" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalServicePeriod", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Available for Grant, Forfeitures in Period, Gross", "terseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAvailableForGrantForfeituresInPeriodGross", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest", "terseLabel": "Number of MSUs (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate", "terseLabel": "Risky rate, cost of equity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "pureItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross", "negatedTerseLabel": "Granted (in shares)", "terseLabel": "Total market-based restricted stock units approved and granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting", "terseLabel": "Market-based stock units holding period during vesting" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "terseLabel": "Purchase period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period", "terseLabel": "Market-based restricted stock share price goal" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Threshold Percentage For Individual's Combined Voting Power Triggering Five Year Option Term", "terseLabel": "Threshold percentage for individual's combined voting power triggering five year option term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentageForIndividualsCombinedVotingPowerTriggeringFiveYearOptionTerm", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available", "terseLabel": "2018 plan annual increase (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]", "terseLabel": "Shares Available for Grant" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "gh_SoftBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SoftBank [Member]", "label": "SoftBank [Member]", "terseLabel": "SoftBank" } } }, "localname": "SoftBankMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised Early", "label": "Stock Issued During Period, Value, Stock Options Exercised Early", "terseLabel": "Vesting of common stock exercised early" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedEarly", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "gh_TrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche One", "label": "Tranche One [Member]", "terseLabel": "Tranche One" } } }, "localname": "TrancheOneMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_TrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche Two", "label": "Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "localname": "TrancheTwoMember", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaudited Interim Condensed Financial Statements [Policy Text Block]", "label": "Unaudited Interim Condensed Financial Statements [Policy Text Block]", "terseLabel": "Unaudited Interim Condensed Financial Statements" } } }, "localname": "UnauditedInterimCondensedFinancialStatementsPolicyTextBlock", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase", "label": "Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase", "terseLabel": "Fair value of joint venture threshold" } } }, "localname": "VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "percentItemType" }, "gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return", "label": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return", "terseLabel": "Threshold percentage of fair value that is no less than internal rate of return" } } }, "localname": "VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn", "nsuri": "http://guardanthealth.com/20210630", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "percentItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [ "r187", "r458" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]", "terseLabel": "President and Chief Operating Officer" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r391", "r392", "r397", "r398", "r560" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r391", "r392", "r397", "r398" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r50", "r101" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r108", "r115", "r211", "r357", "r358", "r359", "r371", "r372" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect adjustment for ASU 2020-06 adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r108", "r115", "r211", "r357", "r358", "r359", "r371", "r372" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r108", "r115", "r211", "r357", "r358", "r359", "r371", "r372" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusinessDetails", "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r185", "r296", "r301", "r534" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r314", "r315", "r470", "r471", "r472", "r473", "r474", "r475", "r494", "r531", "r535" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails", "http://guardanthealth.com/role/LeasesNarrativeDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r314", "r315", "r470", "r471", "r472", "r473", "r474", "r475", "r494", "r531", "r535" ], "lang": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails", "http://guardanthealth.com/role/LeasesNarrativeDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r185", "r296", "r301", "r534" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r181", "r296", "r299", "r495", "r530", "r532" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r181", "r296", "r299", "r495", "r530", "r532" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r305", "r314", "r315", "r470", "r471", "r472", "r473", "r474", "r475", "r494", "r531", "r535" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails", "http://guardanthealth.com/role/LeasesNarrativeDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r305", "r314", "r315", "r470", "r471", "r472", "r473", "r474", "r475", "r494", "r531", "r535" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails", "http://guardanthealth.com/role/LeasesNarrativeDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusinessDetails", "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r182", "r183", "r296", "r300", "r533", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails", "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r182", "r183", "r296", "r300", "r533", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails", "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r187", "r458" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r109", "r110", "r111", "r112", "r208", "r209", "r210", "r211", "r212", "r213", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r371", "r372", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r21", "r188", "r189" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premium (discount) on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r16", "r502", "r518" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Accrued tax liabilities" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails", "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r38" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r9", "r10", "r38" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalty obligations" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r248" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r54", "r55", "r56", "r521", "r543", "r547" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r53", "r56", "r57", "r105", "r106", "r107", "r396", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Remaining Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Condensed Consolidated Balance Sheet Components" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r360" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r105", "r106", "r107", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r316", "r318", "r363", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r273", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Adjustments to additional paid in capital, stock issued, issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r318", "r349", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r72", "r88", "r437" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r88", "r230", "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r99", "r165", "r170", "r177", "r206", "r391", "r397", "r420", "r500", "r517" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r49", "r99", "r206", "r391", "r397", "r420" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r406" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]", "terseLabel": "Assets" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r199" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r200" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r197", "r219" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized cost, debt securities, available-for-sale" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r195", "r198", "r219", "r505" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated fair value, debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r319", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Office and laboratory space" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r87", "r387" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Re-valuation of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r384", "r385", "r386" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Initial fair value of contingent consideration at acquisition date", "verboseLabel": "Contingent liability from business acquisition" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r90" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 }, "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "verboseLabel": "Estimated fair value, cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r90", "r94" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014End of period", "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r423" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r97", "r99", "r124", "r125", "r126", "r128", "r130", "r138", "r139", "r140", "r206", "r420" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r251", "r252", "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r273" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r20" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June\u00a030, 2021 and December\u00a031, 2020; 101,265,100 and 100,213,985 shares issued and outstanding as of June\u00a030, 2021 and December\u00a031, 2020, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r60", "r62", "r63", "r69", "r508", "r527" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Guardant Health, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r60", "r62", "r68", "r389", "r401", "r507", "r526" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r149", "r150", "r185", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r149", "r150", "r185", "r417", "r418", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r149", "r150", "r185", "r417", "r418", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r143", "r515" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r149", "r150", "r185", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r146", "r149", "r150", "r151", "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r149", "r150", "r185", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r284", "r286", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract asset" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r284", "r285", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r287" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Revenue from cash collections exceeding estimated variable consideration" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r284", "r285", "r297" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Deferred revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt", "verboseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible senior notes, net" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r73" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r147", "r185" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r501", "r503", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r258" ], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "totalLabel": "Net amount recorded in equity" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r41", "r274", "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Threshold of consecutive common stock trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Threshold percentage of common stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold of common stock trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r436", "r438" ], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "Principal" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r40", "r261", "r436" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate of the liability component" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r102", "r274", "r278", "r279", "r280", "r435", "r436", "r438", "r514" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r435", "r438" ], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Less: debt discount, net of amortization" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r95", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.", "label": "Debt Securities, Current", "terseLabel": "Debt securities, short-term" } } }, "localname": "DebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Debt Securities, Noncurrent", "terseLabel": "Debt securities, long-term" } } }, "localname": "DebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r303", "r304" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current", "terseLabel": "Accrued compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r34", "r437" ], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: debt issuance costs, net of amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88", "r163" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r281", "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Dividends on common stock" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r70", "r113", "r114", "r115", "r116", "r117", "r121", "r124", "r128", "r129", "r130", "r134", "r135", "r509", "r528" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r70", "r113", "r114", "r115", "r116", "r117", "r124", "r128", "r129", "r130", "r134", "r135", "r509", "r528" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r95", "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Shareholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r423" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Stock based compensation not recognized, period for recognition (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Stock based compensation not recognized, other than options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Stock based compensation not recognized, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares available for issuance under the 2018 Employee Stock Purchase Plan", "verboseLabel": "ESPP obligation" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options issued and outstanding", "verboseLabel": "Shares underlying outstanding stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r105", "r106", "r107", "r110", "r118", "r120", "r137", "r211", "r273", "r281", "r357", "r358", "r359", "r371", "r372", "r425", "r426", "r427", "r428", "r429", "r431", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage", "verboseLabel": "Ownership interest in joint venture" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusinessDetails", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Investment in Joint Venture" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVenture" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Non-marketable equity and other investments" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r406", "r407", "r408", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r407", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r406", "r407", "r409", "r410", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements, Cash Equivalents and Marketable Securities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r306", "r307", "r312", "r313", "r407", "r467" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r306", "r307", "r312", "r313", "r407", "r468" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r407", "r469" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r411", "r413" ], "lang": { "en-us": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Level 3 Activity" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "terseLabel": "Increase (decrease) in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value \u2014 end of period", "periodStartLabel": "Fair value \u2014 beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r412", "r414" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r442", "r447" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments made on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r214", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r223", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesReceivableandRelatedCreditLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life (years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r238" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Intangible assets subject to amortization, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r240" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r240" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r240" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r240" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r231", "r234", "r238", "r242", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r238", "r497" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets subject to amortization, gross carrying amount", "verboseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r231", "r237" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails", "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r238", "r496" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets subject to amortization, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails", "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r95", "r433" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of entity's patents that another entity has allegedly infringed.", "label": "Gain Contingency, Patents Allegedly Infringed upon, Number", "terseLabel": "Gain contingency, patents allegedly infringed upon, number" } } }, "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r224", "r225", "r499" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets, Net and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r95", "r228", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, net" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r226", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Impairment of goodwill" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r88", "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r103", "r165", "r169", "r173", "r176", "r179" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r368", "r369", "r370", "r373", "r375", "r377", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r100", "r119", "r120", "r164", "r367", "r374", "r376", "r529" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r233", "r241" ], "lang": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r241" ], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": { "order": 1.0, "parentTag": "gh_IntangibleAssetsGrossIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "IPR&D" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r233", "r241" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r229", "r236" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "totalLabel": "Net Carrying Amount" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r65", "r162", "r434", "r437", "r510" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r48" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r76", "r161" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lease not yet commenced, term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Liability Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r452" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r99", "r171", "r206", "r392", "r397", "r398", "r420" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r99", "r206", "r420", "r504", "r523" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r99", "r206", "r392", "r397", "r398", "r420" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r406" ], "calculation": { "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Financial and nonfinancial liabilities, fair value disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "verboseLabel": "Acquired license" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Settlement of prior dispute between parties" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r17", "r259", "r503", "r519" ], "calculation": { "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Net carrying amount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r256" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtComponentsofConvertibleSeniorNotesDetails", "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r5", "r37" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetAssetsGeographicAreaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the total assets less the total liabilities of a designated geographic area ( such as a state, country, continent, or market) when it serves as a benchmark in a concentration of risk calculation.", "label": "Net Assets, Geographic Area [Member]", "terseLabel": "Net Assets, Geographic Area" } } }, "localname": "NetAssetsGeographicAreaMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r86", "r89" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "auth_ref": [ "r74" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "negatedLabel": "Adjustment of redeemable noncontrolling interest", "negatedTerseLabel": "Adjustment of redeemable noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r113", "r114", "r115", "r116", "r121", "r122", "r127", "r130", "r165", "r169", "r173", "r176", "r179" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "netLabel": "Net loss attributable to Guardant Health, Inc. common stockholders, basic", "totalLabel": "Net loss attributable to Guardant Health, Inc. common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r123", "r127", "r130" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to Guardant Health, Inc. common stockholders", "totalLabel": "Net loss attributable to Guardant Health, Inc. common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete agreements and other covenant rights" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r169", "r173", "r176", "r179" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r440" ], "calculation": { "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r440" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r440" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r439" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r449", "r453" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/LeasesLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r38" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Others" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets, net" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r51", "r54", "r421", "r422", "r424" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r59", "r62", "r64", "r67", "r273", "r425", "r430", "r431", "r506", "r525" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive gain (loss), net of tax impact", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r59", "r62", "r389", "r390", "r395" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive income (loss) attributable to redeemable noncontrolling interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax impact:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r52", "r54" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r82" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of offering costs related to borrowings on convertible senior notes" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r83" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payment of offering costs related to public offering" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r81" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Taxes paid related to net share settlement of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r79" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible assets and capitalized license obligations" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.", "label": "Payments to Acquire Interest in Joint Venture", "terseLabel": "Payments to acquire interest in joint venture" } } }, "localname": "PaymentsToAcquireInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r196" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "MSUs", "verboseLabel": "Market-based restricted stock units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r319", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "terseLabel": "Preferred stock dividend rate (in usd per share)" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r28", "r29" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets, net" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r80" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from public offering, net of underwriting discounts and commissions" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturity of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r80", "r352" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r80" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuances of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r58", "r61", "r84", "r99", "r109", "r119", "r120", "r165", "r169", "r173", "r176", "r179", "r206", "r389", "r393", "r394", "r400", "r401", "r420", "r511" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r33", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r32", "r247" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r249", "r524" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r247" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://guardanthealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r95", "r190", "r192", "r193", "r194" ], "lang": { "en-us": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "auth_ref": [ "r270", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.", "label": "Reclassifications of Temporary to Permanent Equity", "terseLabel": "Adjustment of redeemable noncontrolling interest" } } }, "localname": "ReclassificationsOfTemporaryToPermanentEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r265", "r266", "r267", "r268" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.", "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value", "terseLabel": "Redeemable noncontrolling interest, redemption value" } } }, "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r455", "r456", "r457", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r366", "r561" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r95", "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r94", "r498", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r14", "r94", "r550" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash \u2013 included in other assets, net" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Shares underlying unvested restricted stock units", "verboseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r281", "r360", "r522", "r542", "r547" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r106", "r107", "r110", "r118", "r120", "r211", "r357", "r358", "r359", "r371", "r372", "r538", "r540" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r66", "r99", "r159", "r160", "r168", "r174", "r175", "r181", "r182", "r185", "r206", "r420", "r511" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenue", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r448", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r149", "r185" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/PatentLicenseAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r42", "r102", "r274", "r278", "r279", "r280", "r435", "r436", "r438", "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instrument Components" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r0", "r99", "r205", "r206", "r420" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r231", "r237", "r496" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r231", "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r241", "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r33", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r165", "r166", "r172", "r228" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r165", "r166", "r172", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]", "terseLabel": "Schedule of Performance-based Restricted Stock Units Vesting Conditions" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r319", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r324", "r335", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r45", "r97", "r138", "r139", "r263", "r271", "r272", "r274", "r275", "r276", "r278", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r18", "r19", "r20", "r264", "r271", "r272", "r274", "r275", "r276", "r278", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Stock by Class" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r146", "r149", "r150", "r151", "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r155", "r157", "r158", "r165", "r167", "r173", "r177", "r178", "r179", "r180", "r181", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SegmentandGeographicInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing expense" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing expense" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Convertible senior notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Non-cash stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Weighted-average derivative service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Market-based stock unit vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of MSU (in usd per share)", "verboseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending unvested balance (in shares)", "periodStartLabel": "Beginning unvested balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance of options outstanding (in usd per share)", "periodStartLabel": "Beginning balance of options outstanding (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested and released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested and released (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions", "terseLabel": "Discount for post-vesting restrictions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum employee subscription rate, ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Ending number of shares, available for grant (in shares)", "periodStartLabel": "Beginning number of shares, available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and exercisable, weighted average exercise price per share (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Exercises in period, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, grants in period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r326", "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending number of shares, outstanding (in shares)", "periodStartLabel": "Beginning number of shares, outstanding (in shares)", "terseLabel": "Stock options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares Subject to Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance of options outstanding (in usd per share)", "periodStartLabel": "Beginning balance of options outstanding (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options vested and exercisable, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r317", "r322" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails", "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche 1 - $120 per share" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Tranche 3 - $200 per share" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche 2 - $150 per share" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r95", "r319", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Common stock share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Option term, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r342", "r361" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options vested and exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested and exercisable, weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock (as a percent of the fair value of common stock)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Share price of stock issued (in usd per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Computer software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r18", "r19", "r20", "r97", "r99", "r124", "r125", "r126", "r128", "r130", "r138", "r139", "r140", "r206", "r273", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/InvestmentinJointVentureDetails", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r105", "r106", "r107", "r110", "r118", "r120", "r137", "r211", "r273", "r281", "r357", "r358", "r359", "r371", "r372", "r425", "r426", "r427", "r428", "r429", "r431", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r137", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r19", "r20", "r273", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited", "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r273", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in public offering, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r19", "r20", "r273", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r273", "r281", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited", "http://guardanthealth.com/role/StockBasedCompensationAMEA2020EquityIncentivePlanDetails", "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r19", "r20", "r273", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "terseLabel": "Common stock issued under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r273", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in public offering, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStockDetails", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r273", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r25", "r26", "r99", "r191", "r206", "r420" ], "calculation": { "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r98", "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r432", "r462" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r432", "r462" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r432", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r432", "r462" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r461", "r463" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r44", "r99", "r206", "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Common stock subject to repurchase" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government debt securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails", "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r141", "r142", "r144", "r145", "r152", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r391", "r392", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://guardanthealth.com/role/InvestmentinJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r123", "r130" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)", "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r121", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "24(b)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r402": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820",

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r433": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r463": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r529": {

Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r563": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r564": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r565": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r566": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r567": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" }